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ABSTRACT 
 
THE EFFECTS OF METHOTREXATE AND GENETIC 
POLYMORPHISMS ON THE FOLATE/HOMOCYSTEINE PATHWAY 
 
Carolyn Summers 
Alexander S. Whitehead 
 
High homocysteine (Hcy) and low folate status are associated with many clinical 
conditions ranging from cardiovascular disease to neural tube defects. Hcy and folate 
levels are affected by diet as well as lifestyle and genetic factors. Associations between 
genetic polymorphisms of the enzymes involved in folate/Hcy metabolism and Hcy 
levels and folate phenotypes were examined. Genetic polymorphisms were studied in a 
range of populations, which included healthy individuals, systemic lupus erythematosus 
(SLE) patients, rheumatoid arthritis (RA) patients, and families with a child affected by 
neural tube defects (NTDs). Chronic low folate is associated with development of a 
“proatherosclerotic” phenotype in the endothelial cell line, EA.hy 926. The effect of the 
anti-folate, methotrexate (MTX), on the expression of inflammatory genes was studied in 
EA.hy 926 cells in the context of folate status and activation by TNF-α.  
Genotyping was performed by TaqMan allelic discrimination assays or by size 
difference PCR. Total Hcy (tHcy) concentrations and levels of plasma and red blood cell 
(RBC) folate derivatives were measured by stable isotope dilution liquid chromatography 
multiple reaction monitoring mass spectrometry. Affymetrix microarrays were used to 
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assess changes in gene expression in vitro. Candidate inflammatory genes were then 
queried using qRT-PCR. ELISAs were performed to confirm changes in protein levels. 
Several polymorphisms had effects on tHcy levels and not only on total RBC 
folate but on individual RBC folate derivatives. Specifically effects were observed within 
the studies in healthy men, healthy women, and RA patients, but not in SLE patients. 
Also none of the polymorphisms studied showed an association with increased risk for 
NTDs using Transmission Disequilibrium Test analyses. Genetic polymorphisms of the 
enzymes of the folate/Hcy pathway impact levels of tHcy and folate, which may then 
impact risk for various clinical conditions.  
MTX increased mRNA expression and protein levels of several inflammatory 
genes, which included C3 and IL-8. Activation of endothelial cells by TNF-α did not 
seem to be affected by treatment with MTX, with exception of the up regulation of C3. 
MTX lowered intracellular folate and altered the distribution of folate derivatives, which 
had an effect on inflammatory gene expression in endothelial cells. 
  
vii 
TABLE OF CONTENTS 
Title Page…..…………………………………………………….………………...………i 
Dedication……………………………………………………………………………..…..ii 
Acknowledgements……..………………………………………………………….…….iii 
Abstract…...……………………………………………………………………...………..v 
Table of Contents……….……………...…………………………………….….....…….vii 
List of Tables………………….………………………………………………….……....xi 
List of Figures…………….……………………………………………………....……..xiii 
Chapter 1: General Introduction 
1.1 The Folate/Homocysteine Metabolic Pathway………………………..………1 
1.2 Folate Transport…………………….…………………………………………3 
1.3 Common Functional Polymorphisms…………………………………………3 
1.3.1 MTHFR……………………………………………………………4 
1.3.2 MTR……………………………………………………….………5 
1.3.3 MTRR……………………………………………………………..6 
1.3.4 CBS………………………………………………………………..6 
1.3.5 DHFR………………………………………………………...…...7 
1.3.6 TYMS………………………………………………………….…..8 
1.3.7 SHMT1……………………………………………………………8 
1.3.8 MTHFD1………………………………………………………….9 
1.3.9 RFC1…………………………………………………………..….9 
1.4 Summary and Specific Aims………………………………………………...10 
  
viii 
Chapter 2: Effect of Polymorphisms on Homocysteine and Folate Levels in Healthy 
Individuals 
 2.1 Abstract………………………………………………………………………12 
 2.2 Introduction…………………………………………………………………..13 
  2.2.1 Factors Affecting Hcy Levels……………………………………...13 
  2.2.2 Interaction of MTHFR 677C>T and CBS 844ins68 genotypes…....13 
  2.2.3 Racial Distributions of Polymorphisms……………………………14 
2.2.4 Association of High Hcy and Low Folate with Cardiovascular 
Disease…………………………………………………………………...14 
2.2.5 Association of High Hcy and Low Folate with Pregnancy 
Complications……………………………………………………………15 
2.2.6 Methods of Folate Measurement…………………………………..15 
 2.3 Methods………………………………………………………………………17 
  2.3.1 Industrial Workers Study…………………………………………..17 
  2.3.2 Premenopausal Women Study……………………………………..19 
 2.4 Results………………………………………………………………………..21 
  2.4.1 Industrial Workers Study…………………………………………..21 
  2.4.2 Premenopausal Women Study……………………………………..24 
 2.5 Discussion……………………………………………………………………37 
Chapter 3: Polymorphisms Associated with the Risk of Neural Tube Defects 
3.1 Abstract………………………………………………………………………46 
 3.2 Introduction…………………………………………………………………..47 
  3.2.1 Neural Tube Defects……………………………………………….47 
  
ix
  3.2.2 Folic Acid Fortification…………………………………………….47 
  3.2.3 Selected Polymorphisms Associated with NTDs………………….49 
 3.3 Methods………………………………………………………………………54 
  3.3.1 NTD Study…………………………………………………………54 
 3.4 Results………………………………………………………………………..56 
  3.4.1 NTD Study…………………………………………………………56 
 3.5 Discussion……………………………………………………………………61 
Chapter 4: Polymorphisms in the Context of Inflammatory Diseases: Systemic Lupus 
Erythematosus and Rheumatoid Arthritis 
4.1 Abstract………………………………………………………………………64 
 4.2 Introduction…………………………………………………………………..66 
  4.2.1 Systemic lupus erythematosus……………………………………..66 
  4.2.2 Rheumatoid arthritis………………………………………………..67 
 4.3 Methods………………………………………………………………………69 
  4.3.1 SLE Study………………………………………………………….69 
  4.3.2 RA Study…………………………………………………………...71 
 4.4 Results………………………………………………………………………..74 
  4.4.1 SLE Study………………………………………………………….74 
  4.4.2 RA Study…………………………………………………………...81 
 4.5 Discussion……………………………………………………………………95 
Chapter 5: The Effect of Methotrexate Alone and on the Activation of Endothelial Cells 
5.1 Abstract………………………………………………………………..……101 
 5.2 Introduction…………………………………………………………………102 
  
x
 5.3 Methods……………………………………………………………………..106 
  5.3.1 EA.hy 926 cell line experiments………………………………….106 
 5.4 Results………………………………………………………………………110 
  5.4.1 EA.hy 926 cell line experiments……………………….…………110 
 5.5 Discussion………………………………………………………….……….130 
Chapter 6: General Discussion and Future Directions 
 6.1 General Discussion…………………………………………………………134 
 6.2 Future Directions…………………………………………………………...136 
  6.2.1 Healthy subjects…………………………………………………..136 
  6.2.2 Families with a child affected by NTDs………………………….137 
  6.2.3 Inflammatory diseases……………………………………………137 
  6.2.4 Cell culture……………………………………………………….138 
References………………………………………………………………………………139 
 
  
xi
List of Tables 
Table 2-1. Associations between CBS 844ins68 genotype and biochemical 
parameters………………………………………………………………………..22 
 
Table 2-2. Subject characteristics and biochemical phenotypes (Mean+SD or n%)…….26 
 
Table 2-3. Genotype distributions (n%)………………………………………………….27 
 
Table 2-4. Proportion of variation (R2) in biochemical variables explained by selected 
subject characteristics and biochemical phenotypes……………………………..29 
 
Table 2-5. Proportion of variation (R2) in biochemical variables explained by selected 
biochemical phenotypes………………………………………………………….31 
 
Table 2-6. Proportion of variation (R2) in biochemical variables explained by selected 
genotypes in African Americans…………………………………………………33 
 
Table 2-7. Proportion of variation (R2) in biochemical variables explained by selected 
genotypes in Caucasians…………………………………………………………35 
 
Table 2-8. Distribution of MTHFR 677 genotypes in Caucasians by detection of RBC 
5,10-MTHF………………………………………………………………………36 
 
Table 2-9. Number of Caucasians in each folate phenotype by MTHFR 677/1298 
combined genotypes……………………………………………………………...37 
 
Table 3-1. Genotype frequencies in the NTD study……………………………………..57 
 
Table 3-2. MTHFR 677/1298 combined genotypes……………………………………..58 
 
Table 3-3. TYMS 5’VNTR/1494del6 combined genotypes……………………………..60 
 
Table 3-4. MTHFR 677C>T mating types in child trios with number of allele 
transmissions……………………………………………………………………..61 
 
Table 4-1. SLE Study Subject Characteristics…………………………………………...75 
Table 4-2. Distributions of genotype frequencies in African American and Caucasian 
controls…………………………………………………………………………...77 
 
Table 4-3. Distributions of carrier frequencies between SLE patients and controls by 
race……………………………………………………………………………….78 
 
Table 4-4. Correlations with total homocysteine levels………………………………….79 
 
  
xii
Table 4-5. Analysis of covariance for total homocysteine………………………...…….79 
 
Table 4-6. Analysis of covariance with two factors (group, race) and one covariate 
(GFR)…………………………………………………………………………….80 
 
Table 4-7. RA study subject characteristics for categorical variables…………………...82  
 
Table 4-8. RA study subject characteristics for continuous variables…………………...84 
 
Table 4-9. Analyses of selected clinical variables in current users: continuous variables 
stratified by categorical variable.………………………………….……………..85 
 
Table 4-10. RA study genotype distributions……………………………………………87 
 
Table 4-11. Effects of MTHFR 677C>T genotypes in Caucasian current users………...89 
 
Table 4-12. Effects of selected genotypes on biochemical variables and current MTX  
dose in African American current users………………………………………….90 
 
Table 4-13. Effects of selected genotypes on biochemical variables in Caucasian current 
users……………………………………………………………………………...91 
 
Table 4-14. Distribution of MTRR 66A>G genotypes in Caucasian current users by 
detection of RBC 5,10-MTHF…………………………………………………...91 
 
Table 4-15. Distribution of MTR 2756A>G genotypes in African American current users 
by type of toxicity……………………………..…………………………………92   
 
Table 4-16. Distribution of MTHFD1 1958G>A genotypes in Caucasian current users by 
type of toxicity…………………………………………………………………...92 
 
Table 4-17. Analyses between selected continuous variables in African American current 
users……………………………………………………………………………...93 
 
Table 4-18. Analyses between selected continuous variables in Caucasian current 
users………………………………………………………………………...……94 
 
Table 5-1. Genes up regulated by MTX in Hi and Lo cells…………………………….119 
Table 5-2. Genes down regulated by MTX in Hi and Lo cells…………………………124 
  
xiii 
List of Figures 
Figure 1-1. The folate/homocysteine metabolic pathway with common functional 
polymorphisms…………………………………………………………………….2 
 
Figure 2-1. Median total homocysteine levels by CBS 844ins68 genotype within each 
MTHFR 677C>T genotype class………………….……………………………..23 
 
Figure 2-2. Median serum folate levels by CBS 844ins68 genotype within each MTHFR 
677C>T genotype class…………………………………………………………..24 
 
Figure 2-3. Relative amounts of RBC folate derivatives in each folate phenotype in 
Caucasians…………………………………………………………….…………37 
 
Figure 5-1. Folate/Homocysteine pathway and MTX inhibition……………………….106 
Figure 5-2. MTX dose finding and viability experiments……………………………...113 
Figure 5-3. Folate derivatives measured by LC/MRM/MS…………………………….117 
Figure 5-4. QRT-PCR…………………………………………………………………..122 
Figure 5-5. ELISAs……………………………………………………………………..129 
  
1 
Chapter 1: Introduction  
1.1 The Folate/Homocysteine Metabolic Pathway 
 The folate/homocysteine pathway supports two biologically important functions, 
methylation and nucleotide biosynthesis. Low folate and high homocysteine (Hcy), 
hyperhomocysteinemia, is associated with a wide range of pathologies including spina 
bifida (van der Put et al. 2001), cardiovascular disease (Refsum et al. 1998), Alzheimer’s 
(Mattson and Shea 2003), cancer (Stover 2004), and many others. It remains to be proven 
whether it is the high Hcy or low folate levels which present more risk. This is further 
complicated by their intrinsic inverse relationship. Dietary intakes of folate and folic acid, 
known as vitamin B9, as well as intake of other B vitamins have an inverse relationship 
with Hcy levels. B vitamins, such as B6 and B12, are cofactors for several enzymes in the 
pathway and thus deficient levels lead to increased Hcy concentrations. Elevated Hcy 
levels are also associated with older age, male gender, and lifestyle factors such as 
smoking, alcohol intake, coffee consumption, and lack of exercise (Schneede et al. 2000). 
Folate is important in methylation because the methyl group from 5-
methyltetrahydrofolate (5-MTHF) is used for the remethylation of Hcy, which becomes 
methionine (Figure 1-1). Methionine then becomes S-adenosylmethionine (SAM) which 
is the methyl donor for hundreds of methylation reactions, which includes methylation of 
DNA and proteins. Once SAM loses its methyl group it becomes S-
adenosylhomocysteine (SAH), which is then converted back to Hcy. Hcy can also be 
methylated to become methionine by betaine-homocysteine S-methyltransferase 
(BHMT), but this enzyme is found mostly in the liver (Pajares and Perez-Sala 2006) and 
uses the methyl group from betaine. The transsulfuration pathway metabolizes Hcy into 
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cystathionine, which is then converted into cysteine and can be used to produce 
glutathione. The transsulfuration pathway is present in only four tissues, liver, kidney, 
small intestine, and pancreas (Finkelstein 1998). There are two folate derivatives which 
are important for nucleotide synthesis. 5,10-methyleneTHF is used for the production of 
the pyrimidine, deoxythymidine monophosphate (dTMP), while 10-formylTHF is used 
for production of purines. 
 
 
Figure 1-1. The folate/homocysteine metabolic pathway with common functional 
polymorphisms. 5-MTHF, 5-methyltetrahydrofolate, 5,10-MTHF, 5,10-
methenyltetrahydrofolate, CBS, cystathionine beta-synthase, DHF, dihydrofolate, DHFR, 
dihydrofolate reductase, dTMP, deoxythymidine monophosphate, dUMP, deoxyuridine 
monophosphate, Hcy, homocysteine, M, methylenetetrahydrofolate dehydrogenase 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase 1958G>A, 
MTHFR, methylenetetrahydrofolate reductase, MTR, methionine synthase, MTRR, 
methionine synthase reductase, RFC1, reduced folate carrier 1, SAH, S-
adenosylhomocysteine, SAM, S-adenosylmethionine, SHMT1, serine 
hydroxymethyltransferase 1, THF, tetrahydrofolate, TYMS, thymidylate synthase. 
(published in (Summers et al. 2010)) 
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1.2 Folate Transport 
 Naturally occurring forms of folate are found mostly in vegetables and some fruits 
and are polyglutamated. During digestion folates are hydrolyzed into monoglutamates by 
two enzymes, gamma-glutamyl hydrolase (GGH) and folate hydrolase 1 (FOLH1). In the 
small intestine reduced folate carrier 1 (RFC1) transports monoglutamated folates and 
folic acid. The circulating form of folate is 5-methyltetrahydrofolate (5-MTHF) 
monoglutamate and once it enters the cell it becomes polyglutamated by 
folylpolyglutamate synthase (FPGS) in order to trap folate within the cell as well as 
increasing their affinity for intracellular enzymes (Stover 2004). RFC1 is ubiquitously 
expressed and transports folate in many tissues as diverse as the kidneys and the central 
nervous system. The folate receptor (FR) family of genes are only expressed in specific 
tissues, during certain developmental times, and tend to be overexpressed in certain 
cancers (Matherly and Goldman 2003). Red blood cell (RBC) folate levels are a 
reflection of folate status during the last 3-4 months while plasma folate levels are a 
reflection of recent folate intake. 
1.3 Common Functional Polymorphisms 
The hereditability of homocysteine was found to be 57% in a twin study (Siva et 
al. 2007) and therefore genetic polymorphisms are likely to contribute to the variation in 
Hcy levels. Common functional polymorphisms within the enzymes of the folate/Hcy 
metabolic pathway affect folate/Hcy phenotype and may therefore increase risk for 
clinical conditions that are associated with dysfunction of folate/Hcy metabolism. 
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1.3.1 MTHFR 
5,10-methylenetetrahydrofolate reductase (MTHFR) irreversibly reduces 5,10-
methyleneTHF into 5-MTHF, which is the methyl donor for the remethylation of Hcy 
into methionine (Figure 1). The cofactor for this enzyme is flavin adenine dinucleotide 
(FAD), which is derived from vitamin B2, riboflavin. This enzyme is important because it 
directs whether folate is used for methylation or for nucleotide synthesis (Ueland et al. 
2001). Frosst et al. (1995) was the first to identify the single nucleotide polymorphism 
(SNP) in MTHFR 677C>T (rs1801133), which causes an alanine to valine substitution at 
position 222 of the protein and the result is a thermolabile form of the enzyme with 
reduced activity. MTHFR 677TT homozygous individuals have higher fasting 
homocysteine levels especially when folate levels are low (Harmon et al. 1996; Jacques 
et al. 1996). From the study by Guenter et al. (1999) on the homologous mutation in 
MTHFR from E. coli the thermolabile properties of the human 677T enzyme are due to 
the decreased binding of FAD. When folate levels are low the thermolabile enzyme loses 
its FAD cofactor more easily than the wildtype enzyme. Conversely, when folate levels 
are high the variant containing enzyme becomes stabilized and less likely to lose its 
cofactor.  
Bagley and Selhub (1998) were the first to discover that MTHFR 677TT 
homozygotes had an altered distribution of folate derivatives, specifically that formylated 
folates were present in red blood cells (RBCs), whereas 677CC homozygotes had 
predominantly 5-MTHF.  Not only does this polymorphism affect Hcy levels and the 
distribution of folate derivatives but it also carries increased and decreased risks of 
clinical conditions. For example, the 677TT genotype in infants carries a pooled odds 
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ratio of 1.8 for risk of spina bifida in a meta-analysis by Botto and Yang (2000) and in 
mothers the pooled odds ratio is 2.0 for risk of carrying a child with spina bifida. Also 
677TT homozygotes are at increased risk of cardiovascular disease (Kluijtmans and 
Whitehead 2001) but carry an increased protection from colon cancer (Ma et al. 1997), 
the rationale for the latter being that the 677T enzyme is inefficient and folates other than 
5-MTHF accumulate and are more readily available for nucleotide synthesis. A study by 
DeVos et al. (2008) showed that the MTHFR 677TT genotype was associated with 34% 
lower DNA uracil content, and the misincorporation of uracil into DNA is believed to be 
one of the first steps of colon cancer (Ma et al. 1997).  
A second MTHFR SNP, 1298A>C (rs1801131), is in linkage disequilibrium with 
the 677C>T SNP, such that the two variant alleles rarely occur together on the same 
chromosome (van der Put et al. 1998). The 1298A>C transition encodes a substitution of 
glutamic acid to alanine at position 429 of the protein. The 1298A>C polymorphism has 
contradictory associations with folate levels in the literature. Parle-McDermott et al. 
(Parle-McDermott et al. 2006b) found that within the MTHFR 677CC genotype those 
with the 1298CC genotype had higher RBC folate than those with the 1298AA genotype, 
while a large-scale study by Ulvik et al. (2007) found that within the MTHFR 677CC 
genotype those with the 1298CC genotype had lower serum folate and higher Hcy than 
those with the 1298AA genotype. Van der Put et al. (1998) have reported that the double 
homozygote 677CT/1298AC is associated with elevated Hcy and lower plasma folate. 
1.3.2 MTR 
 Methionine synthase (MTR) uses the methyl group from 5-MTHF to remethylate 
homocysteine. The products of this reaction are methionine and THF. Vitamin B12 is a 
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cofactor for this enzyme. The most studied SNP in this gene is 2756A>G (rs1805087), 
which mandates an aspartic acid to glycine change at position 919 in the protein. Harmon 
et al. (1999) found that 2756AA homozygotes had higher Hcy levels in a study in Irish 
middle-aged men called the Industrial Workers study. Tsai et al. (2009) confirmed this 
finding in African Americans in the US, but in Caucasians Hcy levels were not associated 
with this polymorphism. A large scale study in Norway also found that 2756AA 
homozygotes had higher Hcy levels (Fredriksen et al. 2007).  
1.3.3 MTRR 
 Methionine synthase reductase (MTRR) keeps MTR in its active form via 
reductive methylation of B12. There is a polymorphism in this gene at position 66 that has 
an A>G transition (rs1801394). This polymorphism leads to an isoleucine to methionine 
change at position 22 in the protein. It was found that 66GG homozygotes have high Hcy 
levels in the Industrial Workers study in Irish men (Gaughan et al. 2001; Gaughan et al. 
2002). 
1.3.4 CBS 
 Cystathionine beta-synthase (CBS) irreversibly metabolizes Hcy as part of the 
transsulfuration pathway, and requires vitamin B6 as a cofactor. Within CBS there is a 68 
base pair (bp) insertion found in exon 8 referred to as 844ins68. This insertion has been 
shown to carry a mutation 833T>C which should cause a premature stop codon but in 
vitro studies showed that the inserted sequence is skipped, allowing a full length 
functional CBS enzyme (Tsai et al. 1996). Only two studies (Dekou et al. 2001; 
Fredriksen et al. 2007) have found that the 844ins68 carriers have lower Hcy levels than 
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noncarriers, while several other studies did not find any association (Bowron et al. 2005; 
Kluijtmans et al. 2003; Wang et al. 1999 Sep). 
 Individuals homozygous for loss of function mutations in CBS, MTR, or MTHFR 
have homocystinuria, which is characterized by extremely high levels of Hcy above 100 
µM. This rare disease manifests as mental retardation, dislocation of the optic lens, 
osteoporosis, and increased cardiovascular events which leads to early mortality (Mudd et 
al. 1985). Hyperhomocysteinemia is defined as an intermediate level of Hcy between 15 
and 100 µM. High levels of Hcy have been proven to be an independent risk factor for 
cardiovascular disease (Refsum et al. 1998). 
1.3.5 DHFR 
 Dihydrofolate reductase (DHFR) metabolizes synthetic folic acid, which is found 
in supplements and fortified foods, into dihydrofolate (DHF) and DHFR also metabolizes 
this into THF. There is a 19bp insertion/deletion polymorphism within the first intron of 
DHFR, which is referred to as c.86 + 60_78. The deletion removes a possible Sp1 
transcription factor binding site, which may affect transcriptional regulation (Johnson et 
al. 2004). The effect of this polymorphism on folate and Hcy levels was consistent in two 
studies in healthy individuals. A study in young reproductive aged adults from Northern 
Ireland found that women with the del/del genotype had increased serum and RBC folate 
concentrations compared to insertion carriers (Stanislawska-Sachadyn et al. 2008a). A 
study from the Netherlands found that del/del homozygotes had decreased Hcy levels 
compared to ins/ins homozygotes (Gellekink et al. 2007). 
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1.3.6 TYMS 
 Thymidylate synthase (TYMS) competes with MTHFR for one of its substrates 
5,10-methyleneTHF, which is used to convert deoxyuridine monophosphate (dUMP) into 
deoxythymidine monophosphate (dTMP). Nucleotide synthesis is important for DNA 
replication and repair. There are two common polymorphisms within this gene, one in the 
5’ untranslated region (UTR) and one in the 3’ UTR. The polymorphism in the 5’ UTR is 
a variable number of tandem repeats (VNTR) consisting of a 28bp repeat with either 2 or 
3 repeats being the most common and 4 and 5 repeats being more rare (Luo et al. 2002). 
Mandola et al. (2003) suggested that the repeat contains a USF1 transcription factor 
binding site, so the higher number of repeats would lead to increased transcription. The 
3R/3R homozygotes had lower plasma folate in a study in Singapore Chinese subjects 
(Trinh et al. 2002). 
 The polymorphism in the 3’ UTR of TYMS is a 6bp insertion/deletion 
polymorphism referred to as 1494del6 (rs16430). A study by Mandola et al. (2004) 
suggests that this polymorphism affects mRNA stability and translation. TYMS del/del 
homozygotes were associated with less mRNA. Del/del homozygotes had higher RBC 
folate and lower Hcy levels compared to ins carriers in young adults from Northern 
Ireland (Kealey et al. 2005). There is linkage disequilibrium between the polymorphisms 
in the 5’ and 3’ UTRs such that the 2R allele rarely occurs on the same chromosome with 
the del allele (Mandola et al. 2004). 
1.3.7 SHMT1 
 Serine hydroxymethyltransferase 1 (SHMT1) encodes an enzyme which localizes 
to the cytoplasm while SHMT2 encodes an enzyme which localizes to the mitochondria. 
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SHMT1 and SHMT2 both catalyze the same reaction, the reversible conversion of serine 
and THF to glycine and 5,10-methyleneTHF. SHMT1 has a polymorphism 1420C>T 
(rs1979277), which substitutes a leucine for a phenylalanine at position 474 of the 
protein. In a study in mothers of children with neural tube defects 1420CC homozygotes 
had increased Hcy levels compared to 1420T carriers. In the combined group of mothers, 
children, and controls 1420CC homozygotes had decreased plasma and RBC folate levels 
(Heil et al. 2001). 
1.3.8 MTHFD1 
 Methylenetetrahydrofolate dehydrogenase 1, methenyltetrahydrofolate 
cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1) is a trifunctional enzyme 
which catalyzes three different reactions. This enzyme provides precursors for nucleotide 
synthesis and converts THF into 10-formylTHF and then into 5,10-methyleneTHF, which 
are used in the synthesis of purines and thymidylate, respectively. The 1958G>A 
polymorphism (rs2236225) present in MTHFD1 substitutes an arginine for a glutamine at 
position 653 in the protein, which is in the formyltetrahydrofolate synthetase region of 
the enzyme. Although one study has not identified any effect of this polymorphism on 
plasma folate, RBC folate, or Hcy concentrations (Brody et al. 2002) two separate sets of 
samples from the Irish population have revealed that the 1958AA genotype is associated 
with an increased risk for mothers to carry a child with spina bifida (Brody et al. 2002; 
Parle-McDermott et al. 2006a). 
1.3.9 RFC1 
 Reduced folate carrier 1 (RFC1), officially known as solute carrier family 19 
member 1 (SLC19A1), transports 5-MTHF bi-directionally with high affinity and also 
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facilitates the transport of folic acid but with lower affinity (Matherly and Goldman 
2003). RFC1 has a polymorphism 80G>A (rs1051266), which substitutes an arginine for 
a histidine at position 27 of the protein. The effect of this polymorphism on folate and 
homocysteine levels is varied in the literature. A few studies did not find any association 
between RFC1 80G>A genotype and folate or homocysteine levels (Chango et al. 2000; 
Devlin et al. 2006; Vesela et al. 2005). A study in young reproductive aged adults from 
Northern Ireland found that women with the 80GG genotype had decreased RBC folate 
levels compared to 80GA and 80AA genotypes (Stanislawska-Sachadyn et al. 2009). A 
study by Morin et al. (2003) found that 80GG homozygous mothers of children with or 
without spina bifida had a borderline significant decrease in RBC folate. In contrast, a 
large-scale study observed the 80A allele was associated with decreased serum folate but 
with only borderline significance (Fredriksen et al. 2007). 
1.4 Summary and Specific Aims 
Folate/Hcy metabolism is important for nucleotide biosynthesis and methylation. 
Dysregulation of folate/Hcy metabolism characterized by low folate and high Hcy levels 
is associated with many clinical conditions, ranging from developmental abnormalities to 
diseases with an inflammatory component. Polymorphisms within the enzymes of the 
folate/Hcy metabolic pathway may have an effect on Hcy and folate levels that could 
affect risk for various clinical conditions. 
Specific Aims: 
1) Examine the effects of the above mentioned polymorphisms on tHcy and 
folate levels in healthy men and women. 
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2) Examine the risk associated with the above mentioned polymorphisms in 
families with children affected by spina bifida. 
3) Examine the effects of the above mentioned polymorphisms in patients with 
inflammatory diseases such as systemic lupus erythematosus and rheumatoid 
arthritis patients taking the anti-folate drug, methotrexate. 
4) Examine the effects of methotrexate, alone and when used prior to treatment 
with TNF-α, on inflammatory gene expression in an endothelial cell culture 
model under high and low folate conditions. 
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Chapter 2: Effect of Polymorphisms on Homocysteine and Folate Levels in Healthy 
Individuals 
 
2.1 Abstract 
 High Hcy and low folate levels are associated with many clinical conditions 
ranging from cardiovascular disease to spina bifida. Genetic polymorphisms within the 
enzymes of the folate/Hcy metabolic pathway may have independent effects or these 
effects may synergize or counteract one another. In the Industrial Workers study, which 
is composed of healthy middle-aged Irish males, the 844ins68 polymorphism within 
cystathionine β-synthase (CBS) was examined alone and in the context of 5,10-
methylenetetrahydrofolate reductase (MTHFR) 677C>T genotypes for an effect on tHcy 
and folate levels. MTHFR 677TT homozygotes had higher tHcy and lower folate 
concentrations relative to individuals with 677CC and 677CT genotypes. CBS 844ins68 
carriers did not have significantly different tHcy or folate levels, but after stratifying by 
MTHFR 677 genotypes, carriers of the 844ins68 allele who were MTHFR 677TT 
homozygotes had normalized levels of tHcy and folate compared to 677TT/844ins68 
noncarriers.  
In the Premenopausal Women study, which was composed of 26 Caucasian and 
23 African American healthy premenopausal women, there were 11 polymorphisms 
within 9 genes of enzymes of the folate/Hcy metabolic pathway which were examined for 
effects on tHcy, plasma folate, and red blood cell (RBC) folate derivative levels. In 
African Americans tHcy levels were associated with polymorphisms in methionine 
synthase (MTR) and thymidylate synthase (TYMS). RBC folate derivative levels were 
associated with polymorphisms in MTR, TYMS, methionine synthase reductase (MTRR), 
and reduced folate carrier 1 (RFC1). In Caucasians tHcy levels were associated with 
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polymorphisms in 5,10-methylenetetrahydrofolate reductase (MTHFR) and MTR. RBC 
folate derivative levels were associated with polymorphisms in MTHFR, TYMS, and 
RFC1. 
2.2 Introduction 
 2.2.1 Factors Affecting Hcy Levels 
Hcy concentrations are impacted by dietary intake of folate and B vitamins, by 
lifestyle factors such as smoking, and by genetic factors such as common functional 
polymorphisms in the enzymes of the folate/Hcy metabolic pathway. B12 levels are 
inversely related to Hcy levels because B12 is a cofactor for MTR, the enzyme 
responsible for the remethylation of Hcy to methionine. The methylfolate trap hypothesis 
states that deficient B12 levels lower the activity of MTR such that 5-MTHF is trapped 
resulting in the build up of Hcy and was demonstrated in a single case of B12 deficiency 
(Smulders et al. 2006). Smoking is associated with increased Hcy, decreased folate, B12, 
and B6 levels (Brown et al. 2004b; Gabriel et al. 2006; Nygard et al. 1998). Smoking is 
also associated with poor pregnancy outcome, which includes oral clefts, preterm birth, 
and low birth weight infants (Meyer et al. 1976; Wyszynski et al. 1997). 
2.2.2 Interaction of MTHFR 677C>T and CBS 844ins68 genotypes 
 Destefano et al. (1998) found that MTHFR 677TT individuals carrying the CBS 
844ins68 allele had lower homocysteine levels than noncarriers in a large study in 
European men. A large study in British men by Dekou et al. (2001) confirmed the finding 
that carriers of the CBS 844ins68 allele who were MTHFR 677TT homozygotes had 
lower Hcy levels than 677TT/844ins68 noncarrier individuals. Folate levels were not 
reported for either of these studies, and the aim of the Industrial Workers Study described 
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here was to examine whether the CBS 844ins68 allele is associated with significantly 
different levels of folate and Hcy, either alone or within classes of MTHFR 677C>T 
genotypes. 
 2.2.3 Racial Distributions of Polymorphisms 
 The population in which the polymorphisms are studied is very important because 
the frequencies of the genotypes vary by race. MTHFR 677C>T genotypes vary 
significantly in frequency among the different racial groups. The percent of MTHFR 
677TT homozygotes ranges from 8-18% in Caucasians, 1% of African Americans, and 
12% of Asians (Botto and Yang 2000). MTHFR 677TT homozygotes are more prevalent 
in Caucasian than African American populations and the implication maybe that risk of 
neural tube defects is higher in Caucasians. The frequency of CBS 844ins68 allele 
carriers also varies by race. Carriers of 844ins68 make up 14% of Caucasians, 41% of 
African Americans, and are absent in Asians (Franco et al. 1998; Tsai et al. 2009).  
2.2.4 Association of High Hcy and Low Folate with Cardiovascular Disease 
Homocystinuria, extremely high levels of Hcy, due to an inborn error of 
metabolism was first discovered in 1962 (Gerritsen et al. 1962) and was associated with 
early onset cardiovascular disease (Mudd et al. 1985). Since then it has been concluded 
that Hcy contributes to formation of atherosclerotic plaques (McCully 2007). Specifically 
Hcy is capable of damaging arterial tissues by inducing the release of cytokines and other 
mediators of inflammation. Hcy also contributes to fibrosis, calcification, and elastic 
tissue damage. Hcy can cause oxidative stress which leads to oxidation of LDL, uptake of 
which leads macrophages to become foam cells (Loscalzo 1996). Many clinical studies 
have established that elevated Hcy is an independent risk factor for cardiovascular 
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disease (McCully 2007). A meta-analysis found that a 5 µmol/L increase in Hcy is 
associated with a 27% increased risk of venous thrombosis in prospective studies and a 
60% increase in retrospective studies (Den Heijer et al. 2005). The best evidence that 
adequate folate is protective against cardiovascular disease is in the early 1960s in the US 
cardiovascular disease reached a peak and subsequently death rates declined by 60% 
(CDC 1999). This time period coincides with the introduction of synthetic folic acid to 
the food supply, before it was mandated by the FDA in 1998. 
 2.2.5 Association of High Hcy and Low Folate with Pregnancy Complications 
 High Hcy and low folate concentrations are associated with pregnancy 
complications such as preeclampsia, premature birth, low birth weight infants, stillbirth, 
and recurrent pregnancy loss (D'Uva et al. 2007; Vollset et al. 2000). A high Hcy and low 
folate phenotype has also been associated with congenital abnormalities such as NTDs, 
clubfoot, heart defects, limb deficiencies, cleft lip/palate, and Down syndrome (Czeizel 
1998; James et al. 1999; Little et al. 2008; Vollset et al. 2000). Suboptimal folate status in 
the mother is associated with an eight-fold increased risk of carrying a child with an NTD 
(Molloy et al. 1998a). The adverse pregnancy outcomes listed above have been shown to 
be reduced by maternal periconceptional folic acid supplementation (Bukowski et al. 
2009; Czeizel and Dudas 1992; Timmermans et al. 2009; Yang et al. 1997). 
 2.2.6 Methods of Folate Measurement 
 There were two common methods by which RBC folate was typically measured. 
Microbiological assays were based on the growth of a specific strain of folate-dependent 
bacteria which was directly related to folate concentration (Molloy and Scott 1997). 
Radiometric competitive binding assays (radioassays) were then developed to measure 
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RBC folate via competition of radiolabeled tracer folate and unlabeled folate from the 
sample for protein binding sites. The problem that arose was the conflicting association 
of RBC folate levels with the MTHFR 677TT genotype. One study had shown that 
677TT individuals had higher RBC folate than 677CT or 677CC individuals when using 
a radioassay to measure RBC folate (van der Put et al. 1995). Another study measured 
RBC folate by microbiological assay and revealed that MTHFR 677TT homozygotes had 
lower RBC folate than 677CT heterozygotes or 677CC homozygotes (Molloy et al. 
1997). A study by Molloy et al. (1998b) addressed this problem by using both methods of 
RBC folate measurement on the same samples of various MTHFR 677C>T genotypes. 
The results confirmed that the radioassay measured lower folates in MTHFR 677C 
carriers compared to 677TT homozygotes, while the microbiological assay showed the 
opposite. The results also showed that the radioassay measured less folate in MTHFR 
677CT and 677CC individuals than the microbiological assay while the radioassay 
measured more folate in MTHFR 677TT individuals than the microbiological assay.  
 A possible explanation lies in the difference in the distribution of folate 
derivatives between the MTHFR 677C>T genotypes. MTHFR 677TT homozygotes have 
an altered distribution of RBC folate derivatives, which favors formylated folates, while 
677CC homozygotes have mostly 5-MTHF (Bagley and Selhub 1998). It is possible that 
a specific folate derivative may be more readily measurable in the radioassay but not 
utilized efficiently by the bacteria in the microbiological assay. The recent development 
of stable isotope dilution liquid chromatography multiple reaction monitoring mass 
spectrometry (LC/MRM/MS) provides higher specificity than previous methods through 
the use of [13C5]-labeled internal standards. Also the capacity to measure three distinct 
  
17 
folate derivatives (THF, 5-MTHF, and 5,10-MTHF) instead of just total RBC folate gives 
this method an advantage. Specifically individual RBC folate derivatives will used to 
characterize in detail the effects of polymorphisms in enzymes of folate/Hcy metabolic 
pathway. While Smulders et al. (2007) using a similar method has shown that non-
methylfolate accumulation in RBCs is associated with the MTHFR 677TT genotype, it 
remains to be explored what effects the other polymorphisms in the enzymes of the 
folate/Hcy metabolic pathway have on specific RBC folate derivatives. 
 Certain genetic variants or folate/Hcy phenotypes may be associated with an 
individual woman’s risk of pregnancy complications. The Premenopausal Women Study 
was undertaken to examine the relationships of 11 polymorphisms in 9 genes to 
folate/Hcy phenotype using stable isotope dilution LC/MRM/MS to measure total Hcy 
and folate derivatives in plasma and RBCs. The analyses were divided into two racial 
groups, African Americans and Caucasians, because these groups have different 
prevalences of certain pregnancy complications.   
2.3 Methods 
 2.3.1 Industrial Workers Study 
Subjects 
 Subjects from the Industrial Workers study (n=614) were recruited from an 
industrial company in Belfast, Northern Ireland as previously described (Harmon et al. 
1996; Summers et al. 2008b). Subjects were men that were 29-53 years old. The study 
was approved by the Research Ethics Committee of the Faculty of Medicine, The 
Queen’s University of Belfast. All subjects provided written informed consent. Fasting 
subjects gave blood samples for biochemical and genetic analysis.  
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 Biochemical Assays 
THcy concentrations were determined previously using high-performance liquid 
chromatography and serum folate concentrations were determined previously using a 
commercial kit (ICN Pharmaceuticals) (Harmon et al. 1996).  
 Genotyping 
MTHFR 677C>T genotyping was RFLP based and genotypes for the study 
population have previously been reported (Harmon et al. 1996). CBS 844ins68 genotypes 
were obtained using a PCR-based size difference method. PCR amplifications were 
performed in a total volume of 25 µl containing 50 ng genomic DNA, 0.4 µM of each 
forward and reverse primer (sequences of which were previously published (Barbaux et 
al. 2000)), 0.8 µM dNTPs, 10x PCR Buffer (Applied Biosystems, Foster City, CA), 1.5 
mM MgCl2, and 1U AmpliTaq DNA polymerase (Applied Biosystems). Cycling 
conditions were as follows:  94°C 5 min, 35 cycles of 94°C 1 min, 55°C 1 min, 72°C 1 
min. PCR products were separated on 3% agarose gels, run for 45 min at 140V, and 
stained with ethidium bromide. 
Statistics 
Statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, 
NC). Even after logarithmic transformation, distributions of total homocysteine and 
serum folate were positively skewed, so all analyses were performed using untransformed 
data. Hardy–Weinberg equilibrium was assessed for the MTHFR 677C>T and CBS 
844ins68 genotypes. Differences between genotype groups for homocysteine and serum 
folate were assessed using the Wilcoxon rank-sum or Kruskal–Wallis test. 
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2.3.2 Premenopausal Women Study 
Subjects 
Premenopausal female staff and students were recruited at the University of 
Pennsylvania School of Medicine from January 9, 2007 to July 26, 2007. A similar 
number of subjects who self-reported as Caucasians and African Americans were 
recruited. Study subjects who had a major medical condition, such as an autoimmune 
disease, or who were currently taking an anti-folate drug, or were pregnant were 
excluded. This study was approved by the Institutional Review Board of the University of 
Pennsylvania School of Medicine. All subjects gave written informed consent. Subjects 
provided fasting blood samples and completed an in-person interview. This study was 
previously described (Summers et al. 2010). 
Biochemical Assays 
THcy levels and plasma and RBC folate derivatives were measured using stable 
isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry 
(LC/MRM/MS) as previously described (Huang et al. 2007; Huang et al. 2008). The 
measured folate derivatives include 5-MTHF, THF, and 5,10-MTHF. The measurement 
of 5,10-MTHF is representative of the sum of 5-formylTHF and 10-formylTHF, which 
under acidic conditions convert to 5,10-MTHF. 
Vitamin B12 levels were measured with Immulite 2000 Vitamin B12 Assays 
(Diagnostic Products Corp., Los Angeles, CA). 
Genotyping 
QIAamp DNA Mini Kits (Qiagen, Santa Clarita, CA) were used to extract DNA 
from whole blood. TaqMan genotyping methods were previously described for MTHFR 
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677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G (Summers et al. 2008a), 
MTHFD1 1958G>A, RFC1 80A>G, and SHMT1 1420C>T (Summers et al. 2010). 
Briefly, real-time polymerase chain reaction (PCR) assays were performed on a DNA 
Engine Opticon 2 continuous fluorescence detection system (Bio-Rad, Hercules, CA). 
PCR amplifications took place in 20 µl volumes containing 20 ng genomic DNA, forward 
and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions consisted of 
an initial incubation at 50°C for 2 min, 95°C for 10 min, and 50 cycles of assay specific 
temperatures for denaturation and extension. Dual fluorescence was measured at the end 
of each cycle. Genotype interpretations were performed with Opticon Monitor Analysis 
software, version 2.02 (Bio-Rad). 
  Size difference PCR methods were used to genotype CBS 844ins68, TYMS 
1494del6, TYMS 5’ VNTR, and DHFR c.86+60_78 as previously described (Summers et 
al. 2010). Briefly, PCR amplifications were performed using 50 ng genomic DNA, 
forward and reverse primers, dNTPs, 10x PCR buffer (Applied Biosystems), and 
AmpliTaq DNA polymerase (Applied Biosystems) in 25 µl volumes. PCR products were 
separated on 3% agarose gels run for 45 min at 140V then stained with ethidium bromide. 
Statistics 
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, 
NC). Discrete variables were presented as counts and proportions and continuous 
variables were presented as means and standard deviations. Total RBC folate is the sum 
of RBC 5-MTHF, THF, and 5,10-MTHF. THF values which were not detectable (n=4) 
were given a value corresponding to the lower limit of quantitation (4.5 nmol/L) with 
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adjustment for individual hematocrit values, allowing both absolute THF levels and the 
ratio of RBC 5-MTHF:THF to be analyzed as continuous variables. RBC 5,10-MTHF 
levels were not detectable in a large portion of the samples and therefore this variable 
was treated as dichotomous (detectable/not detectable). 
Hardy-Weinberg equilibrium was calculated for each polymorphism within each 
race (Caucasian and African American). Fisher’s Exact test was used to check for 
significant differences in genotype distributions between the two groups. Simple linear 
regression analyses estimated the coefficient of determination (R2), which measures the 
proportion of variation in tHcy and various folates (dependent variable) that is explained 
by each predictor variable. Significance in each model was assessed using either the t-
statistic or Fisher’s exact test. Unadjusted p values <0.10 were considered significant 
because of the small sample size of this study. The large number of comparisons made 
are exploratory in nature and the results should be interpreted in that context. 
2.4 Results 
 2.4.1 Industrial Workers Study 
MTHFR 677C>T and CBS 844ins68 genotypes were each in Hardy-Weinberg 
equilibrium. Frequencies of MTHFR 677C>T genotypes were 45% CC, 43.6% CT, 
11.4% TT and frequencies of CBS 844ins68 genotypes were 82.2% W/W, 17.6% W/I, 
0.2% I/I. A previous report from the Industrial Workers Study found that MTHFR 677TT 
homozygotes had increased homocysteine and decreased serum folate relative to 677CT 
and 677CC individuals (Harmon et al. 1996). CBS 844ins68 genotypes did not have 
significantly different tHcy and serum folate levels (Table 2-1). 
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Table 2-1. Associations between CBS 844ins68 genotype and biochemical 
parameters. 
 
Plasma tHcy and serum folate concentrations are expressed as median [interquartile 
range]. Statistical significance for CBS genotypes was assessed by Wilcoxon Rank Sum. 
1Combined genotype class comprises 108 W/I and one I/I. (Summers et al. 2008b) 
 
 When CBS 844ins68 genotypes were stratified by MTHFR 677 genotypes, CBS 
844ins68 carriers had significantly different tHcy levels than noncarriers only within 
MTHFR 677TTs. CBS 844ins68 carrier status had no significant impact on tHcy or serum 
folate concentrations within either MTHFR 677CT or 677CC genotypes. MTHFR 
677TT/CBS 844ins68 carriers had 24.1% lower tHcy levels compared to 677TT/844ins68 
noncarriers (6.66 vs 8.77 umol/L, respectively p=0.045) (Figure 2-1). 
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Figure 2-1. Median total homocysteine levels by CBS 844ins68 genotype within each 
MTHFR 677C>T genotype class. Bars represent total homocysteine levels in each 
MTHFR 677C>T genotype class: regardless of CBS 844ins68 genotype, in CBS 
844ins68 non-carriers, and in CBS 844ins68 carriers.  The number of subjects in each 
group is given. † MTHFR 677TT homozygotes have significantly higher total 
homocysteine concentrations than CT heterozygotes and CC homozygotes (p<0.0001 by 
Kruskal-Wallis). (Summers et al. 2008b) 
 
When CBS genotypes were stratified by MTHFR 677 genotypes, CBS 844ins68 
carriers had significantly different serum folate concentrations than noncarriers only 
within MTHFR 677TTs. MTHFR 677TT/CBS 844ins68 carriers had 27.7% higher serum 
folate concentrations compared to 677TT/844ins68 noncarriers (11.16 vs 8.74 nmol/L, 
respectively p=0.034) (Figure 2-2). The tHcy raising and folate lowering effect of the 
MTHFR 677TT genotype appears to be ‘counterbalanced’ by the CBS 844ins68 allele. 
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Figure 2-2. Median serum folate levels by CBS 844ins68 genotype within each 
MTHFR 677C>T genotype class. Bars represent serum folate levels in each MTHFR 
677C>T genotype class: regardless of CBS 844ins68 genotype, in CBS 844ins68 
non-carriers, and in CBS 844ins68 carriers.  The number of subjects in each group is 
given. † MTHFR 677TT homozygotes have significantly lower serum folate 
concentrations than CT heterozygotes and CC homozygotes (p<0.0001 by Kruskal-
Wallis). (Summers et al. 2008b) 
 
2.4.2 Premenopausal Women study 
 Subject Characteristics 
 In the study 53% (n=26) self-reported as Caucasian and 47% (n=23) as African 
American. Subject characteristics are presented in Table 2-2. Several of the biochemical 
variables were significantly different between African Americans and Caucasians. Total 
RBC folate was higher in Caucasians (1186.0 vs 939.1 nmol/L, p=0.013). Out of the 
individual RBC folate derivatives THF levels were higher (118.2 vs 19.1 nmol/L, 
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p=0.030) and 5,10-MTHF was detectable in more Caucasians than African Americans 
(61.5% vs 8.7%, p<0.0001). Additionally, plasma 5-MTHF levels were higher in 
Caucasians (48.4 vs 33.5 nmol/L, p=0.009), while B12 levels were lower in Caucasians 
(390.5 vs 542.4 pmol/L, p=0.013). Since many biochemical variables were different by 
race all analyses were performed separately for each group. A Caucasian subset was 
created in order to perform analyses without MTHFR 677TT homozygotes, since this 
genotype is known to have a profound impact on folate/Hcy phenotype. Removal of these 
subjects also ensured that analyses of other variables would not contain 677TT 
individuals. Since the Premenopausal Women study is relatively small the 677TT 
individuals could be inadvertently grouped together during the analysis of other variables 
leading to false associations. All analyses in Caucasians were done in the subset which 
excluded 677TT individuals except those analyses designed to examine the effect of the 
MTHFR 677TT genotype.  
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Table 2-2. Subject characteristics and biochemical phenotypes (Mean+SD or n%).    
Subject Characteristics 
African American 
(N = 23) 
Caucasian 
(N = 26) 
Caucasian 
Subset (N=21)1 
  Age (years) 31.6 + 6.0 33.3 + 6.5 32.7 + 6.1 
  Body mass index (kg/m2) 28.3 ± 5.9  23.5 ± 3.4 23.6 + 3.8 
  Smoking    
     Yes 4 (17.4) 5 (19.2) 4 (19.0) 
     No 19 (82.7) 21 (80.8) 17 (81.0) 
  Alcohol use    
     Yes 16 (69.6) 22 (84.6) 18 (85.7) 
     No 7 (30.4) 4 (15.4) 3 (14.3) 
  Vitamin use2    
     Yes 15 (65.2) 17 (65.4) 15 (71.4) 
     No 8 (34.8) 9 (34.6) 6 (28.6) 
Biochemical Phenotypes    
  tHcy (µmol/L) 8.9 ± 2.5  9.6 ± 2.7  8.9 ± 1.9 
  Total RBC folate (nmol/L)3 939.1 ± 339.0  1186.0 ± 328.5  1165.3 ± 282.6 
  RBC 5-MTHF (nmol/L) 919.3 ± 334.1  1040.3 ± 333.0  1122.3 ± 278.8 
  RBC THF (nmol/L)  19.1 ± 9.1  118.2 ± 214.3  37.5 ± 31.2 
  RBC 5,10-MTHF     
      Not Detectable 21 (91.3) 10 (38.5) 9 (42.9) 
      Detectable 2 (8.7) 16 (61.5) 12 (57.1) 
  Ratio RBC 5-MTHF: THF  51.5 ± 15.3 35.7 ± 23.6 42.9 ± 19.9 
  Plasma 5-MTHF (nmol/L) 33.5 ± 17.2 48.4 ± 20.5 50.2 ± 22.0 
  B12 (pmol/L) 542.4 ± 231.6 390.5 ± 176.6 393.0 ± 173.0 
1After exclusion of MTHFR 677TT individuals.  
2Includes multivitamins, B vitamins, and folic acid. 
3Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF) (Summers et 
al. 2010) 
 
 Genotype Distributions 
 African American and Caucasian genotype distributions were significantly 
different for 5 out of the 11 polymorphisms and included: MTHFR 677C>T, MTRR 
66A>G, CBS 844ins68, TYMS 1494del6, and MTHFD1 1958G>A (Table 2-3). MTHFD1 
1958G>A was the only polymorphism that was not in Hardy-Weinberg equilibrium and 
this was only in Caucasians (data not shown). 
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Table 2-3. Genotype distributions (n%). 
SNP (dbSNP rs no.) Genotypes 
African 
American 
(N = 23) 
Caucasian 
(N = 26) 
Caucasia
n Subset 
(N=21)1 
P 
Value2 
MTHFR 677C>T CC 16 (69.6) 8 (30.8) 8 (38.1) 0.009 
rs1801133 CT 7 (30.4) 13 (50.0) 13 (61.9)  
 TT 0 5 (19.2) 0  
MTHFR 1298A>C AA 13 (56.5) 14 (53.8) 9 (42.9) 0.61 
rs1801131 AC 10 (43.5) 10 (38.5) 10 (47.6)  
 CC 0 2 (7.7) 2 (9.5)  
MTR 2756A>G AA 10 (43.5) 15 (57.7) 14 (66.7) 0.17 
rs1805087 AG 10 (43.5) 11 (42.3) 7 (33.3)  
 GG 3 (13.0) 0 0  
MTRR 66A>G AA 13 (56.5) 6 (23.1) 5 (23.8) 0.039 
rs1801394 AG 7 (30.4) 17 (65.4) 13 (61.9)  
 GG 3 (13.0) 3 (11.5) 3 (14.3)  
CBS 844ins68 WW               12 (52.2) 21 (80.8) 17 (80.9) 0.040 
 WI                 8 (34.8) 5 (19.2) 4 (19.1)  
 II 3 (13.0) 0 0  
TYMS 5’ VNTR 2R/2R        3 (13.0) 2 (7.7) 1 (4.8) 0.14 
 2R/3R 8 (34.8) 17 (65.4) 13 (61.9)  
 3R/3R 9 (39.1) 7 (26.9) 7 (33.3)  
 2R/4R 2 (8.7) 0 0  
 3R/4R 1 (4.4) 0 0  
TYMS 1494del6 ins/ins  2 (8.7) 9 (34.6) 7 (33.3) 0.006 
rs16430 ins/del 11 (47.8) 15 (57.7) 12 (57.1)  
 del/del 10 (43.5) 2 (7.7) 2 (9.5)  
DHFR c.86+60_78 ins/ins      5 (21.7) 6 (23.1) 6 (28.6) 1 
 ins/del 13 (56.5) 14 (53.8) 12 (57.1)  
 del/del 5 (21.7) 6 (23.1) 3 (14.3)  
RFC1 80A>G AA 8 (34.8) 7 (26.9) 6 (28.6) 0.59 
rs1051266 AG 12 (52.2) 16 (61.5) 13 (61.9)  
 GG 3 (13.0) 3 (11.5) 2 (9.5)  
MTHFD1 1958G>A GG 13 (56.5) 12 (46.2) 8 (38.1) 0.082 
rs2236225 GA 8 (34.8) 5 (19.2) 3 (14.3)  
 AA 2 (8.7) 9 (34.6) 10 (47.6)  
SHMT1 1420C>T CC 10 (43.5) 14 (53.8) 13 (61.9) 0.59 
rs1979277 CT 8 (34.8) 9 (34.6) 8 (38.1)  
 TT 5 (21.7) 3 (11.5) 0  
1After exclusion of MTHFR 677TT individuals.  
2P values by Fisher’s exact test are comparison of genotype distributions in African 
Americans (n=23) and Caucasians (n=26). (Summers et al. 2010) 
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Associations with Biochemical Phenotypes 
 Since this study included a small number of subjects in each group p values <0.10 
were considered to be significant.  
Lifestyle Factors 
Alcohol Use. In African Americans alcohol users had tHcy concentrations that 
were 2.0 µmol/L higher than nonusers (9.5 vs 7.5 µmol/L, p=0.068, Table 2-4). In 
Caucasians alcohol users had total RBC folate that was 316.5 nmol/L higher than 
nonusers (1210.0 vs 893.5 nmol/L, p=0.072) and this was due to RBC 5-MTHF levels 
being 288.5 nmol/L higher in alcohol users (1163.5 vs 875.0 nmol/L, p=0.098). 
Smoking. Total RBC folate concentrations were 380.1 nmol/L lower in African 
American smokers than nonsmokers (625.1 vs 1005.2 nmol/L, p=0.038, Table 2-4). This 
difference was largely attributable to the difference in RBC 5-MTHF levels which were 
375.4 nmol/L lower in smokers than nonsmokers (609.2 vs 984.6 nmol/L, p=0.038). Also 
plasma 5-MTHF levels were 16.4 nmol/L lower in smokers (20.0 vs 36.4 nmol/L, 
p=0.083) and B12 levels were 239.6 pmol/L lower in smokers (344.5 vs 584.1 pmol/L, 
p=0.058). In Caucasians similar relationships were observed but were not significant. For 
example, total RBC folate concentrations were 189.7 nmol/L lower in smokers than 
nonsmokers (p=0.24). 
Vitamin Use. In Caucasians vitamin users had total RBC folate concentrations 
that were 326.5 nmol/L higher than nonusers (1398.6 vs 1072.1 nmol/L, p=0.013) and 
this was mostly due to RBC 5-MTHF levels being 326.9 nmol/L higher than nonusers 
(1355.8 vs 1028.9 nmol/L, p=0.011). Plasma 5-MTHF levels were 23.7 nmol/L higher in 
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users than nonusers (67.2 vs 43.5 nmol/L, p=0.022). Similar associations were not 
observed in African Americans. 
Table 2-4. Proportion of variation (R2) in biochemical variables explained by 
selected subject characteristics and biochemical phenotypes. 
 Subject Characteristics 
African-American 
(N=23) 
Caucasian Subset 
(N=21)1 
Dependent 
Variables 
Explan-
atory 
Variables  
Parameter 
Estimate (SE) 
R2 (P-
value) 
Parameter 
Estimate (SE) 
R2 (P-
value) 
tHcy (µmol/L) Alcohol Intercept-No 
              Yes 
7.5 (0.9) 
2.0 (1.1) 
 0.15 
(0.068) 
8.3 (1.1) 
0.8 (1.2) 
0.02 
(0.52) 
Total RBC 
folate 
(nmol/L) 2 
Smoking Intercept-No 
              Yes 
1005.2 (71.7) 
-380.1 (171.9) 
0.19 
(0.038) 
1200.9 (68.0) 
-189.7 (155.7) 
0.07 
(0.24) 
 Alcohol Intercept-No 
              Yes 
1009.7 (130.6) 
-103.7 (156.5) 
0.02 
(0.51) 
897.4 (153.7) 
312.6 (166.0) 
0.16 
(0.075) 
 Vitamin use Intercept-No 
              Yes 
926.4 (90.0) 
31.8 (152.6) 
0.002 
(0.84) 
1072.1 (63.3) 
326.5 (118.4) 
0.29 
(0.013) 
RBC 5-MTHF 
(nmol/L) 
Smoking Intercept-No 
              Yes 
984.6 (70.6) 
-375.4 (169.4) 
0.19 
(0.038) 
1155.8 (67.1) 
-175.5 (153.8) 
0.06 
(0.27) 
 Alcohol Intercept-No 
              Yes 
987.5 (128.0) 
-98.0 (153.5) 
0.02 
(0.53) 
875.0 (153.4) 
288.5 (165.7) 
0.14 
(0.098) 
 Vitamin use Intercept-No 
              Yes 
910.5 (88.3) 
25.2 (149.6) 
0.001 
(0.87) 
1028.9 (62.0) 
326.9 (116.1) 
0.29 
(0.011) 
RBC THF 
(nmol/L) 
RBC 5,10-
MTHF 
Intercept-ND3 
                D 
17.9 (1.8) 
13.8 (6.2) 
0.19 
(0.037) 
24.1 (9.9) 
23.3 (13.0) 
0.14 
(0.089) 
Ratio RBC 5-
MTHF: THF 
RBC 5,10-
MTHF 
Intercept-ND 
                D 
52.0 (3.4) 
-6.7 (11.5) 
0.02 
(0.57) 
52.3 (6.2) 
-16.4 (8.2) 
0.18 
(0.059) 
Plasma 5-
MTHF 
(nmol/L) 
Smoking Intercept-No 
              Yes 
36.4 (3.8) 
-16.4 (9.0) 
0.14 
(0.083) 
51.1 (5.5) 
-4.4 (12.5) 
0.01 
(0.73) 
 Vitamin use Intercept-No 
              Yes 
32.1 (4.5) 
4.0 (7.7) 
0.013 
(0.60) 
43.5 (5.1) 
23.7 (9.5) 
0.25 
(0.022) 
B12 (pmol/L) Smoking Intercept-No 
              Yes 
584.1 (49.8) 
-239.6 (119.5) 
0.16 
(0.058) 
414.1 (41.6) 
-110.8 (95.3) 
0.07 
(0.26) 
The parameter estimate for the intercept refers to the mean, and in the second line the 
parameter estimate is the difference between the two categories. Comparisons with P-
values <0.10 in at least one group are listed. 
1MTHFR 677TT individuals were removed for this analysis. 
2Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF)  
3ND = Not Detectable, D = Detectable (Summers et al. 2010) 
 
Biochemical Variables 
Relationships between tHcy and folate derivatives. In African Americans tHcy 
concentrations were inversely associated with total RBC folate (p=0.022, Table 2-5) and 
RBC 5-MTHF levels (p=0.022) and trended towards being inversely associated with 
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RBC THF (p=0.12) while being positively associated with plasma 5-MTHF levels 
(p=0.028). In Caucasians the ratio of RBC 5-MTHF:THF was inversely related to tHcy 
concentrations (p=0.009) and accordingly tHcy was inversely associated with RBC 5-
MTHF but only as a trend (p=0.12). In contrast to the inverse trend in African Americans, 
RBC THF levels were positively associated with tHcy concentrations in Caucasians 
(p=0.010). 
 Relationships among the folate derivatives. African Americans with detectable 
levels of RBC 5,10-MTHF had RBC THF levels that were 13.8 nmol/L higher than those 
with undetectable levels (31.7 vs 17.9 nmol/L, p=0.037, Table 2-4). In Caucasians a 
similar relationship was observed where detectable RBC 5,10-MTHF was associated with 
RBC THF levels that were 23.3 nmol/L higher than those with undetectable levels (47.4 
vs 24.1 nmol/L, p=0.089). Only in Caucasians was detectable RBC 5,10-MTHF 
associated with a lower ratio of RBC 5-MTHF:THF (35.9 vs 52.3, p=0.059). This 
suggests that these two folate derivatives, THF and 5,10-MTHF, share some degree of 
metabolic control.  
In African Americans, RBC 5-MTHF levels were positively associated with RBC 
THF levels (p=0.017, Table 2-5). Plasma 5-MTHF levels were positively associated with 
total RBC folate (p<0.0001), specifically with RBC 5-MTHF levels (p<0.0001) as well as 
the ratio of 5-MTHF:THF (p=0.001). In Caucasians, plasma 5-MTHF levels were 
positively associated with total RBC folate concentrations (p=0.017), specifically with 
RBC 5-MTHF levels (p=0.015). This relationship was similar to that observed in African 
Americans. 
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Relationships of tHcy and folate derivatives to B12 levels. In African 
Americans B12 levels were inversely associated with tHcy levels (p=0.049) and positively 
associated with total RBC folate (p=0.063), in particular with the folate derivatives 5-
MTHF (p=0.069) and THF (p=0.028). In Caucasians, B12 levels were positively 
associated with total RBC folate only as a trend (p=0.13), in particular B12 was 
significantly associated with THF levels (p=0.018). 
Table 2-5. Proportion of variation (R2) in biochemical variables explained by 
selected biochemical phenotypes. 
 Biochemical 
Phenotypes 
African-American (N=23) Caucasian (N=21)1 
Dependent 
Variables 
Explanatory 
Variables 
Parameter 
Estimate 
(SE) R2 (P-value) 
Parameter 
Estimate 
(SE) 
R2 (P-
value) 
tHcy (µmol/L) Total RBC folate 
(nmol/L) 2 
-0.003 
(0.001) 
0.23 (0.022) -0.002 
(0.001) 
0.08 
(0.22) 
 RBC 5-MTHF 
(nmol/L) 
-0.004 
(0.001) 
0.23 (0.022) -0.002 
(0.001) 
0.12 
(0.12) 
 RBC THF (nmol/L) -0.090 
(0.056) 
0.11 (0.12) 0.034 
(0.012) 
0.30 
(0.010) 
 Ratio RBC 5-
MTHF: THF 
-0.006 
(0.035) 
0.002 (0.86) -0.054 
(0.018) 
0.31 
(0.009) 
 Plasma 5-MTHF 
(nmol/L) 
0.065 
(0.028) 
0.21 (0.028) -0.026 
(0.019) 
0.09 
(0.19) 
 B12 (pmol/L) -0.004 
(0.002) 
0.17 (0.049) 0.003 
(0.002) 
0.07 
(0.24) 
Total RBC folate 
(nmol/L) 2 
Plasma 5-MTHF 
(nmol/L) 
16.12 
(2.46) 
0.67 
(<0.0001) 
6.63 (2.52) 0.27 
(0.017) 
 B12 (pmol/L) 0.58 (0.29) 0.16 (0.063) 0.56 (0.35) 0.12 
(0.13) 
RBC 5-MTHF 
(nmol/L) 
RBC THF (nmol/L) 18.06 
(6.95) 
0.24 (0.017) 0.46 (2.01) 0.003 
(0.82) 
 Plasma 5-MTHF 
(nmol/L) 
16.05 
(2.37) 
0.69 
(<0.0001) 
6.65 (2.47) 0.28 
(0.015) 
 B12 (pmol/L) 0.56 (0.29) 0.15 (0.069) 0.46 (0.35) 0.08 
(0.21) 
RBC THF 
(nmol/L) 
B12 (pmol/L) 0.018 
(0.008) 
0.21 (0.028) 0.09 (0.04) 0.26 
(0.018) 
Ratio RBC 5-
MTHF: THF 
Plasma 5-MTHF 
(nmol/L) 
0.57 (0.15) 0.41 (0.001) 0.09 (0.21) 0.01 
(0.68) 
Parameter estimate refers to the change in units of the dependent variable for every 1 unit 
increase in the explanatory variable. Comparisons with P-values <0.10 in at least one 
group are listed. (Summers et al. 2010) 1MTHFR 677TT individuals were removed for 
this analysis. 2Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF)  
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 Genetic associations with tHcy concentrations 
 In African Americans tHcy levels were 2.3 µmol/L higher in TYMS 1494del6 
del/del homozygotes than insertion carriers (10.2 vs 7.9 µmol/L, p=0.023, Table 2-6). 
MTR 2756AA homozygotes had 2.7 µmol/L higher tHcy than 2756G carriers (10.4 vs 7.7 
µmol/L, p=0.006). In Caucasians there were no MTR 2756GG homozygotes, however 
there was a significant difference between MTR 2756AA and 2756AG genotypes, 
specifically 2756AA homozygotes had 2.0 µmol/L higher tHcy than 2756AG 
heterozygotes (9.6 vs 7.6 µmol/L, p=0.017, Table 2-7). Caucasian MTHFR 677TT 
homozygotes had 3.2 µmol/L higher tHcy than 677C carriers (12.2 vs 9.0 µmol/L, 
p=0.012). MTHFR 1298C carriers had tHcy concentrations that were 1.8 µmol/L higher 
than 1298AA homozygotes (9.7 vs 7.9, p=0.031). 
Genetic associations with folate derivatives  
MTR 2756A>G. African American MTR 2756AA homozygotes had total RBC 
folate concentrations that were 286.4 nmol/L lower than 2756G carriers (777.2 vs 1063.6 
nmol/L, p=0.042, Table 2-6). In particular RBC 5-MTHF was 280.6 nmol/L lower in 
2756AA homozygotes (760.7 vs 1041.3 nmol/L, p=0.043). MTR 2756AA homozygotes 
also had 14.1 nmol/L lower plasma 5-MTHF (25.5 vs 39.6 nmol/L, p=0.049). In 
Caucasians MTR 2756AA homozygotes had a lower ratio of 5-MTHF:THF (37.2 vs 54.2, 
p=0.061, Table 2-7), which indicated that this polymorphism was associated with the 
proportional distribution of these two key forms of folate. 
MTRR 66A>G. African American MTRR 66G carriers had higher levels of 5-
MTHF and lower levels of THF than 66AA homozygotes, but neither of these differences 
were statistically significant. These differences were substantial enough for 66G carriers 
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Table 2-6. Proportion of variation (R2) in biochemical variables explained by 
selected genotypes in African Americans. 
   African-American (N=23) 
Dependent 
Variables Genotype 
 Parameter 
Estimate (SE) 
R2 
(P-value) 
tHcy (µmol/L) MTR 
2756A>G 
Intercept-AA 
      G Carrier 
10.4 (0.7) 
-2.7 (0.9) 
0.31 
(0.006) 
 TYMS 
1494del6 
Intercept-del/del 
      Ins Carrier 
10.2 (0.7) 
-2.3 (0.9) 
0.22 
(0.023) 
Total RBC folate 
(nmol/L) 1 
MTR 
2756A>G 
Intercept-AA 
      G Carrier 
777.2 (99.2) 
286.4 (131.9) 
0.18 
(0.042) 
RBC 5-MTHF 
(nmol/L) 
MTR 
2756A>G 
Intercept-AA 
      G Carrier 
760.7 (97.9) 
280.6 (130.2) 
0.18 
(0.043) 
RBC THF 
(nmol/L) 
RFC1 
80A>G 
Intercept-AA 
      G Carrier 
25.7 (2.8) 
-10.2 (3.4) 
0.30 
(0.007) 
Ratio RBC 5-
MTHF: THF 
MTRR 
66A>G 
Intercept-AA 
      G Carrier 
45.4 (3.9) 
13.8 (5.9) 
0.21 
(0.028) 
 TYMS 
5’ VNTR2 
Intercept-3R/3R 
      2R Carrier               
41.3 (4.4) 
17.2 (5.9) 
0.32 
(0.010) 
 RFC1 
80A>G 
Intercept-AA 
      G Carrier 
39.3 (4. 5) 
18.7 (5.5) 
0.35 
(0.003) 
Plasma 5-MTHF 
(nmol/L) 
MTR 
2756A>G 
Intercept-AA 
      G Carrier 
25.5 (5.1) 
14.1 (6.8) 
0.17 
(0.049) 
 TYMS 
5’ VNTR2 
Intercept-3R/3R 
      2R Carrier               
26.1 (5.7) 
14.4 (7.7) 
0.16 
(0.077) 
P-values <0.10 are listed. 
1Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF)  
2Genotypes containing 4R were removed from the analysis. (Summers et al. 2010) 
 
to have a higher ratio of 5-MTHF:THF (59.3 vs 45.5, p=0.028). In Caucasians there was 
no such relationship observed between this polymorphism and any of the folate 
derivatives. 
MTHFR 677C>T. In Caucasians, although total RBC folate concentrations were 
not significantly different between MTHFR 677C carriers and 677TT homozygotes, the 
individual folate derivatives were drastically different. MTHFR 677TT homozygotes had 
426.3 nmol/L lower RBC 5-MTHF levels (696.0 vs 1122.3 nmol/L, p=0.007). RBC THF 
was 419.7 nmol/L higher in 677TT homozygotes (457.2 vs 37.5 nmol/L, p<0.0001). 
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Hence the ratio of RBC 5-MTHF:THF was drastically lower in 677TT homozygotes (5.4 
vs 42.9, p=0.0004). RBC 5,10-MTHF was detectable in 4 out of 5 677TT homozygotes, 
in 10 out of 13 677CT heterozygotes, and in only 2 out of 8 677CC homozygotes 
(p=0.043, Table 2-8). The mean of the detectable concentrations was much higher in 
677TT homozygotes than the means of the detectable concentrations in 677CC and CT 
genotypes (149.4, 9.8, and 9.7 nmol/L, respectively). 
MTHFR 1298A>C. Caucasian MTHFR 1298C carriers had 27.0 nmol/L higher 
RBC THF levels than 1298AA homozygotes (49.1 vs 22.1 nmol/L, p=0.046). Although 
RBC 5-MTHF levels were not significantly different, the ratio of 5-MTHF:THF was 
lower in 1298C carriers (33.4 vs 55.6, p=0.008). 
TYMS 5’ VNTR and 1494del6. In African Americans TYMS 5’ VNTR 2R 
carriers had higher ratios of 5-MTHF:THF than 3R/3R homozygotes (58.5 vs 41.3, 
p=0.010). 2R carriers also had 14.4 nmol/L higher plasma 5-MTHF (40.5 vs 26.1 nmol/L, 
p=0.077). In Caucasians TYMS 1494del6 deletion carriers had total RBC folate levels that 
were 218.1 nmol/L higher than ins/ins homozygotes (1238.0 vs 1019.9 nmol/L, p=0.096). 
Specifically RBC 5-MTHF levels were 217.4 nmol/L higher in 1494del6 deletion carriers 
(1194.8 vs 977.4 nmol/L, p=0.092). Plasma 5-MTHF levels were 21.7 nmol/L higher in 
1494del6 deletion carriers (57.5 vs 35.8 nmol/L, p=0.030). 
RFC1 80A>G. African American RFC1 80G carriers had 10.2 nmol/L lower 
RBC THF levels than 80AA homozygotes (15.5 vs 25.7 nmol/L, p=0.007). Even though 
RBC 5-MTHF levels were not statistically different, 80G carriers had ratios of 5-
MTHF:THF that were higher than 80AA homozygotes (58.0 vs 39.3, p=0.003). A similar 
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relationship was observed in Caucasians, 80G carriers had higher ratios of 5-MTHF:THF 
(49.5 vs 26.5, p=0.012). 
Table 2-7. Proportion of variation (R2) in biochemical variables explained by 
selected genotypes in Caucasians. 
   Caucasian (N=26) 
Dependent 
Variables Genotype 
 Parameter 
Estimate (SE) 
R2 
(P-value) 
tHcy (µmol/L) MTHFR 
677C>T 
Intercept-C Carrier 
                         TT 
8.9 (0.5) 
3.2 (1.2) 
0.24 
(0.012) 
RBC 5-MTHF 
(nmol/L) 
MTHFR 
677C>T 
Intercept-C Carrier 
                         TT 
1122.3 (63.6) 
-426.3 (145.0) 
0.26 
(0.007) 
RBC THF 
(nmol/L) 
MTHFR 
677C>T 
Intercept-C Carrier 
                         TT 
37.5 (29.4) 
419.7 (67.1) 
0.62 
(<0.0001) 
Ratio RBC 5-
MTHF: THF 
MTHFR 
677C>T 
Intercept-C Carrier 
                         TT 
42.9 (4.0) 
-37.6 (9.2) 
0.41 
(0.0004) 
   Caucasian (N=21)1 
Homocysteine 
(µmol/L) 
MTHFR 
1298A>C 
Intercept-AA 
       C Carrier 
7.9 (0.6)  
1.8 (0.8)  
0.22 
(0.031) 
 MTR 
2756A>G 
Intercept-AA 
                AG 
9.6 (0.5)  
-2.0 (0.8)  
0.27 
(0.017) 
Total RBC folate 
(nmol/L) 2 
TYMS 
1494del6 
Intercept-ins/ins 
       Del Carrier 
1019.9 (101.7) 
218.1 (124.6) 
0.14 
(0.096) 
RBC 5-MTHF 
(nmol/L) 
TYMS 
1494del6 
Intercept-ins/ins 
       Del Carrier 
977.4 (100.2) 
217.4 (122.7) 
0.14 
(0.092) 
RBC THF 
(nmol/L) 
MTHFR 
1298A>C 
Intercept-AA 
       C Carrier 
22.1 (9.6) 
27.0 (12.7) 
0.19 
(0.046) 
Ratio RBC 5-
MTHF: THF 
MTHFR 
1298A>C 
Intercept-AA 
       C Carrier 
55.6 (5.6) 
-22.1 (7.4) 
0.32 
(0.008) 
 MTR 
2756A>G 
Intercept-AA 
                AG 
37.2 (5.0) 
17.0 (8.6) 
0.17 
(0.061) 
 RFC1 
80A>G 
Intercept-AA 
      G Carrier 
26.5 (7.0) 
23.0 (8.3) 
0.29 
(0.012) 
Plasma 5-MTHF 
(nmol/L) 
TYMS 
1494del6 
Intercept-ins/ins 
       Del Carrier 
35.8 (7.5) 
21.7 (9.2) 
0.23 
(0.030) 
P-values <0.10 are listed. (Summers et al. 2010) 
1MTHFR 677TT individuals were removed for this analysis. 
2Total RBC folate = (RBC 5-MTH) + (RBC THF) + (RBC 5, 10-MT) 
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Table 2-8. Distribution of MTHFR 677 genotypes in Caucasians by detection of RBC 
5,10-MTHF. 
  RBC 5,10-MTHF   
Genotype  
Not 
Detectable 
(n) 
Detectable 
(n) 
P 
value 
Detectable Mean 
(nmol/L) [Range]1 
MTHFR 
677 CC 6 2 0.043 9.8 [6.8-12.7] 
 CT 3 10 
 
9.7 [4.9-20.0] 
 TT 1 4 
 
149.4 [74.6-224.7] 
1Mean of individuals having detectable levels. (Summers et al. 2010) 
 
 Folate Phenotypes 
 Type I-IV folate phenotypes were defined in the publication of the LC/MRM/MS 
method of RBC folate derivative measurements (Huang et al. 2008). A Type I 
distribution of RBC folate derivatives was considered to be 5-MTHF >95% of total folate 
with THF and 5,10-MTHF each <5%. A Type II was considered to be 5-MTHF <95% 
with THF 5-20% and 5,10-MTHF still <5%. A Type III was 5-MTHF >55% with THF 
>20% and 5,10-MTHF >5%. A Type IV was 5-MTHF <55% with THF >20% and 5,10-
MTHF >5%. A depiction of Types I-IV with the Caucasians in this study is presented in 
Figure 2-3. When the number of individuals in each folate phenotype was broken down 
by MTHFR 677/1298 combined genotypes, it was obvious that the double heterozygotes 
(677CT/1298AC) and the 677TT/1298AA homozygotes were associated with Types II-
IV, while the four other combined genotypes were strictly Type I (Table 2-9). 
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Figure 2-3. Relative amounts of RBC folate derivatives in each folate phenotype in 
Caucasians. 
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Table 2-9. Number of Caucasians in each folate phenotype by MTHFR 677/1298 
combined genotypes. 
MTHFR 
677/1298 
Type I  II III IV 
CC/AA 4 0 0 0 
CC/AC 2 0 0 0 
CC/CC 2 0 0 0 
CT/AA 5 0 0 0 
CT/AC 5 3 0 0 
TT/AA 1 0 1 3 
(n) 
2.5 Discussion 
 High Hcy and low folate are associated with cardiovascular disease, which is 
relevant to the male population in the Industrial Workers study. Therefore, 
polymorphisms or interactions of polymorphisms which affect Hcy and folate levels 
could alter an individual’s risk of developing cardiovascular disease. MTHFR 677TT 
individuals have high tHcy levels and low folate levels in the Industrial Workers Study 
and other populations (Harmon et al. 1996; Jacques et al. 1996). MTHFR 677 TT 
individuals not only have altered folate/Hcy phenotypes but also they have altered risk of 
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diseases, whish are associated with high Hcy and low folate. A meta-analysis has 
established that MTHFR 677TT individuals are at 20% increased risk of venous 
thrombosis compared to 677CC individuals (Den Heijer et al. 2005).  
Large-scale studies by Dekou et al. (2001) and Fredriksen et al. (2007) found that 
CBS 844ins68 carriers had Hcy levels significantly lower than noncarriers. Other studies 
have not been able to find a statistically significant difference in fasting Hcy levels 
between CBS 844ins68 genotypes (De Stefano et al. 1998; Kluijtmans et al. 2003; Tsai et 
al. 2000; Tsai et al. 2009). Since the 844ins68 allele is reported to result in skipping of 
the inserted sequence, the proposed mechanisms by which the 844ins68 allele could have 
an effect are: an increase in CBS activity, an up regulation of the amount of mRNA, or 
perhaps this polymorphism is in linkage disequilibrium with another functional 
polymorphism (Tsai et al. 1996; Tsai et al. 1999).  
 MTHFR 677C>T and CBS 844in68 genotypes were shown to interact and effect 
Hcy levels in two studies in European males. The first study included several countries in 
Europe and found that the CBS 844ins68 allele may counterbalance the Hcy raising effect 
of the MTHFR 677TT genotype (De Stefano et al. 1998). The second study was from the 
United Kingdom and confirmed this finding (Dekou et al. 2001) while a third study also 
in the UK did not replicate this finding in a population at high risk for coronary artery 
disease (Bowron et al. 2005). The Industrial Workers study was based on a population of 
Northern Irish males and the results supported the finding that MTHFR 677TT 
homozygotes who were also CBS 844ins68 allele carriers had significantly lower tHcy 
levels than 677TT/844ins68 noncarriers. In addition serum folate concentrations were 
higher in 677TT/844ins68 carriers and this was a novel finding. Concentrations of tHcy 
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and folate in 677TT/844ins68 carriers were similar to those found in 677CC and 677CT 
individuals. The interaction of these polymorphisms has an impact on Hcy and folate 
phenotypes, therefore it is possible that gene-gene interactions could contribute to risk for 
diseases such as cardiovascular disease. The excess risk conferred by MTHFR 677TT 
homozygosity may be negated by CBS 844ins68 carrier status. Large studies with enough 
power to examine gene-gene interactions will be required to test this observation and to 
examine the effects of gene-gene interactions on disease risk. 
  A high Hcy and low folate phenotype is associated with pregnancy complications 
such as neural tube defects (NTDs), which is relevant to the female population in the 
Premenopausal Women study. The first proof that multivitamins containing folic acid 
could prevent NTDs came from a nonrandomized controlled trial by Smithells et al. 
(1980), which showed 0.6% of mothers given multivitamins had a child with an NTD 
compared to 5% of unsupplemented mothers who had a child with an NTD. The 
Premenopausal Women study represents a relevant population in which to study the 
effects of genetic polymorphisms and lifestyle factors on Hcy and folate levels. In this 
study African American and Caucasian analyses were carried out separately for several 
reasons. Biochemical variables as well as genotype distributions were significantly 
different between the two groups. African American and Caucasian women have 
different prevalences of pregnancy related complications. Caucasians have a higher 
prevalence of carrying a child with spina bifida compared to African Americans 
(Feuchtbaum et al. 1999) and conversely, African Americans have a higher prevalence of 
preeclampsia (Eskenazi et al. 1991), low-birth-weight infants, and preterm birth (Heron et 
al. 2010). An individual woman’s risk for poor pregnancy outcome is multifactorial and 
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complex, but may be due to lifestyle factors and genetic background. Therefore the 
Premenopausal Women Study was designed to use high precision methodology to 
compare the effect of folate related genotypes and lifestyle factors on biochemical 
phenotypes in a small number of African American and Caucasian women in order to 
elucidate the reasons for the differences in risk detailed above. 
 The MTHFR 677TT genotype is associated with high Hcy and low folate levels 
(Harmon et al. 1996; Jacques et al. 1996), and with increased risk for NTDs (van der Put 
et al. 1995; Whitehead et al. 1995). In the Premenopausal Women study there were no 
MTHFR 677TT homozygotes in African Americans and there were 5 (19.2%) in 
Caucasians. We observed that MTHFR 677TT homozygotes had higher tHcy levels and 
altered RBC folate distributions compared to 677C carriers. RBC folate distributions in 
677TT homozygotes consisted of relatively high THF and 5,10-MTHF and relatively low 
5-MTHF levels. These quantitative changes resulted in ratios of RBC 5-MTHF:THF that 
were lower in 677TT homozygotes. These altered RBC folate distributions are consistent 
with a study by Bagley and Selhub (1998) which found that MTHFR 677TT 
homozygotes had low RBC 5-MTHF and high RBC formylated THF levels. Since the 
677TT genotype was responsible for a large amount of the variation present in tHcy and 
folate levels, biochemical and genetic analyses in the Premenopausal Women study were 
performed in the subset of Caucasians that excluded the 677TT homozygotes. 
 Logically polymorphisms in enzymes of the folate/Hcy pathway should be 
associated with risk for NTDs based on their association with changes in the levels of 
Hcy and folate. The following polymorphisms confer risk via the mother’s genotype: 
MTR 2756G carriers, MTRR 66A carriers, MTHFD1 1958AA, RFC1 80GG, and DHFR 
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c.86+60_78 del/del (Brody et al. 2002; De Marco et al. 2003; Doolin et al. 2002; Johnson 
et al. 2004; Wilson et al. 1999). Polymorphisms which have an effect on Hcy and folate 
levels in the Premenopausal Women Study therefore are relevant to risk for carrying a 
child with NTDs. Genotype distributions for 5 of the 11 polymorphisms which we 
studied were significantly different between African American and Caucasian women. Of 
the above mentioned risk-associated genotypes only MTHFR 677TT and MTHFD1 
1958AA had higher frequencies in Caucasians while the other above mentioned genotype 
distributions were not significantly different. In Caucasians, the MTHFD1 1958G>A 
polymorphism was the only one that was not in Hardy-Weinberg equilibrium. This 
observation has been documented in other control populations, such as the Irish (Parle-
McDermott et al. 2006a). 
 In the Premenopausal Women study polymorphisms other than MTHFR 677C>T 
had a significant effect on folate/Hcy phenotype. The ratio of RBC 5-MTHF:THF may be 
a better indicator of alterations in RBC folate distribution than the absolute concentration 
of either of the individual folate derivatives. The following findings involving the ratio of 
5-MTHF:THF have not been previously investigated and are therefore novel. The 
MTHFR 1298A>C polymorphism has conflicting associations in the literature. The 
1298C allele has been associated with both increased RBC folate (Parle-McDermott et al. 
2006b) and increased Hcy (Ulvik et al. 2007). In the Premenopausal Women study 
Caucasians 1298C carriers had increased tHcy and were consistent with the finding by 
Ulvik et al. (2007). Also we found that Caucasian 1298C carriers had increased RBC 
THF and a lower ratio of 5-MTHF:THF.  
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The MTR 2756A>G polymorphism is associated with decreased Hcy levels 
(Fredriksen et al. 2007; Harmon et al. 1999; Tsai et al. 2009) and in the Premenopausal 
Women study both African American and Caucasian 2756G carriers had lower tHcy 
levels. Only African American 2756G carriers had higher total RBC folate, in particular 
RBC 5-MTHF, and higher plasma 5-MTHF. This agrees with a study by Chen et al. 
(2001) which also found that MTR 2756GG homozygotes had higher plasma folate and 
lower Hcy levels. 
 The TYMS 1494del6 polymorphism has been associated with increased RBC 
folate and decreased Hcy levels (Kealey et al. 2005). Results from the Premenopausal 
Women study were consistent; Caucasian deletion carriers had higher total RBC folate, in 
particular RBC 5-MTHF, and also had higher plasma 5-MTHF concentrations. In 
contrast to Caucasians, African American insertion carriers had lower tHcy levels. 
African Americans had a different distribution of TYMS 1494del6 genotypes than 
Caucasians such that there were not enough ins/ins individuals (n=2) to be analyzed 
separately and were therefore combined with the heterozygous genotype for analysis. In 
Caucasians the same was true for del/del individuals (n=2) and hence the small number of 
study subjects may be limiting the analyses of ‘rare’ homozygotes. The other 
polymorphism in TYMS examined in the Premenopausal Women study was the 5’ VNTR 
with 2 or 3 repeats (2R or 3R). African American 2R carriers had higher plasma 5-MTHF 
levels. This was in agreement with a study by Trinh et al. (2002), which showed that 
3R/3R homozygotes had lower plasma folate levels. Also in the Premenopausal Women 
study African American 2R carriers had higher ratios of RBC 5-MTHF:THF. 
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 The RFC1 80A>G polymorphism is associated with lower RBC folate 
concentrations (Stanislawska-Sachadyn et al. 2009). Our study found that African 
American 80G carriers had lower RBC THF levels and that in both African Americans 
and Caucasians 80G carriers had a higher ratio of RBC 5-MTHF:THF. It is unclear 
though how this polymorphism, which is in a transport protein, would have an effect on 
the distribution of RBC folates. 
 Multiple reports have established that Hcy and folate levels have an inverse 
relationship (Kang et al. 1987; Selhub et al. 1993). In the Premenopausal Women study 
total RBC folate, and in particular RBC 5-MTHF, had inverse relationships with tHcy in 
African Americans. In Caucasians RBC THF had a direct association with tHcy while the 
ratio of RBC 5-MTHF:THF had an inverse relationship with tHcy. This well established 
inverse relationship between Hcy and folate levels may not be so simple. Observations 
from our study indicate that individual folate derivatives or the ratio of RBC 5-
MTHF:THF may be more useful in predicting Hcy concentrations. Short term pools of 
folate represented by plasma folate should be directly related to long term pools of folate 
represented by RBC folate. In the Premenopausal Women study plasma 5-MTHF levels 
had a direct association with RBC 5-MTHF levels in both African Americans and 
Caucasians. 
 Vitamin B12 levels were inversely associated with Hcy and directly associated with 
folate levels in several studies (Konstantinova et al. 2007; Thuesen et al. 2010). In 
African Americans in the Premenopausal Women study B12 levels had an inverse 
relationship with tHcy and with the ratio of RBC 5-MTHF:THF and a direct relationship 
with total RBC folate, RBC 5-MTHF, and RBC THF. In Caucasians B12 levels only had a 
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direct relationship with RBC THF. These relationships indicate that B12 levels are 
important determinants of the generation of RBC THF from 5-MTHF, because MTR 
requires B12 as a cofactor in this reaction. 
 Smoking has been associated with higher Hcy and lower folate levels (Brown et al. 
2004b; Gabriel et al. 2006; Stanislawska-Sachadyn et al. 2008b) as well as poor 
pregnancy outcome, including orofacial clefts, preterm birth, and low-birth-weight 
infants (Meyer et al. 1976; Wyszynski et al. 1997). In the Premenopausal Women study 
African American smokers had lower total RBC folate, specifically 5-MTHF, as well as 
lower plasma 5-MTHF, which is consistent with other studies that found lower RBC 
folate in Caucasian smokers (Brown et al. 2004b; Gabriel et al. 2006). 
 In the literature alcohol use is associated with higher Hcy levels (Jacques et al. 2001; 
Laufer et al. 2004) and contradictorily with higher folate levels (Ubbink et al. 1998). 
African American alcohol users in the Premenopausal Women study had higher tHcy 
levels while Caucasian alcohol users had higher total RBC folate, in particular 5-MTHF. 
There are two plausible reasons that alcohol intake could be associated with higher folate 
levels. It is possible that the primary alcoholic beverage consumed was beer which 
contains folic acid (Ubbink et al. 1998) or that alcohol is capable of inhibiting MTR and 
causes a methylfolate trap, allowing for the accumulation of 5-MTHF (Mason and Choi 
2005). 
 Caucasians have a higher risk of carrying a child with spina bifida compared to 
African Americans (CDC 2009). The explanation for this difference in prevalence may 
lie in the differences in genotype frequencies and in the effect of lifestyle factors on 
biochemical phenotypes. The quantitatively precise methods used in this study to 
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measure individual folate derivatives allowed a detailed description of the effect of the 
polymorphisms in enzymes of the folate/Hcy pathway. Genetic and lifestyle factors 
which contribute to a dysregulation of folate/Hcy metabolism may increase risk for 
various clinical conditions, such as carrying a child with spina bifida. This study was 
relatively small and these preliminary findings should be confirmed in larger studies 
using similar analytical methods.  
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Chapter 3: Polymorphisms Associated with the Risk of Neural Tube Defects 
3.1 Abstract 
 Spina bifida is a neural tube defect which is associated with high Hcy and low 
folate. Spina bifida can be prevented with periconceptional supplementation with folic 
acid. The mechanism by which folate can prevent spina bifida is unknown. Common 
functional polymorphisms within genes of the enzymes of the folate/Hcy metabolic 
pathway are good candidates for examining the effect of genetic variants on the risk of 
spina bifida. These genetic variants are capable of conferring risk at both levels, the risk 
of the child and the risk of the mother for carrying a child with spina bifida.  
In the Neural Tube Defects study, which included approximately 500 families, we 
examined 7 polymorphisms within 5 genes of the enzymes of the folate/Hcy pathway. 
Transmission disequilibrium tests (TDT) were applied to child trios and mother trios to 
check for preferential transmission of any allele at both the level of the child and the 
mother. Hardy-Weinberg equilibrium was also assessed within each of the five subject 
types, which included children, mothers, fathers, maternal grandmothers, and maternal 
grandfathers, as a measure of deviation from the expected, and hence a possible causative 
genotype.  
We did not find any of the 7 polymorphisms to be significant within the TDT 
analyses. There were only two polymorphisms which deviated from Hardy-Weinberg 
equilibrium, which were MTHFR 677C>T in fathers and TYMS 1494del6 in children. In 
both instances the observed genotypes lacked a significant number of expected 
heterozygous genotypes while both wild-type and variant homozygous genotypes were 
equally overrepresented. This did not provide any clear evidence of at risk genotypes.   
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3.2 Introduction 
3.2.1 Neural Tube Defects 
Neural tube defect (NTD) is a general term which includes the birth defects spina 
bifida, anencephaly, and encephalocele. Spina bifida is itself a broad term for a group of 
medical conditions (such as myelomeningocele and meningocele). More specifically 
myelomeningocele is an open defect where a herniation of neural tissue is present as a 
saclike membrane on the spine due to failure of fusion of the neural tube. Meningocele is 
a closed defect, skin covered, where the meninges are herniated through the spine 
(Mitchell 2008). Anencephaly refers to failure of the neural tube to close resulting in 
missing parts of the brain and skull. Encephalocele refers to a saclike protrusion of the 
brain through the skull, again caused by failure of the neural tube to close completely. 
Spina bifida is a common congenital defect with a prevalence ranging from 0.2-3 
per 1,000 births according to regional and population-specific variation. The health costs 
associated with medical care for an individual with spina bifida are substantial because of 
increased risk for hydrocephalus, leg weakness and paralysis, bowel and bladder 
dysfunction, and orthopedic abnormalities such as hip dislocation (Mitchell et al. 2004).  
3.2.2 Folic Acid Fortification 
In 1991 a study was published by the Medical Research Council which showed 
that folic acid had a 72% protective effect (RR 0.28 [0.12-0.71]) in women who 
previously had a pregnancy affected by a NTD (Medical Research Council 1991). This 
established that periconceptional folic acid could prevent recurrence of NTDs. 
Subsequently a study by Cziezel and Dudas (1992) showed that first occurrence of NTDs 
could be prevented by periconceptional folic acid. Although the specific mechanism by 
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which folic acid provides a protective effect is unknown, the US Public Health service in 
1992 recommended that women planning to get pregnant should have 400 µg of folic 
acid per day (CDC 1992). This recommendation was supported by the results of a large 
nonrandomized intervention study which took place in the north and south regions of 
China (Berry et al. 1999). The protective effect of 400 µg folic acid was greater in the 
northern region which had a higher prevalence of NTDs, but still showed a protective 
effect in the southern region. 
United States 
Mandatory folic acid fortification of grain products was in place by 1998. It was 
designed to improve the folate status of reproductive aged women by increasing folic 
acid intake by an estimated 100 µg a day. A study by Jacques et al. (Jacques et al. 1999) 
compared pre- and post-fortification levels of folate and Hcy and found significantly 
increased folate and decreased Hcy concentrations as well as a reduction in the 
prevalence of folate deficiency (<7 nmol/L in plasma) from 22.0% to 1.7% (p<0.001) and 
also a reduction in the prevalence of hyperhomocysteinemia (>13 µmol/L) from 18.7% to 
9.8% (p<0.001). Rates of spina bifida births declined by approximately 20% after 
fortification (Honein et al. 2001; Williams et al. 2002). 
Canada 
Folic acid fortification of cereal grain products was mandatory by 1998 in Canada 
providing an estimated additional intake of 200 µg a day (Ray et al. 2002b). RBC folate 
levels in women of reproductive age increased by 41% after fortification (Ray et al. 
2002a). The prevalence of NTDs had declined by 46% when pre- fortification was 
compared with post-fortification rates (De Wals et al. 2007). 
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South America 
In Chile the Ministry of Health has required the addition of folic acid to wheat 
flour since 2000. The estimated additional intake of folic acid was designed to be 400 µg 
a day. Fortification caused both serum and RBC folate levels to increase in women of 
reproductive age when pre- and post-fortification levels were compared (Hertrampf et al. 
2003). The prevalence of NTDs decreased by 31% after fortification (Castilla et al. 
2003). 
Concerns 
Reservations about implementing folic acid fortification include the masking of 
B12 deficiency and increasing the risk for cancer. B12 deficiency is common in the elderly 
due to loss of ability to digest and absorb B12 from food. High intakes of folic acid may 
appear to cure macrocytic anemia, which is often the result of B12 deficiency (Johnson 
2007). In a recent study in the elderly high serum folate levels accompanying B12 
deficiency were associated with twice the rate of anemia and cognitive impairment when 
compared with normal serum folate levels and B12 deficiency (Morris et al. 2007). As for 
cancer risk, in a study in ischemic heart disease patients those taking folic acid had an 
increased rate of cancer, hazard ratio (HR) 1.21 [1.03-1.41] (Ebbing et al. 2009). Folic 
acid supplementation is also associated with increased risk of colorectal neoplasia in 
those with a recent history of colorectal adenomas (Cole et al. 2007), and hence the worry 
is that pre-existing cancers will grow.   
3.2.3 Selected Polymorphisms Associated with NTDs 
The process of neural tube closure involves tightly controlled expression of genes, 
which relies upon specific methylation patterns, proliferation/apoptosis, migration, and 
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differentiation of specific cells (Beaudin and Stover 2007). Many of these processes 
overlap with important functions of the folate/Hcy pathway such as methylation of DNA 
and proteins as well as nucleotide synthesis. Compared to mothers that had normal 
pregnancies, mothers that gave birth to children with spina bifida had lower folate levels 
and also higher Hcy concentrations (Lucock et al. 1998). This dysregulation of folate/Hcy 
phenotype has led to the examination of genetic variants in candidate genes, specifically 
of common functional polymorphisms within enzymes of the folate/Hcy metabolic 
pathway. 
Family history of NTDs is a strong risk factor and in siblings of affected 
individuals risk of NTD ranges from 2.4-5.2%, which is much higher than prevalences in 
the general population (Carter and Evans 1973; Hunter 1984). There are two basic study 
types which are capable of analyzing the risk between genetic variants and NTDs. A 
case-control study compares genotype frequencies between these two groups and arrives 
at an estimate of the odds ratio (OR). A family-based study uses either the transmission 
disequilibrium test (TDT) or log-linear modeling to assess the transmission of alleles or 
the frequencies of mating types (parents’ genotypes) and outcomes (child’s genotype), 
respectively. Another less specific test for association is whether the genotypes are in 
Hardy-Weinberg equilibrium. Overrepresentation of a homozygous genotype above the 
expected value calculated from the Hardy-Weinberg equation could mean that the 
genotype is associated with the medical condition. This test is less specific because there 
is a range of reasons that genotype frequencies could deviate from Hardy-Weinberg 
equilibrium, including inbreeding, non-random mating, selection, or even a problem with 
the genotyping method itself.  
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MTHFR 677C>T and 1298A>C 
Two studies initially found that the MTHFR 677TT genotype was associated with 
increased risk of spina bifida via case-control studies (van der Put et al. 1995; Whitehead 
et al. 1995). Some studies were not able to show that this polymorphism confers risk for 
NTDs (Mornet et al. 1997; Papapetrou et al. 1996). A meta-analysis by Botto and Yang 
(2000) confirmed that the MTHFR 677TT genotype carried increased risk for spina bifida 
in both infants as well as mothers with a pooled odds ratio of 1.8 and 2.0, respectively. 
Subsequently Kirke et al. (2004)  showed that the 677CT genotype also carried increased 
risk in a case-control study. When the population attributable fraction was calculated the 
677CT genotype was responsible for a similar number of NTDs within the Irish 
population as the 677TT genotype (14.9% vs 11.3%, respectively). 
When MTHFR 1298A>C genotypes were studied in combination with the 
677C>T genotypes in a NTD study from the Netherlands, none of the combination 
genotypes had a significantly increased OR (van der Put et al. 1998), but in vitro 
experiments on MTHFR enzyme activity showed the 677CT/1298AC double 
heterozygotes had decreased activity compared to heterozygosity for either 
polymorphism alone. An Italian NTD study found increased risk for 1298C carriers in 
children and mothers (OR 2.2 and 2.7, respectively) although there was no stratification 
by 677C>T genotypes (De Marco et al. 2002).  
CBS 844ins68 
CBS 844ins68 genotypes were not associated with the risk of NTDs in an Irish 
study (Ramsbottom et al. 1997). It was noted that in this study among those who were 
MTHFR 677TT homozygotes there was a higher percentage of CBS 844ins68 carriers in 
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children with NTDs compared to controls (27.0% vs 12.8%, respectively) but this was 
not statistically significant. Reanalysis of this study’s data by Botto and Mostroiacovo 
(1998) found significantly increased risk of NTDs in MTHFR 677TT/CBS 844ins68 
carriers, OR 5.2 [1.4-21.2]. Another study found similar results that the CBS 844ins68 
polymorphism alone carries no significant risk but that the combination genotype 
MTHFR 677TT/CBS 844ins68 carrier had an OR of 3.69 [1.04-13.50] (de Franchis et al. 
2002). A UK study also found that MTHFR 677C>T and CBS 844in68 interacted to 
significantly increase NTD risk in children (Relton et al. 2004 Apr). A study in Germany 
was unable to replicate these findings using case-control and TDT analyses (Richter et al. 
2001). Overall the evidence is compelling that this combination of genotypes may 
increase risk for NTDs. Although this combination of genotypes has been associated with 
lower Hcy concentrations in men (De Stefano et al. 1998; Dekou et al. 2001; Summers et 
al. 2008b), it is possible that during development it could have a different effect.  
TYMS 5’ VNTR and 1494del6 
A study by Volcik et al. (2003) found that in Caucasians both the TYMS 1494del6 
ins/ins genotype, OR 3.6 [1.3-10.1], and the TYMS 5’ VNTR 2R/2R genotype, OR 4.0 
[1.8-8.8], were associated with increased NTD risk in children. Also the combined TYMS 
ins/ins and 2R/2R genotype was significantly associated with increased risk, OR 4.7 [1.1-
19.8]. A subsequent study in the UK did not find any association between TYMS 5’ 
VNTR genotypes and risk of NTDs using case-control and TDT analyses (Wilding et al. 
2004). 
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DHFR c.86+60-78 
 In a US study by Johnson et al. (2004) found that the DHFR c.86+60_78 del/del 
genotype was more frequent in mothers than controls, OR 2.04 [0.94-4.29], and genotype 
frequencies were not in Hardy-Weinberg equilibrium in mothers. In contrast a study 
found that the DHFR c.86+60_78 deletion allele provided a protective effect in mothers 
in an Irish population (Parle-McDermott et al. 2007). A study in the Netherlands did to 
find any association between DHFR c.86+60_78 genotypes and NTD risk in a case-
control study (van der Linden et al. 2007). 
 MTHFD1 1958G>A 
 A study by Brody et al. (2002) in the Irish showed that the MTHFD1 1958AA 
genotype was overrepresented in mothers of NTD children compared to controls, OR 
1.52 [1.16-1.99]. A second Irish study confirmed that the MTHFD1 1958AA genotype 
was associated with increased NTD risk in mothers, OR 1.49 [1.07-2.09] (Parle-
McDermott et al. 2006a), which was consistent with their earlier finding using a separate 
cohort. In an Italian population it was found that both 1958GA (OR 1.69) and 1958AA 
(OR 1.91) individuals had increased risk of NTD in children (De Marco et al. 2006). Also 
this study found that mothers who were carriers of the 1958A allele had increased risk 
(OR 1.67) and that TDT analyses confirmed there was a significant excess transmission 
of the 1958A allele. 
 The selected polymorphisms discussed above were chosen based on their 
association with NTD risk and were genotyped in a large family based study in the US 
population. 
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3.3 Methods 
3.3.1 NTD Study 
Subjects 
The NTD study included 671 families with at least one member affected with 
spina bifida., as previously described (Mitchell 2008). The family structure that this study 
intended to capture was a “pent”. A complete pent includes the affected child, mother, 
father, and maternal grandparents. This design allows for assessment of maternal and 
embryonic genetic effects. Families were recruited between November 1997 and April 
2006 by the Spina Bifida Research Resource through the Children’s Hospital of 
Philadelphia in Philadelphia, Pennsylvania; the Alfred I. Dupont Hospital for Children in 
Wilmington, Delaware; local chapters of the Spina Bifida Association of America; 
colleagues; and the study website. The study was approved by the Institutional Review 
Boards of the Texas A&M University, the University of Pennsylvania School of 
Medicine, and each of the participating hospitals. Each subject gave informed consent 
and when appropriate assent was given. Interview information included pregnancy 
history, supplement use, and details of the affected individual’s lesion. 
Affected individuals and their families were excluded if spina bifida was 
determined to be syndromic (due to pregestational diabetes, teratogenic exposure to 
anticonvulsant medication, or suspected co-occurring syndrome such as deletion of 
22q11), failure to complete the interview, or type of neural tube defect. Subsequent 
analyses were based on affected individuals with open spina bifida. The characteristics of 
the affected individuals include a slight predominance of females and a majority of non-
Hispanic Caucasians as previously described (Mitchell 2008). It should be noted that 
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interview data was not directly accessible during these statistical analyses and therefore 
subgroup analyses are not included. 
Genotyping 
Genomic DNA was extracted from whole blood using Generation Capture 
Columns (Gentra Systems) or using QIAamp DNA Mini Kits (Qiagen) according to the 
manufacturer’s instructions. DNA was extracted from saliva samples using Oragene kits 
(DNA Genotek Inc, Ontario, Canada) according to the manufacturer’s instructions. DNA 
was also extracted from buccal swabs using the following procedure. Samples were 
vortexed for 5min in 600ul 50mM NaOH, heated at 95°C for 10min and neutralized with 
120ul 1M Tris (pH 8.0). 
TaqMan genotyping methods were performed as previously described for 
MTHFR 677C>T (Summers et al. 2008a), MTHFR 1298A>C (Summers et al. 2008a), 
and MTHFD1 1958G>A (Summers et al. 2010). Genotypes were only accepted as valid 
for TaqMan runs in which the Fam or Vic signals crossed the threshold, which was set 
based on background signals of Fam and Vic, with Ct fewer than 40 cycles. The MTHFR 
677C>T assay had a 10% failure rate compared to 1-3% for the other TaqMan assays; 
most of the MTHFR 677C>T assay failures occurred in DNA derived from buccal 
samples. 
Size difference PCR assays were performed essentially as previously described 
for CBS 844ins68 (Summers et al. 2010), DHFR c.86+60_78, TYMS 1494del6 (Summers 
et al. 2008a), and TYMS 5’ VNTR (Summers et al. 2010) with the following changes. The 
CBS 844ins68 assay used modified primer sequences, forward (5’-
GGTTTCTCATCCTGCCTCTG-3’) and reverse (5’-GTTGTCTGCTCCGTCTGGTT-
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3’). TYMS 5’UTR genotypes were deemed unreliable in buccal samples and therefore 
genotypes were accepted for only blood and saliva samples, which were considered to be 
high quality DNA samples. 
Statistics 
 All statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, 
NC). Hardy-Weinberg equilibrium was tested for all 7 polymorphisms within each of the 
subject types. The transmission disequilibrium test (TDT) (Spielman et al. 1993) 
determines whether the frequency of allele transmission from heterozygous parents to 
affected offspring differs significantly from the Mendelian expectation of equal 
transmission of the alleles. TDT analyses were calculated for each polymorphism in child 
trios (child, mother, and father) and mother trios (mother, maternal grandmother, and 
maternal grandfather). Individuals with TYMS 5’ VNTR genotypes containing the 4R 
allele were excluded from the TDT analyses. Families with more than one affected child 
were included with one trio for each child. 
3.4 Results 
 3.4.1 NTD Study 
 After applying exclusion criteria there were 490 children with spina bifida, 501 
mothers, 399 fathers, 240 maternal grandmothers, and 182 maternal grandfathers. 
Genotype frequencies within each of the subject types are listed in Table 3-1. All 
genotypes were in Hardy-Weinberg equilibrium except for MTHFR 677C>T in fathers 
and TYMS 1494del6 in children. Deviation from Hardy-Weinberg equilibrium would be 
expected if a polymorphism was associated with risk of spina bifida. In fathers the 
expected values for MTHFR 677CC, CT, and TT genotypes were 153, 164, and 44, 
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respectively. There was a lack of heterozygotes and an almost equal over abundance of 
CC and TT individuals, which does not indicate a clear at risk genotype. The same was 
true for TYMS 1494del6 genotypes in children for which the expected values for ins/ins, 
ins/del, and del/del were 231, 204, and 45, respectively.  
Table 3-1. Genotype frequencies in the NTD study. 
  
Child Mother Father 
Maternal 
Grandmother 
Maternal 
Grandfather 
CC 197 (44.7) 210 (44.5) 161 (44.6)* 87 (42.7) 77 (51.3) 
CT 188 (42.6) 204 (43.2) 147 (40.7) 91 (44.6) 57 (38.0) 
MTHFR 
677 
TT 56 (12.7) 58 (12.3) 53 (14.7) 26 (12.8) 16 (10.7) 
AA 234 (50.2) 243 (49.2) 190 (49.1) 108 (47.6) 82 (48.0) 
AC 190 (40.8) 201 (40.7) 154 (39.8) 101 (44.5) 68 (39.8) 
MTHFR 
1298 
CC 42 (9.0) 50 (10.1) 43 (11.1) 18 (7.9) 21 (12.3) 
W/W 407 (86.2) 402 (81.7) 334 (86.5) 182 (79.8) 145 (84.3) 
W/I 62 (13.1) 84 (17.1) 50 (13.0) 44 (19.3) 24 (14.0) 
CBS 
844ins68 
I/I 3 (0.6) 6 (1.2) 2 (0.5) 2 (0.9) 3 (1.7) 
GG 147 (31.3) 161 (32.9) 112 (29.0) 75 (32.6) 63 (36.4) 
GA 239 (51.0) 234 (47.9) 197 (51.0) 118 (51.3) 78 (45.1) 
MTHFD1 
1958 
AA 83 (17.7) 94 (19.2) 77 (20.0) 37 (16.1) 32 (18.5) 
Ins/ins 154 (32.2) 165 (33.7) 124 (32.5) 75 (33.0) 57 (33.7) 
Ins/del 222 (46.4) 229 (46.8) 183 (47.9) 109 (48.0) 80 (47.3) 
DHFR 
c.86+60_78 
Del/del 102 (21.3) 95 (19.4) 75 (19.6) 44 (19.0) 32 (19.0) 
Ins/ins 243 (50.6)* 221 (44.3) 196 (49.6) 107 (45.3) 85 (48.9) 
Ins/del 180 (37.5) 220 (44.1) 165 (41.8) 105 (44.5) 71 (40.8) 
TYMS 
1494del6 
Del/del 57 (11.9) 58 (11.6) 34 (8.6) 24 (10.2) 18 (10.3) 
2R/2R 65 (23.6) 65 (21.2) 49 (21.3) 24 (22.0) 20 (27.0) 
2R/3R 120 (43.6) 153 (50.0) 116 (50.4) 58 (53.2) 31 (41.9) 
3R/3R 87 (31.6) 86 (28.1) 63 (27.4) 27 (24.8) 23 (31.1) 
2R/4R 1 (0.4) 0 0 0 0 
TYMS 5’ 
VNTR 
3R/4R 2 (0.7) 2 (0.7) 2 (0.9) 0 0 
N (%). *Hardy-Weinberg equilibrium p<0.05. 
MTHFR 677 and 1298 genotypes were combined and are displayed in Table 3-2 
by subject type. The MTHFR 677T allele is in linkage disequilibrium with the 1298A 
allele, and therefore the 677T allele does not occur on the same chromosome as the 
1298C allele unless a very rare crossover event has occurred. There was evidence of two 
such chromosomal crossover events in the genotypes of this study, evidenced by MTHFR 
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677TT/1298AC and MTHFR 677CT/1298CC genotypes, which were both found in 
mothers. 
Table 3-2. MTHFR 677/1298 combined genotypes. 
  MTHFR 1298 
Child  AA AC CC 
CC 63 (14.4) 93 (21.3) 39 (8.9) 
CT 101 (23.1) 86 (19.7) 0 MTHFR 677 
TT 55 (12.6) 0 0 
  MTHFR 1298 
Mother  AA AC CC 
CC 60 (12.8) 99 (21.1) 48 (10.2) 
CT 111 (23.7) 92 (19.6) 1 (0.2) MTHFR 677 
TT 57 (12.2) 1 (0.2) 0 
  MTHFR 1298 
Father  AA AC CC 
CC 44 (12.4) 71 (19.9) 42 (11.8) 
CT 75 (21.1) 72 (20.2) 0 MTHFR 677 
TT 52 (14.6) 0 0 
Maternal  MTHFR 1298 
Grandmother  AA AC CC 
CC 24 (11.9) 47 (23.3) 16 (7.9) 
CT 47 (23.3) 44 (21.8) 0 MTHFR 677 
TT 24 (11.9) 0 0 
Maternal  MTHFR 1298 
Grandfather  AA AC CC 
CC 25 (16.8) 32 (21.5) 20 (13.4) 
CT 34 (22.8) 23 (15.4) 0 MTHFR 677 
TT 15 (10.1) 0 0 
N (overall %). 
TYMS 5’ VNTR and 1494del6 genotypes were combined and are displayed in 
Table 3-3 by subject type. Since TYMS 5’ VNTR genotypes were completed only on high 
quality DNA samples, there were combined genotypes available for only 275 children, 
305 mothers, 230 fathers, 109 maternal grandmothers, and 73 maternal grandfathers. The 
TYMS 5’ VNTR 2R allele is in linkage disequilibrium with the TYMS 1494del6 insertion 
allele, and therefore the 2R allele does not occur on the same chromosome as the 
1494del6 deletion allele unless a very rare crossover event has occurred. The TYMS 
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2R/2R and del/del combined genotype only appeared in mothers and children and not in 
the other subject types. Also the TYMS 2R/3R and del/del combined genotype frequency 
was highest in children (2.6%) compared to mothers (2.0%), fathers (1.7%), maternal 
grandmothers (1.8%), and maternal grandfathers (absent). The TYMS 5’ VNTR 4R allele 
is rare and only appeared in children, mothers, and fathers, although this could be due to 
the smaller number of maternal grandparents in the study. 
None of the 7 polymorphisms had significant results in the TDT analyses in child 
trios and in mother trios (data not shown). An example of the data used in the TDT 
analyses is presented in Table 3-4 for MTHFR 677C>T in child trios. There were 304 
complete child trios that had no MTHFR 677C>T genotypes missing, and 147 trios were 
considered to be non-informative mostly because both parents were homozygous. There 
were 191 heterozygous parents which provided informative transmissions and 90 (47.1%) 
of those were for the 677T allele. 
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Table 3-3. TYMS 5’VNTR/1494del6 combined genotypes. 
  TYMS 1494del6 
Children  Ins/ins Ins/del Del/del 
2R/2R 52 (18.9) 11 (4.0) 2 (0.7) 
2R/3R 67 (24.4) 46 (16.7) 7 (2.6) 
3R/3R 24 (8.7) 35 (12.7) 28 (10.2) 
2R/4R 1 (0.4) 0 0 
TYMS 5’ 
VNTR 
3R/4R 0 2 (0.7) 0 
  TYMS 1494del6 
Mothers  Ins/ins Ins/del Del/del 
2R/2R 48 (15.7) 15 (4.9) 1 (0.3) 
2R/3R 66 (21.6) 81 (26.6) 6 (2.0) 
3R/3R 21 (6.9) 41 (13.4) 24 (7.9) 
2R/4R 0 0 0 
TYMS 5’ 
VNTR 
3R/4R 1 (0.3) 0 1 (0.3) 
  TYMS 1494del6 
Fathers  Ins/ins Ins/del Del/del 
2R/2R 41 (17.8) 8 (3.5) 0 
2R/3R 59 (25.7) 53 (23.0) 4 (1.7) 
3R/3R 17 (7.4) 32 (13.9) 14 (6.1) 
2R/4R 0 0 0 
TYMS 5’ 
VNTR 
3R/4R 1 (0.4) 0 1 (0.4) 
Maternal  TYMS 1494del6 
Grandmothers  Ins/ins Ins/del Del/del 
2R/2R 16 (14.7) 8 (7.3) 0 
2R/3R 33 (30.3) 23 (21.1) 2 (1.8) 
3R/3R 5 (4.6) 16 (14.7) 6 (5.5) 
2R/4R 0 0 0 
TYMS 5’ 
VNTR 
3R/4R 0 0 0 
Maternal  TYMS 1494del6 
Grandfathers  Ins/ins Ins/del Del/del 
2R/2R 17 (23.3) 3 (4.1) 0 
2R/3R 17 (23.3) 14 (19.2) 0 
3R/3R 5 (6.9) 10 (13.7) 7 (9.6) 
2R/4R 0 0 0 
TYMS 5’ 
VNTR 
3R/4R 0 0 0 
N (overall %). 
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Table 3-4. MTHFR 677C>T mating types in child trios with number of allele 
transmissions. 
Mating Type (Mother 
x Father = Child) 
Transmission of 
Specific Allele 
Number of 
Transmissions n(%) 
Informative Trios   
CC x CT = CC 
CT x CC = CC 
CT x CT = CC* 
TT x CT = CT 
CT x TT = CT 
C 101 (52.9) 
CC x CT = CT 
CT x CC = CT 
CT x CT = TT* 
TT x CT = TT 
CT x TT = TT 
T 90 (47.1) 
Non-Informative Trios   
CC x CC = CC 
CT x CT = CT 
TT x TT = TT 
CC x TT = CT 
TT x CC = CT 
  
*Counts as transmission of 2 C or 2 T alleles, respectively. 
3.5 Discussion 
 The NTD study investigated 7 polymorphisms in enzymes of the folate/Hcy 
metabolic pathway for risk of NTDs. TDT analyses did not find over transmission of any 
of the alleles. Hardy-Weinberg equilibrium was distorted for two of the polymorphisms 
but examination of expected values revealed no over representation of either homozygous 
genotype. In MTHFR 677/1298 combined genotypes two rare crossover events were 
observed only in mothers’ genotypes. In TYMS 5’VNTR/1494del6 combined genotypes 
children and mothers were the only groups that had the rare 2R/2R and del/del combined 
genotypes. It is possible that these rare combination genotypes may carry increased risk. 
A large study in NTDs based in California examined 118 SNPs and found that 15 
polymorphisms in 7 genes were significantly associated in children with spina bifida 
(Shaw et al. 2009). This California based study found that the MTHFR 677C>T 
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polymorphism was significantly associated OR 2.0 [1.2-3.1]. Another US study in NTDs 
which examined 28 polymorphisms in 11 genes found that only a SNP in betaine-
homocysteine methyltransferase (BHMT) was significantly associated with NTDs in the 
overall data set, although the MTHFR 677C>T polymorphism was not associated with 
increased risk. The association with the polymorphism in BHMT was stronger in mothers 
who took folate containing supplements before conception and when the MTHFR 677T 
allele was also transmitted from parent to offspring (Boyles et al. 2006).  
There have been several publications which found that specific genotypes were 
associated with risk for NTDs using the early phases of the NTD study before sample 
collection had been completed. It was previously published that increased NTD risk was 
associated with transcription factor T IVS7C allele in children (Jensen et al. 2004), NOS3 
894T in children (Brown et al. 2004a), MCP1 -2518AA in mothers (Jensen et al. 2006a), 
and that loss of function polymorphisms in NAT1 protect against spina bifida in mothers 
and children (Jensen et al. 2006b). Brown et al. (2004a) evaluated the NOS3 894G>T 
genotypes by TDT and log-linear analyses. The TDT revealed no association while the 
log-linear analyses revealed that the embryonic, but not maternal, genotype was 
associated with risk of spina bifida. While we have genotyped the full collection of 
samples, we have used the methodologically simpler TDT analyses and a lack of more 
complex analyses may have resulted in failure to see an association with any of these 7 
polymorphisms. Another important classification which should be applied would be to 
subset the analyses by year of birth to account for folic acid fortification. Some genetic 
polymorphisms may have more of an influence on NTD risk in the pre-fortification era 
when folate levels were lower.   
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 The primary strength of this study was the ability to assess the risk associated 
with 7 polymorphisms in 5 genes at the level of the child and the mother. The limitation 
of this study is that a control population was not collected during the study and hence the 
calculation of odds ratios and gene-gene interactions is absent. Although the results of the 
TDT analyses did not indicate that any allele was associated with the risk of spina bifida, 
further analyses of these genotypes using other statistical models or subsets of the study 
may reveal a significant impact.  
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Chapter 4: Polymorphisms in the Context of Inflammatory Diseases: Systemic 
Lupus Erythematosus and Rheumatoid Arthritis 
 
4.1 Abstract 
 High Hcy and low folate levels are associated with inflammatory diseases such as 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In healthy 
individuals common functional polymorphisms of enzymes in the folate/Hcy pathway 
have a significant impact on these metabolite levels. The SLE study was designed to 
examine the effects of these polymorphisms on tHcy concentrations and coronary artery 
calcification (CAC) scores. Genotypes for 7 polymorphisms within 6 genes of the 
enzymes of the folate/Hcy pathway were completed in 163 female SLE cases and 160 
matched controls. African American SLE cases had higher tHcy levels than Caucasian 
cases and African American controls. For 6 of the 7 polymorphisms genotype 
distributions were significantly different between African American and Caucasian 
controls. There were no significant differences in genotype distributions between SLE 
cases and controls even after stratification by race.  
The effects of genetic polymorphisms on tHcy levels were examined within 
general linear models which adjusted for glomular filtration rate (GFR) as a covariate 
because it was strongly negatively correlated to tHcy levels. In SLE patients of both races 
none of the 7 polymorphisms had a significant impact on tHcy levels. In Caucasian 
controls MTHFR 677CT and 677TT individuals had higher tHcy levels than 677CC 
homozygotes. Also in Caucasian controls MTHFR 1298C carriers had lower tHcy levels 
than 1298AA homozygotes. None of the polymorphisms were associated with CAC 
scores in SLE patients or controls even after stratification by race. In SLE cases 
  
65 
polymorphisms in folate/Hcy metabolizing enzymes do not have an impact on tHcy 
concentrations or CAC scores. 
Rheumatoid arthritis is a chronic inflammatory disease associated with elevated 
Hcy levels. Methotrexate (MTX), an anti-folate, is classified as a disease-modifying anti-
rheumatic drug (DMARD), and used at low doses to treat inflammatory diseases. 
Polymorphisms in the enzymes of the folate/Hcy pathway are involved in the metabolism 
of MTX and may therefore influence efficacy and/or toxicity. The RA study was 
designed to examine the effects of these polymorphisms on tHcy and folate derivative 
levels in plasma and red blood cells. Also associations between these polymorphisms and 
clinical variables, such as physician global assessment (PGA) scores, were examined. In 
the RA study there were 252 RA subjects defined as current users of MTX and 37 RA 
subjects defined as discontinued users of MTX. Genotypes were completed for 11 
polymorphisms in 9 genes in enzymes of folate/Hcy metabolism. THcy, plasma folic 
acid, and folate derivatives in plasma and red blood cells were measured using stable 
isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry. 
C reactive protein and B12 levels were measured and PGA scores and American 
Rheumatism Association classes were assigned by physicians. 
In African Americans MTHFD1 1958G>A genotypes had significantly different 
distributions when current users and discontinued users were compared. MTHFD1 
1958G>A genotypes may be associated with discontinuation of MTX therapy. In 
Caucasians discontinuation of MTX therapy was associated with MTHFR 1298A>C 
genotypes. Several of the investigated polymorphisms were found to have a significant 
impact on tHcy and folate derivative levels in African American and Caucasian current 
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users. MTR 2756A>G genotypes were associated with attributable toxicities in African 
American current users. In Caucasian current users MTHFD1 1958G>A genotypes were 
associated with attributable toxicities. In both African American and Caucasian current 
users CRP levels were positively correlated with total RBC folate levels and with levels 
of specific RBC folate derivatives. 
4.2 Introduction 
4.2.1 Systemic lupus erythematosus 
 Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which 
predominates in women and African Americans (Simard and Costenbader 2007). 
Premature atherosclerotic cardiovascular disease is a common comorbidity in those with 
SLE (Manzi et al. 1997). Electron beam computed tomography (EBCT) is used to 
measure coronary artery calcification (CAC), which is a subclinical sign of premature 
atherosclerotic cardiovascular disease. CAC scores are positively correlated with risk of 
future cardiovascular events (Arad et al. 2005). Atherosclerosis progression depends on 
multiple factors and a low folate/high Hcy phenotype is associated with increased risk of 
cardiovascular disease. In the general population elevated Hcy levels are associated with 
a relative risk (RR) of 2.2 [1.6-2.9] for cardiovascular disease (Graham et al. 1997). SLE 
patients have higher Hcy concentrations compared to matched controls (Afeltra et al. 
2005; Bruce et al. 2003; Von Feldt et al. 2006). Hcy levels were found to be positively 
correlated with CAC scores in SLE patients (Von Feldt et al. 2006). The SLE study was 
undertaken to examine if polymorphisms in enzymes of the folate/Hcy metabolic 
pathway have any effect on tHcy levels and/or CAC scores in SLE patients. 
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4.2.2 Rheumatoid arthritis 
 Rheumatoid arthritis (RA) is a systemic inflammatory disease where 
inflammation leads to joint damage and eventually functional impairment. RA affects 
about 1% of the general population (Pugner et al. 2000). RA is associated with elevated 
Hcy levels compared to controls (Hernanz et al. 1999; Wallberg-Jonsson et al. 2002). 
High Hcy levels were associated with atherothrombotic events in a study in RA patients 
from Sweden (Berglund et al. 2009). 
 Methotrexate 
 Low dose methotrexate (MTX) therapy is one of the most commonly prescribed 
disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatoid 
arthritis (Whittle and Hughes 2004). MTX therapy is associated with decreases in joint 
swelling and pain as well as stopping progression of joint damage (Brinker and 
Ranganathan 2010). MTX is an anti-folate drug, which at high doses is used to treat 
cancers due to its anti-proliferative effect. The anti-inflammatory mechanisms of MTX in 
the treatment of RA have not been clearly defined. MTX is transported into cells by 
reduced folate carrier 1 (RFC1) and once it enters the cell it becomes polyglutamated. 
MTX is a structural analog of folic acid that inhibits enzymes involved in folate 
metabolism and nucleotide synthesis. MTX inhibits the following enzymes: dihydrofolate 
reductase (DHFR), thymidylate synthase (TYMS), glycinamide ribonucleotide 
transformylase (GART), and aminoimidazolecarboxamide ribonucleotide transformylase 
(AICART) (Kremer 2004). 
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Folic acid 
 RA patients taking MTX also take folic acid supplements for the prevention of 
adverse events (Whittle and Hughes 2004). Evidence from a randomized placebo-
controlled trial of folic acid supplementation showed that folic acid decreased toxicity 
without affecting efficacy in RA patients taking MTX (Morgan et al. 1990). The 
protective effect of folic acid was confirmed by a randomized, double-blind study in 
which the substitution of placebo for folic acid in RA patients that had been taking MTX 
and folic acid for a mean of 30 months showed that placebo was associated with 
discontinuation of MTX because of adverse events (Griffith et al. 2000). The use of MTX 
alone to treat RA is associated with increased Hcy levels and addition of folic acid is 
associated with decreased Hcy levels (van Ede et al. 2002). Concomitant folic acid is 
protective against adverse events and favorably affects Hcy levels. 
 Associations of specific polymorphisms with efficacy or toxicity 
Genetic polymorphisms may be able to predict an individual’s therapeutic 
outcome and this field of science is known as pharmacogenetics. Pharmacogenetics is the 
study of how interindividual differences in drug response are due to polymorphisms in 
genes for drug metabolizing enzymes, drug transporters, and drug targets (Evans and 
McLeod 2003). Several polymorphisms in enzymes of the folate/Hcy pathway are 
associated with either MTX efficacy or toxicity. An RA study in Slovenia found that the 
RFC1 80GG genotype was associated with increased risk of overall toxicity with OR 
3.57 and that the MTHFR 1298CC genotype was associated with a protective effect OR 
0.17 (Bohanec Grabar et al. 2008). A study in US RA patients found that a favorable 
response to MTX was associated with the RFC1 80AA genotype (Dervieux et al. 2004). 
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RFC1 80AA genotype was also found to be associated with decreased RA symptoms and 
the frequency of the 80A allele was higher in MTX responders (Drozdzik et al. 2007). 
The RFC1 80AA genotype seems to be consistently associated with MTX efficacy. In a 
study in Dutch RA patients MTHFR 1298AA genotype was associated with efficacy and 
less overall toxicities (Wessels et al. 2006), which is in contrast to the RA study from 
Slovenia. In a US-based RA study TYMS 5’ VNTR 2R/2R genotype was associated with 
a specific toxicity, alopecia, OR 5.6 (Weisman et al. 2006). Polymorphisms in enzymes 
of folate/Hcy metabolism require further study to establish their predictive ability.  
4.3 Methods 
4.3.1 SLE Study 
Subjects 
Nonpregnant women attending University of Pennsylvania clinics with SLE and 
race and age matched controls were invited to participate in the study. There were 163 
SLE cases and 160 controls enrolled in the study. SLE cases fulfilled at least 4 of the 
American College of Rheumatology revised criteria for the classification of SLE 
(Hochberg 1997). Controls had no underlying inflammatory disease or exposure to 
corticosteroids. The study was approved by the Institutional Review Board of the 
University of Pennsylvania. Each participant gave written informed consent. This study 
was previously described (Summers et al. 2008a). 
Biochemical Assays 
All subjects’ medical histories and fasting blood samples were collected, as well 
as undergoing electron beam computed tomography (EBCT) (Von Feldt et al. 2006). 
Framingham point scores were calculated based on a published method of scoring various 
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cardiovascular risk factors (National Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III) 2002). Glomular filtration rate (GFR) was calculated using 
the Modification of Diet in Renal Disease equation (Levey et al. 2003). Plasma tHcy 
levels were measured by fluorescence polarization immunoassay (AxSYM 
Homocysteine; Abbott Laboratories, Abbott Park, IL), which was performed by the 
hospital’s clinical laboratory.  
Genotyping 
Generation Capture Column kits (Gentra Systems, Minneapolis, MN) were used 
to isolate DNA from whole blood. A heteroduplex generator method was used for 
MTHFR 677C>T genotypes (Barbaux et al. 2000) and a portion of samples were repeated 
using the TaqMan assay. MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, and 
MTRR 66A>G TaqMan assays were previously described (Summers et al. 2008a). 
Briefly, real-time polymerase chain reaction (PCR) assays were performed on a DNA 
Engine Opticon 2 continuous fluorescence detection system (Bio-Rad, Hercules, CA). 
PCR amplifications took place in 20ul volumes containing 20ng genomic DNA, forward 
and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions consisted of 
an initial incubation at 50°C for 2min, 95°C for 10min, and 50 cycles of assay specific 
temperatures for denaturation and extension. Dual fluorescence was measured at the end 
of each cycle. Genotype interpretations were performed with Opticon Monitor Analysis 
software, version 2.02 (Bio-Rad). 
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Size-difference PCR methods were used to genotype CBS 844ins68, TYMS 
1494del6, and DHFR c.86+60_78 as previously described (Summers et al. 2008a). 
Briefly, PCR amplifications were performed using 50ng genomic DNA, forward and 
reverse primers, dNTPs, 10x PCR buffer (Applied Biosystems), MgCl2, and AmpliTaq 
DNA polymerase (Applied Biosystems) in 25ul volumes. PCR products were separated 
on 3% agarose gels run for 45min at 140V then stained with ethidium bromide. 
Statistics 
All statistical analyses were performed with SAS version 9.1 and p values were 
considered significant if <0.05. Log-transformation of tHcy was necessary to better 
approximate normality. Hardy-Weinberg equilibrium for each polymorphism was 
assessed by chi-square test. Differences in genotype distributions between African 
American and Caucasian controls and between case and control groups were assessed by 
chi-square and Fisher’s Exact test. Pearson’s correlation coefficients for age, GFR, and 
Framingham point scores were assessed in relation to log tHcy. The effects of smoking 
status, use of B6, B12, and folic acid on log tHcy were assessed by Student’s t-test. The 
above significantly correlated variables were used in general linear modeling as 
covariates in the assessment of the effect of genotype on log tHcy. Results of log tHcy 
analyses were back-transformed to report results in original measurement units (µmol/L). 
4.3.2 RA Study 
Subjects 
Subjects were recruited who fulfilled the 1987 American College of 
Rheumatology revised criteria for rheumatoid arthritis (Arnett et al. 1988). This study 
was approved by the Institutional Review Board of the University of Pennsylvania 
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School of Medicine. All subjects provided written informed consent. Study subjects 
described as current users were taking MTX for a minimum of 17 weeks, and were 
excluded if they did not report that they were taking folic acid. Study subjects described 
as discontinued users had taken MTX previously but were not currently taking the drug. 
Subjects gave a blood sample for biochemical and genetic analysis and completed a short 
in-person interview. The interview questions covered alcohol use, smoking status, folic 
acid supplementation, and medical history. Doctors performed physical assessments and 
gave physician global assessment (PGA) scores and American Rheumatism Association 
(ARA) classes. 
Biochemical Assays 
THcy, FA, and folate derivatives were measured in plasma and RBCs using stable 
isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry 
(LC/MRM/MS) as previously described (Huang et al. 2007; Huang et al. 2008).  
C-reactive protein (CRP) levels were measured by the clinical laboratory of the 
Hospital of the University of Pennsylvania using VITROS MicroSlides (Ortho-Clinical 
Diagnostics, Rochester, NY). Vitamin B12 levels were measured with the Immulite 2000 
Vitamin B12 assay (Diagnostic Products Corp., Los Angeles, CA). 
Genotyping 
QIAamp DNA Mini Kits (Qiagen, Santa Clarita, CA) were used to extract DNA 
from whole blood. TaqMan genotyping methods were previously described for MTHFR 
677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G (Summers et al. 2008a), 
MTHFD1 1958G>A, RFC1 80A>G, and SHMT1 1420C>T (Summers et al. 2010). 
Briefly, real-time polymerase chain reaction (PCR) assays were performed on a DNA 
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Engine Opticon 2 continuous fluorescence detection system (Bio-Rad, Hercules, CA). 
PCR amplifications took place in 20ul volumes containing 20ng genomic DNA, forward 
and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions consisted of 
an initial incubation at 50°C for 2min, 95°C for 10min, and 50 cycles of assay specific 
temperatures for denaturation and extension. Dual fluorescence was measured at the end 
of each cycle. Genotype interpretations were performed with Opticon Monitor Analysis 
software, version 2.02 (Bio-Rad). 
Size difference PCR methods were used to genotype CBS 844ins68, TYMS 
1494del6, TYMS 5’ VNTR, and DHFR c.86+60_78 as previously described (Summers et 
al. 2010). Briefly, PCR amplifications were performed using 50ng genomic DNA, 
forward and reverse primers, dNTPs, 10x PCR buffer (Applied Biosystems), and 
AmpliTaq DNA polymerase (Applied Biosystems) in 25µl volumes. PCR products were 
separated on 3% agarose gels run for 45min at 140V then stained with ethidium bromide. 
Statistics 
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, 
NC). Discrete variables were presented as counts and proportions and continuous 
variables were presented as medians and interquartile ranges. Total RBC folate was the 
sum of RBC 5-MTHF, THF, and 5,10-MTHF. THF values which were not detectable 
(n=4) were given a value corresponding to the lower limit of quantitation (4.5nmol/L), 
allowing both absolute THF levels and the ratio of RBC 5-MTHF:THF to be analyzed as 
continuous variables. RBC 5,10-MTHF levels were not detectable in a large portion of 
the samples and therefore was treated as a dichotomous (detectable/not detectable) 
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variable. CRP values reported by the clinical laboratory as <0.3 were given values of 0.3 
and B12 values reported as >1000 were given values of 1000 in order to analyze the data 
with nonparametric tests, which is based on ranking values. 
For the purposes of classification, severe toxicities included pneumonitis, 
hemorrhagic enteritis, and bone marrow depression; attributable toxicities included the 
severe toxicities and leucopenia, thrombocytopenia, abnormal mcv, abnormal 
ALP/ALT/AST, other abnormal LFTs, elevated homocysteine, 
photosensitivity/hyperpigmentation, urticaria/puritis, alopecia, and mucositis; and any 
toxicity was defined as having at least one of the twenty five defined events or otherwise 
listed as other event. 
4.4 Results 
 4.4.1 SLE Study 
 Subject Characteristics 
 The study included 163 SLE cases and 160 controls, of which approximately 50% 
self-reported as African American, 39% as Caucasian, 5% as Asian, 4% as Hispanic, and 
1% as other as presented in Table 4-1. The average age in SLE cases and controls was 
about 43 years. Median CAC scores were significantly higher in SLE cases than controls 
(p=0.0003). THcy levels were also higher in SLE cases than controls (10.4 vs 9.2 
µmol/L, p<0.0001). When analyses were applied to specific races, African American 
SLE cases had higher tHcy levels than African American controls (12.1 vs 9.7 µmol/L, 
p<0.0001). Caucasian SLE cases had higher tHcy levels than Caucasian controls but this 
was not statistically significant (10.0 vs 9.0 µmol/L, p=0.12). African American SLE 
cases had higher tHcy levels than Caucasian SLE cases (p=0.0009), but African 
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American controls did not have significantly different tHcy levels than Caucasian 
controls (p=0.21). Framingham point scores and GFR were not significantly different 
between SLE cases and controls. 
Table 4-1. SLE Study Subject Characteristics. 
Characteristic SLE cases Controls P value 
No. 163 160 ND 
Age, yrs, mean ± SD 43.3 ± 11.0  43.5 ± 10.5  0.90 
Race, %(n)    
   African American 50.3 (82) 50.6 (81) 1.00 
   Caucasian 39.3 (64) 39.4 (63)  
   Asian 4.9 (8) 5.0 (8)  
   Hispanic 4.3 (7) 3.8 (6)  
   Other 1.2 (2) 1.2 (2)  
CAC, median [IQR]  0 [0-7.2]  0 [0-0]  0.0003 
tHcy, µmol/L, mean ± SD 
(n) 
10.4 ± 1.4 9.2 ± 1.4 <0.0001 
    African American* 12.1 ± 1.4 (82) 9.7 ± 1.3 (81) <0.0001 
    Caucasian 10.0 ± 1.3 (64) 9.0 ± 1.5 (63) 0.12 
Framingham point scores, 
median [IQR] (n) 
8 [3-13] (161) 8 [2-12] (156) 0.39 
GFR, ml/min/1.73m2, 
mean ± SD 
90.0 ± 32.5 94.5 ± 20.8 0.14 
SD = standard deviation, ND = not determined, IQR = interquartile range. 
*For African American SLE cases vs. Caucasian SLE cases p=0.0009; for African 
American controls vs. Caucasian controls p=0.21(Summers et al. 2008a) 
 
 Genotype frequencies in African American and Caucasian controls 
 SLE cases and controls were genotyped for 7 polymorphisms in 6 genes in the 
folate/Hcy metabolic pathway and included: MTHFR 677C>T and 1298A>C, MTR 
2756A>G, MTRR 66A>G, CBS 844ins68, TYMS 1494del6, and DHFR c.86+60_78. All 
genotypes were in Hardy-Weinberg equilibrium for SLE cases and controls even after 
stratification by race. The genotype frequency distributions were significantly different 
between African American and Caucasian controls for all of the polymorphisms except 
for MTR 2756A>G (Table 4-2). For example, MTHFR 677TT homozygotes made up 
2.5% of African American controls compared to 19.0% of Caucasian controls 
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(p=0.0003). The wildtype genotype tends to be the higher frequency homozygote and the 
lower frequency homozygote is usually the variant genotype. For 3 of the polymorphisms 
(MTRR 66A>G, TYMS 1494del6, and DHFR c.86+60_78) the homozygous genotype that 
had the higher frequency in African Americans had the lower frequency in Caucasians. In 
analyses involving genotypes African Americans and Caucasians were therefore analyzed 
separately. 
Risk of SLE as determined by genotype frequency 
 Specific genotypes may be associated with development of SLE if SLE cases 
have an overrepresentation in genotype frequency when compared to the control 
frequency. None of the carrier frequencies of the 7 polymorphisms were significantly 
different when stratified by race (Table 4-3). The only polymorphism that approached 
significance was in Caucasians, MTR 2756G carriers were overrepresented in controls 
(p=0.07) meaning that 2756AA homozygotes are at increased risk of developing SLE. 
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Table 4-2. Distributions of genotype frequencies in African American and 
Caucasian controls. 
Polymorphism Genotype 
African 
Americans Caucasians P 
MTHFR 677C>T CC 67.9 (55) 39.7 (25) 0.0003 
 CT 29.6 (24) 41.3 (26)  
 TT 2.5 (2) 19.0 (12)  
     
MTHFR 1298A>C AA 69.1 (56) 55.6 (35) 0.0347 
 AC 30.9 (25) 38.1 (24)  
 CC 0 6.3 (4)  
     
MTHFR 677/1298 CC/AA 46.9 (38) 11.1 (7) <0.0001 
 CC/AC 21.0 (17) 22.2 (14)  
 CC/CC 0 6.3 (4)  
 CT/AA 19.7 (16) 25.4 (16)  
 CT/AC 9.9 (8) 15.9 (10)  
 TT/AA 2.5 (2) 19.0 (12)  
     
CBS 844ins68 WW 58.0 (47) 87.3 (55) 0.0005 
 WI 39.5 (32) 12.7 (8)  
 II 2.5 (2) 0  
     
MTR 2756A>G AA 58.0 (47) 47.6 (30) 0.19 
 AG 33.3 (27) 47.6 (30)  
 GG 8.7 (7) 4.8 (3)  
     
MTRR 66A>G AA 48.2 (39) 20.6 (13) 0.0009 
 AG 40.7 (33) 50.8 (32)  
 GG 11.1 (9) 28.6 (18)  
     
TYMS 1494del6 Ins/ins 19.7 (16) 39.7 (25) 0.0012 
 Ins/del 53.1 (43) 54.0 (34)  
 Del/del 27.2 (22) 6.3 (4)  
     
DHFR c.86+60_78 Ins/ins 19.7 (16) 38.1 (24) 0.0068 
 Ins/del 45.7 (37) 47.6 (30)  
 Del/del 34.6 (28) 14.3 (9)  
%(n). P values by χ2 test. (Summers et al. 2008a) 
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Table 4-3. Distributions of carrier frequencies between SLE cases and controls by 
race. 
Genotype SLE cases Controls p 
MTHFR 677T carriers    
   African American 31.7 (26) 32.1 (26) 1.00 
   Caucasian 65.6 (42) 60.3 (38) 0.58 
MTHFR 1298C carriers    
   African American 32.9 (27) 30.9 (25) 0.87 
   Caucasian 54.7 (35) 44.4 (28) 0.29 
CBS 844ins68 carriers    
   African American 48.8 (40) 42.0 (34) 0.43 
   Caucasian 15.6 (10) 12.7 (8) 0.80 
MTR 2756G carriers    
   African American 46.3 (38) 42.0 (34) 0.64 
   Caucasian 35.9 (23) 52.4 (33) 0.07 
MTRR 66G carriers    
   African American 43.9 (36) 51.9 (42) 0.35 
   Caucasian 78.1 (50) 79.4 (50) 1.00 
TYMS 1494del6 ins carriers    
   African American 63.4 (52) 72.8 (59) 0.24 
   Caucasian 89.1 (57) 93.7 (59) 0.53 
DHFR c.86+60_78 ins carriers    
   African American 59.8 (49) 65.4 (53) 0.52 
   Caucasian 78.1 (50) 85.7 (54) 0.36 
Carriers of alleles subset by race %(n). P values by Fisher’s exact test. (Summers et al. 
2008a) 
  
Predictors of tHcy concentrations 
 The continuous variables which were selected for correlation analysis with tHcy 
concentrations were age, GFR, and Framingham point scores. Displayed in Table 4-4 are 
the Pearson’s correlation coefficients and corresponding p values for all study subjects. 
All 3 continuous variables were significantly correlated with tHcy concentrations. Age 
and Framingham point scores were positively correlated while GFR was negatively 
correlated with tHcy concentrations. Uncontrolled sources of variation were categorical 
variables and the following were selected for analysis: folic acid use, B6 use, B12 use, and 
smoking status. None of these variables were significantly associated with tHcy 
concentrations (data not shown). The results of the above analyses were similar when 
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stratified by group (SLE cases and controls) except that smoking status was significantly 
associated with tHcy concentrations in controls (smokers 11.8 (n=25) vs nonsmokers 9.5 
(n=133), p=0.0046). 
Table 4-4. Correlations with homocysteine levels. 
Variable 
Pearson’s Correlation 
Coefficient n p 
Age 0.22917 323 <0.0001 
GFR -0.42930 323 <0.0001 
Framingham 
Point Scores 0.22249 317 <0.0001 
(Summers et al. 2008a)  
 From the above analysis the explanatory variables age, GFR, and Framingham 
point scores along with race and group were put into a general linear model with tHcy as 
the dependent variable, with no interactions between any of the terms. In this analysis of 
covariance GFR along with race and group were the only variables significantly 
associated with tHcy (Table 4-5). These variables were used in modeling the effect of 
genotype on tHcy concentrations.  
Table 4-5. Analysis of covariance for homocysteine. 
Source Variation Sum of Squares  Df F p 
GFR 1.11 1 60.18 <0.0001 
Group* 5.53 1 12.04 0.0006 
Race† 2.14 1 23.28 <0.0001 
*Refers to case and control groups 
†Refers to African Americans and Caucasians(Summers et al. 2008a) 
 Modeling the effects of polymorphisms of folate/Hcy metabolizing enzymes on 
tHcy concentrations 
 More complex models were explored and a clinically sound parsimonious model 
was arrived at with variables that significantly contributed to the variation in tHcy. For 
each polymorphism a general linear model was used with tHcy as the dependent variable 
and classified by race, group, and genotype with the addition of the covariate GFR and its 
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interaction with that genotype. The classification resulted in 4 categories, which were 
African American SLE cases, African American controls, Caucasian SLE cases, 
Caucasian controls. The least-square mean estimates of tHcy were adjusted for the 
uncontrolled variable GFR. Two polymorphisms (MTHFR 1298A>C and CBS 844ins68) 
were modeled based on carriers of the variant allele, which is the combination of 
heterozygotes and variant homozygotes. This was because there were no variant 
homozygotes present in at least one of the four categories. Out of the 7 polymorphisms 
only 2 were significantly associated with tHcy concentrations. In Caucasian controls 
MTHFR 677CC homozygotes had lower tHcy levels than 677CT heterozygotes (7.7 vs 
9.4 µmol/L, p=0.0196) and 677CC homozygotes also had lower tHcy levels than 677TT 
homozygotes (7.7 vs 9.8 µmol/L, p=0.0275). Also MTHFR 1298AA homozygotes had 
higher tHcy levels than 1298C carriers (9.6 vs 7.8 µmol/L, p=0.0083) (Table 4-6). 
Table 4-6. Analysis of covariance with two factors (group, race) and one covariate 
(GFR). 
Category Genotype  
Adjusted means of 
tHcy P* 
Caucasian Controls MTHFR 677 CC 7.7 - 
                       CT 9.4 0.0196 
                       TT 9.8 0.0275 
Caucasian Controls MTHFR 1298 AA 9.6 - 
                         AC/CC† 7.8 0.0083 
*p value for comparison to wildtype genotype 
†These genotypes were combined because of low numbers of homozygotes(Summers et 
al. 2008a) 
 
 CAC scores and polymorphisms of folate/Hcy metabolizing enzymes 
 None of the genotypes were associated with median CAC scores even after 
stratification by race (data not shown). 
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4.4.2 RA Study 
 Subject Characteristics 
 The RA study included 252 subjects classified as current (MTX) users, of which 
47 (18.7%) were African American and 37 subjects classified as discontinued (MTX) 
users, of which 11 (29.7%) were African American (Table 4-7). Toxicities were reported 
and categorized into several categories. Severe toxicities would require discontinuation of 
MTX, and therefore were present only in the discontinued users group. Attributable 
toxicities are those known to be associated with MTX therapy, such as elevated liver 
function tests (LFTs), and could require a decrease in MTX dose. Non-attributable 
toxicities were side effects which could have come from a different source, such as 
headache and diarrhea. ARA class 1 was defined as RA having almost no impact on the 
subject’s daily activities while class 4 was defined as RA having a severe impact on the 
subject’s daily activities resulting in limitations in ability to perform daily activities.  
RBC 5,10-MTHF levels were measured and due to a large number of undetectable values 
were determined to be either detectable or undetectable for subsequent analyses. 
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Table 4-7. RA study subject characteristics for categorical variables.  
 African American Caucasian 
 Current 
Users 
Discontin-
ued Users 
Current 
Users 
Discontin-
ued Users 
Gender – Male 6 (12.8) 1 (9.1) 62 (30.2) 6 (23.1) 
                Female 41 (87.2) 10 (90.9) 143 (69.8) 20 (76.9) 
Smoker – Yes 8 (17.8) 1 (11.1) 29 (14.6) 0 
                 No 37 (82.2) 8 (88.9) 170 (85.4) 23 (100.0) 
Drinker – Yes 7 (16.3) 4 (44.4) 88 (44.0) 11 (50.0) 
                 No 36 (83.7) 5 (55.6) 112 (56.0) 11 (50.0) 
Severe Toxicity 0 3 (27.3) 0 2 (7.7) 
Attributable Toxicity 5 (10.6) 4 (36.4) 28 (13.7) 6 (23.1) 
Non-Attributable 
Toxicity 
12 (25.5) 4(36.4) 49 (23.9) 13 (50.0) 
No Toxicity 30 (63.8) 0 128 (62.4) 5 (19.2) 
Morning Stiffness – Yes 36 (80.0) 10 (90.9) 132 (68.0) 17 (68.0) 
                                  No 9 (20.0) 1 (9.1) 62 (32.0) 8 (32.0) 
ARA Class    I 15 (35.7) 1 (10.0) 75 (40.5) 12 (52.2) 
                      II 18 (42.9) 3 (30.0) 89 (48.1) 8 (34.8) 
                      III 7 (16.7) 5 (50.0) 13 (7.0) 2 (8.7) 
                      IV 2 (4.8) 1 (10.0) 8 (4.3) 1 (4.4) 
RBC 5,10-MTHF – D* 16 (39.0) 3 (50.0) 96 (54.9) 3 (27.3) 
                                ND 25 (61.0) 3 (50.0) 79 (45.1) 8 (72.7) 
N (%) 
*D=Detectable, ND=Not Detectable 
 
 Continuous variables were assessed for differences between African American 
current users and Caucasian current users (Table 4-8). The following observations were 
associated with p values <0.05. African Americans were taking slightly higher doses of 
MTX than Caucasians (17.5 vs 15.0 mg, respectively). PGA scores were slightly higher 
in African Americans (32 vs 24). RBC THF levels were slightly lower in African 
Americans (24.7 vs 29.4 nmol/L) and therefore the ratio of 5-MTHF:THF was slightly 
higher (39.1 vs 29.4). When current users were compared to discontinued users in 
African Americans PGA scores were much higher in discontinued users (61 vs 32). Since 
current users were taking folic acid, levels of plasma folic acid were higher in current 
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users (12.4 vs 0 nmol/L). Total RBC folate levels were decreased in current users (993.1 
vs 1283.4 nmol/L) and this possibly due to the anti-folate effects of MTX. Also 5-MTHF 
levels were lower in current users (957.8 vs 1004.3 nmol/L). When Caucasian current 
users were compared to discontinued users plasma 5-MTHF levels were lower in current 
users (35.9 vs 66.1 nmol/L). In Caucasians similar observations were seen as those 
observed in African Americans with respect to plasma folic acid (FA), total RBC folate, 
and RBC 5-MTHF. 
Clinical variables of RA severity are associated 
 The clinical continuous variables PGA score and CRP levels were stratified by the 
clinical categorical variables morning stiffness and ARA class to assess differences in 
median levels of the continuous variables within current users (Table 4-9). In Caucasians 
PGA scores were higher in those who experienced morning stiffness compared to those 
that did not experience morning stiffness (27 vs 17, p=0.0003). In African Americans 
PGA scores were higher in those who experienced morning stiffness but this was not 
statistically significant. PGA scores in African Americans were higher in individuals 
categorized as ARA classes II-IV compared to those categorized as ARA class I (41 vs 
18, p=0.0005). 
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Table 4-8. RA study subject characteristics for continuous variables. 
 Current Users Discontinued Users 
 African 
American Caucasian  
African 
American Caucasian  
Age, years 57 [46-67] (47) 56 [48-66] 
(202) 
59 [54-64] (10)  56 [38-71] (26) 
Current 
MTX Dose, 
mg 
17.5 [12.5-20.0] 
(46) 
15.0 [10.0-17.5] 
(202)* 
- - 
Cumulative 
MTX Dose, 
mg 
539.8 [346.5-
3038.6] (40) 
556.1 [325.0-
3513.6] (194) 
851.6 [480.0-
2780.0] (10) 
556.1 [267.5-
2380.0] (22) 
PGA score 32 [18-50] (41) 24 [12-35] 
(187)* 
61 [41-72] (10) 
† 
29 [11-56] (23) 
Plasma 5-
MTHF, 
nmol/L 
33.4 [21.3-46.0] 
(41) 
35.9 [24.9-47.7] 
(178) 
58.6 [26.2-66.2] 
(6) 
66.1 [33.6-
96.4] (11) ‡ 
Plasma 
Folic Acid, 
nmol/L 
12.4 [1.0-35.1] 
(41) 
12.6 [1.1-52.7] 
(178) 
0 [0-0.8] (6) † 1.1 [0-5.4] (11) 
‡ 
Total RBC 
folate°, 
nmol/L 
993.1 [855.2-
1160.9] (41) 
1095.4 [863.2-
1382.0] (175) 
1283.4 [1108.8-
1752.9] (6) † 
1489.8 
[1132.5-
2251.5] (11) ‡ 
RBC 5-
MTHF, 
nmol/L 
957.8 [746.9-
1055.0] (41) 
1004.3 [768.0-
1273.8] (175) 
1249.3 [1049.0-
1700.5] (6) † 
1464.1 
[1033.4-
2220.4] (11) ‡ 
RBC THF, 
nmol/L 
24.7 [16.9-37.4] 
(41) 
29.4 [15.8-44.7] 
(175)* 
34.9 [24.2-43.2] 
(6) 
35.5 [25.7-
71.7] (11) 
Ratio 5-
MTHF:TH
F 
39.1 [26.6-48.8] 
(41) 
29.4 [15.8-44.4] 
(176)* 
41.9 [38.1-44.0] 
(6) 
39.2 [20.8-
60.8] (11) 
CRP°, 
mg/L 
0.7 [0.4-1.2] 
(44) 
0.5 [0.3-1.0] 
(174) 
1.3 [0.7-2.4] (8) 0.4 [0.3-0.9] 
(11) 
B12°, 
pmol/L 
600 [354-855] 
(37) 
615 [388-839] 
(169) 
907 [708-1000] 
(6) 
736 [356-
1000] (12) 
tHcy, 
µmol/L 
 
10.5 [9.3-13.6] 
(41) 
10.4 [9.0-12.3] 
(178) 
10.2 [7.0-12.1] 
(6) 
12.9 [9.3-14.3] 
(11) 
Median [IQR] (n) 
* p values <0.05 for comparison of African American current users to Caucasian current 
users by Wilcoxon 
† p values <0.05 for comparison of African American current users to African American 
discontinued users by Wilcoxon 
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‡ p values <0.05 for comparison of Caucasian current users to Caucasian discontinued 
users by Wilcoxon 
° Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; CRP values of 
“<0.3” were given the value of 0.3; B12 values of “>1000” were given values of 1000 
 
  In Caucasians the same observation was significant, individuals in ARA classes 
II-IV had higher PGA scores (31 vs 12, p<0.0001). CRP levels in Caucasians were higher 
in individuals in ARA classes II-IV (0.7 vs 0.4, p=0.001). Although CRP levels in 
African Americans were higher in individuals in ARA classes II-IV, this was not 
statistically significant. It was observed that worse RA severity in clinical continuous 
variables was associated with worse RA severity in clinical categorical variables.   
Table 4-9. Analyses of selected clinical variables in current users: continuous 
variables stratified by categorical variables. 
Race 
Continuous 
Variables Categorical Variables P Values 
  
Morning 
Stiffness – Yes No  
African 
American 
PGA 34 [19-58] (32) 26 [10-41] (9) 0.17 
Caucasian PGA 27 [14-37] (123) 17 [8-28] (58) 0.0003 
  ARA Class I ARA Classes II-IV  
African 
American  
PGA 18 [12-22] (14) 41 [30-61] (27) 0.0005 
Caucasian PGA 12 [5-19] (75) 31 [22-38] (109) <0.0001 
African 
American  
CRP* 0.5 [0.4-0.7] (13) 1.0 [0.3-1.8] (26) 0.18 
Caucasian CRP* 0.4 [0.3-0.7] (64) 0.7 [0.3-1.2] (92) 0.001 
*CRP values of “<0.3” were given the value of 0.3 
Differences in genotype distribution between races 
 Genotyping was completed for 11 polymorphisms in 9 genes of the enzymes of 
the folate/Hcy pathway. Genotype distributions are presented in Table 5-10. In current 
users the genotype frequencies were compared by Fisher’s Exact test. There were 
significant differences in genotype distributions between African American and 
Caucasian current users. Only 3 of the 11 polymorphisms were not significantly different. 
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Genotype distribution differences between current and discontinued users 
Overall there were 3 polymorphisms which were not in Hardy-Weinberg 
equilibrium. In African American current users there were two polymorphisms, which 
deviated from Hardy-Weinberg equilibrium: MTHFR 677C>T (p=0.047) and DHFR 
c.86+60_78 (p=0.045). In Caucasian current users there was only one polymorphism not 
in Hardy-Weinberg equilibrium and that was MTHFR 1298A>C (p=0.021). Deviation 
from Hardy-Weinberg equilibrium suggests that there may be increased risk of RA 
associated with these polymorphisms. Without a healthy control group with which to 
compare genotype frequencies the conclusion cannot be made that these genotypes 
increase risk for RA. The discontinued users served as a reference group for assessing the 
tolerability of MTX therapy. African American discontinued users had significantly 
different genotype frequencies for the polymorphism MTHFD1 1958A>G when 
compared to African American current users. Examination of these genotype frequencies 
suggests that there were more MTHFD1 1958GA and 1958AA individuals. This suggests 
that the 1958A allele may be associated with discontinuation of MTX therapy in African 
Americans. In Caucasian discontinued users the distribution of MTHFR 1298A>C 
genotypes were significantly different from current users. There seemed to be more 
1298CC homozygotes when compared to current users, which suggests that this genotype 
may be associated with discontinuation of MTX therapy. 
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Table 4-10. RA study genotype distributions.  
  Current Users Discontinued Users 
  African 
American Caucasian 
African 
American Caucasian 
MTHFR  CC 37 (82.2) 83 (40.7)* 8 (72.7) 10 (43.5) 
677C>T CT 6 (13.3) 102 (50.0) 2 (18.2) 10 (43.5) 
 TT 2 (4.4) 19 (9.3) 1 (9.1) 3 (13.0) 
MTHFR  AA 33 (73.3) 93 (45.6)* 6 (54.6) 9 (39.1) ‡ 
1298A>C AC 12 (26.7) 98 (48.0) 5 (45.4) 7 (30.4) 
 CC 0 13 (6.4) 0 7 (30.4) 
CBS 844ins68 WW 30 (66.7) 177 (86.8)* 7 (63.6) 18 (78.3) 
 WI 12 (26.7) 26 (12.8) 3 (27.3) 5 (21.7) 
 II 3 (6.7) 1 (0.5) 1 (9.1) 0 
MTR  AA 29 (64.4) 137 (67.2) 7 (63.6) 16 (69.6) 
2756A>G AG 14 (31.1) 61 (29.9) 4 (36.4) 6 (26.1) 
 GG 2 (4.4) 6 (2.9) 0 1 (4.4) 
MTRR 66A>G AA 18 (40.0) 45 (22.1)* 7 (63.6) 4 (17.4) 
 AG 24 (53.3) 95 (46.6) 4 (36.4) 15 (65.2) 
 GG 3 (6.7) 64 (31.4) 0 4 (17.4) 
MTHFD1  GG 33 (73.3) 68 (33.3)* 4 (36.4) † 7 (30.4) 
1958G>A GA 10 (22.2) 91 (44.6) 4 (36.4) 10 (43.5) 
 AA 2 (4.4) 45 (22.1) 3 (27.3) 6 (26.1) 
SHMT1  CC 22 (48.9) 98 (48.0) 6 (54.6) 9 (39.1) 
1420C>T CT 21 (46.7) 87 (42.7) 5 (45.4) 11 (47.8) 
 TT 2 (4.4) 19 (9.3) 0 3 (13.0) 
DHFR  del/del 12 (26.7) 44 (21.6)* 3 (27.3) 5 (21.7) 
c.86+60_78 ins/del 30 (66.7) 104 (51.0) 8 (72.7) 13 (56.5) 
 ins/ins 3 (6.7) 56 (27.5) 0 5 (21.7) 
TYMS 5’  2R/2R 7 (15.9) 41 (20.1) 4 (36.4) 8 (34.8) 
VNTR 2R/3R 25 (56.8) 103 (50.5) 5 (45.5) 8 (34.8) 
 3R/3R 12 (27.3) 59 (28.9) 1 (9.1) 6 (26.1) 
 2R/4R 0 1 (0.5) 0 0 
 3R/4R 0 0 1 (9.1) 1 (4.4) 
TYMS  del/del 14 (31.1) 23 (11.3)* 3 (27.3) 3 (13.0) 
1494del6 ins/del 23 (51.1) 86 (42.2) 5 (45.4) 12 (52.2) 
 ins/ins 8 (17.8) 95 (46.6) 3 (27.3) 8 (34.8) 
RFC1 80A>G AA 27 (60.0) 41 (20.1)* 6 (54.5) 5 (21.7) 
 AG 16 (35.6) 101 (49.5) 4 (36.4) 15 (65.2) 
 GG 2 (4.4) 62 (30.4) 1 (9.1) 3 (13.0) 
n(%) 
* p values <0.05 for comparison of African American current users to Caucasian current 
users by Fisher’s Exact Test 
† p values <0.05 for comparison of African American current users to African American 
discontinued users by Fisher’s Exact Test 
‡ p values <0.05 for comparison of Caucasian current users to Caucasian discontinued 
users by Fisher’s Exact Test 
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MTHFR 677C>T substantially impacts biochemical variables 
 In African American current users there were only 2 MTHFR 677TT 
homozygotes and this was not enough to support further analyses. In Caucasian current 
users there were enough MTHFR 677TT homozygotes to permit the analysis of the effect 
of this genotype on biochemical variables. MTHFR 677TT individuals had marginally 
higher tHcy levels than 677C carriers but this was not statistically significant (Table 5-
11). Although MTHFR 677TT homozygotes had slightly more total RBC folate, which 
was not significant, they had drastically lower levels of RBC 5-MTHF (679.8 vs 1022.3 
nmol/L, p=0.002). MTHFR 677TT homozygotes had substantially more RBC THF 
(447.8 vs 34.0 nmol/L, p<0.0001). This alteration of the distribution of RBC folate 
derivatives led to a dramatically lower ratio of 5-MTHF:THF in 677TT individuals (1.8 
vs 30.9, p<0.0001). RBC 5,10-MTHF levels were detectable in 16 out of 18 (88.9%) 
MTHFR 677TT individuals compared to 80 out of 157 (51.0%) 677C carriers (p=0.002). 
Vitamin B12 levels were also impacted by this polymorphism. MTHFR 677TT 
homozygotes had lower levels of B12 (541 vs 634 pmol/L, p=0.002). Since the 677TT 
genotype had such a widespread and substantial impact on folate/Hcy metabolism, all 
MTHFR 677TT individuals were excluded for analyses which involved metabolites of the 
folate/Hcy pathway. 
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Table 4-11. Effects of MTHFR 677C>T genotypes in Caucasian current users. 
MTHFR 677 CC/CT TT P Value 
tHcy, µmol/L 10.4 [9.0-12.3] (160) 11.2 [9.2-14.1] (18) 0.50 
Total RBC Folate*, 
nmol/L 
1088.2 [869.2-1361.2] 
(157) 
1155.5 [863.2-1745.4] 
(18) 0.29 
RBC 5-MTHF, 
nmol/L 
1022.3 [832.5-1279.5] 
(157) 
679.8 [537.0-1068.5] 
(18) 0.002 
RBC THF, nmol/L 
34.0 [22.6-60.5]  
(157) 
447.8 [118.6-492.6] 
(18) <0.0001 
Ratio 5-MTHF:THF 30.9 [18.7-47.6] (157) 1.8 [0.9-7.5] (18) <0.0001 
RBC 5,10-MTHF - D† 80 (51.0) 16 (88.9) 0.002 
                               ND 77 (49.0) 2 (11.1) 
 
B12*, pmol/L 634 [401-858] (152) 541 [289-600] (17) 0.018 
Median [IQR] (n) 
*Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; B12 values of 
“>1000” were given values of 1000 
†D=Detectable, ND=Not Detectable 
 
 Effects of other polymorphisms on biochemical variables 
 In African American current users the DHFR c.86+60_78 polymorphism had an 
effect on RBC THF levels and the ratio of 5-MTHF:THF. DHFR del/del homozygotes 
had lower THF levels than ins carriers (15.3 vs 27.7 nmol/L, p=0.008, Table 5-12). This 
difference influenced the ratio of 5-MTHF:THF such that del/del individuals had higher 
ratios (53.3 vs 37.4, p=0.010). DHFR del/del individuals were also being prescribed 
lower doses of MTX (15.0 vs 20.0 mg, p=0.025). Another polymorphism was also 
associated with currently prescribed dose. TYMS 1494del6 ins/ins individuals were 
prescribed 12.5 mg, which was lower than 20.0 mg for del/ins and 16.3 mg for del/del 
individuals (p=0.028). 
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Table 4-12. Effects of selected genotypes on biochemical variables and current MTX 
dose in African American current users. 
Genotype  Biochemical Variable P Value 
  RBC THF, nmol/L  
DHFR c.86+60_78 Ins carriers 27.7 [19.1-37.9] (27) 0.008 
 Del/del 15.3 [13.5-32.3] (11)  
  Ratio of 5-MTHF:THF  
DHFR c.86+60_78 Ins carriers 37.4 [25.9-45.7] (27) 0.010 
 Del/del 53.3 [39.1-72.1] (11)  
  Current MTX Dose, mg  
DHFR c.86+60_78 Ins carriers 20.0 [15.0-20.0] (31) 0.025 
 Del/del 15.0 [10.0-17.5] (11)  
TYMS 1494del6 Del/del 16.3 [12.5-17.5] (14) 0.028 
 Del/ins 20.0 [15.0-20.0] (20)  
 Ins/ins 12.5 [11.3-17.5] (8)  
Median [IQR] (n) 
 
 In Caucasian current users total RBC folate concentrations were lowest in RFC1 
80AA homozygotes (934.5 vs 1071.5 for AG vs 1293.0 for GG, p=0.001, Table 5-13). In 
particular RBC 5-MTHF levels were lowest in 80AA homozygotes (859.4 vs 1002.1 for 
AG vs 1252.1 for GG, p=0.0005). The MTRR 66A>G polymorphism altered RBC folate 
derivative distributions. MTRR 66GG individuals had the lowest level of RBC THF (22.7 
vs 42.8 for AG vs 43.1 for AA, p<0.0001). Consequently the ratio of 5-MTHF:THF was 
highest in GG individuals (44.8 vs 24.7 for AG vs 23.7 for AA, p<0.0001). B12 levels 
were lower in MTR 2756AA homozygotes compared to 2756G carriers (590.0 vs 784.0, 
p=0.006). 
 The MTRR 66A>G polymorphism not only affected RBC THF levels and the 
ratio of 5-MTHF:THF but also determined whether RBC 5,10-MTHF levels were 
detectable or not. In Caucasian current users there were 16 out of 52 (32.7%) MTRR 
66GG individuals who had detectable RBC 5,10-MTHF levels compared to 60% of 
66AA and 66AG individuals (p=0.006, Table 5-14). 
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Table 4-13. Effects of selected genotypes on biochemical variables in Caucasian 
current users. 
Genotype  Biochemical Variable P Value 
  Total RBC Folate*, nmol/L  
RFC1 80A>G AA 934.5 [763.4-1156.7] (33) 0.001 
 AG 1071.5 [875.4-1306.5] (80)  
 GG 1293.0 [997.4-1514.3] (44)  
  RBC 5-MTHF, nmol/L  
RFC1 80A>G AA 859.4 [680.2-1085.6] (33) 0.0005 
 AG 1002.1 [836.1-1242.4] (80)  
 GG 1252.1 [946.9-1464.3] (44)  
  RBC THF, nmol/L  
MTRR 66A>G AA 43.1 [28.0-79.4] (35) <0.0001 
 AG 42.8 [25.5-72.3] (70)  
 GG 22.7 [17.5-35.9] (52)  
  Ratio 5-MTHF:THF  
MTRR 66A>G AA 23.7 [14.1-34.4] (35) <0.0001 
 AG 24.7 [16.5-37.5] (70)  
 GG 44.8 [32.3-56.3] (52)  
  B12*, pmol/L  
MTR 2756A>G AA 590.0 [359.0-793.0] (103) 0.006 
 
G 
carriers 
784.0 [514.0-908.0] (49) 
 
Median [IQR] (n) 
*Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; B12 values of 
“>1000” were given values of 1000 
 
Table 4-14. Distribution of MTRR 66A>G genotypes in Caucasian current users by 
detection of RBC 5,10-MTHF. 
 MTRR 66A>G 
RBC 5,10-MTHF AA AG GG 
Detectable 21 (60.0) 42 (60.0) 17 (32.7) 
Not Detectable 14 (40.0) 28 (40.0) 35 (67.3) 
n(%), Fishers Exact P=0.006 
 
 Genotypes associated with toxicities 
 Genotype distributions were compared between various categories of toxicities. In 
African American current users MTR 2756G carriers had 5 out of 16 (31.2%) individuals 
experience an attributable toxicity compared to 0 out of 29 individuals who were 
2756AA homozygotes (p=0.004, Table 5-15). The same association was significant for 
attributable toxicities compared to no toxicities (data not shown). In Caucasian current 
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users MTHFD1 1958GG homozygotes had 14 out of 68 (20.6%) individuals experience 
an attributable toxicity compared to 12.1% of 1958GA and 4.4% of 1958AA individuals 
(p=0.043, Table 5-16). The same association was significant for attributable toxicities 
compared to no toxicities (data not shown). 
Table 4-15. Distribution of MTR 2756A>G genotypes in African American current 
users by type of toxicity.   
 MTR 2756A>G  
 AA AG/GG 
Attributable 
Toxicity  
0 5 (31.2) 
Non-Attributable 
and No 
Toxicities  
29 (100.0) 11 (68.8) 
n (%), Fishers exact p=0.004 
 
Table 4-16. Distribution of MTHFD1 1958G>A genotypes in Caucasian current 
users by type of toxicity.  
 
 
 
 
 
 
 
 
n (%), Fishers exact p=0.043 
 
 Associations among biochemical and other continuous variables 
 In African American current users tHcy levels were negatively correlated with 
plasma 5-MTHF levels (p=0.011) and positively correlated with age (p=0.003, Table 5-
17). Plasma 5-MTHF levels were positively correlated with total RBC folate levels 
(p=0.003) and specifically there was a positive correlation with RBC 5-MTHF (p=0.005). 
Total RBC folate was positively correlated with CRP levels (p=0.004) and B12 levels 
(0.027). In particular RBC 5-MTHF was positively correlated with CRP levels (p=0.034) 
and B12 levels (p=0.042). Plasma folic acid was positively associated with age (p=0.021). 
 MTHFD1 1958G>A 
 GG GA AA 
Attributable 
Toxicity  
14 (20.6) 11 (12.1) 2 (4.4) 
Non Attributable 
and No 
Toxicities  
54 (79.4) 80 (87.9) 43 (95.6) 
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There was a profile which develops and consists of the following relationships being 
associated with high tHcy: low plasma 5-MTHF, older age, low total RBC folate, low 
RBC 5-MTHF, low CRP, low B12, and high plasma folic acid.  
Table 4-17. Correlation of selected continuous variables in African American 
current users. 
 Spearman 
Correlation 
Coefficient (n) 
Significant 
P values 
 tHcy  
Plasma 5-MTHF -0.39 (41) 0.011 
Age 0.46 (41) 0.003 
 Plasma 5-MTHF  
Total RBC folate 0.46 (41) 0.003 
RBC 5-MTHF 0.43 (41) 0.005 
 Total RBC folate*  
CRP* 0.45 (41) 0.004 
B12* 0.36 (37) 0.027 
 RBC 5-MTHF  
CRP* 0.33 (41) 0.034 
B12* 0.34 (37) 0.042 
 Plasma FA  
Age 0.36 (41) 0.021 
*Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; CRP values of 
“<0.3” were given the value of 0.3; B12 values of “>1000” were given values of 1000 
 
 In Caucasian current users tHcy levels were positively correlated with age 
(p=<0.0001) and plasma folic acid (p=0.013, Table 5-18). Plasma 5-MTHF was 
positively correlated with total RBC folate (p<0.0001) and in particular RBC 5-MTHF 
(p<0.0001). Plasma 5-MTHF was negatively correlated with plasma folic acid (p=0.047). 
Total RBC folate was positively correlated with the following: plasma folic acid 
(p=0.025), CRP (p<0.0001), and age (p=0.002). In particular it was RBC 5-MTHF which 
was positively correlated with the following: plasma folic acid (p=0.018), CRP 
(p=0.0003), and also B12 (p=0.029). RBC THF was another folate derivative also 
positively correlated with plasma folic acid (p=0.020) and CRP (p=0.046). In addition 
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RBC THF was positively correlated with age (p=0.011). Plasma folic acid was positively 
correlated with age (p<0.0001) and B12 (p=0.0002). PGA scores were positively 
correlated with CRP levels (p=0.003). CRP was negatively correlated with B12 (p=0.014). 
B12 was positively correlated with age (p=0.006). There were no clear profiles which 
developed because plasma folic acid was negatively correlated with plasma 5-MTHF and 
positively correlated with total RBC folate but plasma 5-MTHF was positively correlated 
with total RBC folate.    
Table 4-18. Correlation of selected continuous variables in Caucasian current users. 
 Spearman 
Correlation 
Coefficient (n) 
Significant 
P values 
 tHcy  
Age 0.35 (175) <0.0001 
Plasma FA 0.19 (178) 0.013 
 Plasma 5-MTHF  
Total RBC folate 0.32 (175) <0.0001 
RBC 5-MTHF 0.34 (175) <0.0001 
Plasma FA -0.15 (178) 0.047 
 Total RBC folate*  
Plasma FA 0.17 (175) 0.025 
CRP* 0.34 (168) <0.0001 
Age 0.24 (172) 0.002 
 RBC 5-MTHF  
Plasma FA 0.18 (175) 0.018 
CRP* 0.29 (168) 0.0003 
B12* 0.17 (167) 0.029 
 RBC THF  
Plasma FA 0.18 (175) 0.020 
CRP* 0.15 (168) 0.046 
Age 0.19 (172) 0.011 
 Plasma FA  
Age 0.37 (175) <0.0001 
B12 0.28 (168) 0.0002 
 PGA  
CRP* 0.24 (157) 0.003 
 CRP*  
B12* -0.19 (161) 0.014 
 B12*  
Age 0.21 (166) 0.006 
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* Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; CRP values of 
“<0.3” were given the value of 0.3; B12 values of “>1000” were given values of 1000 
 
4.5 Discussion 
 The SLE study was designed to study associations between polymorphisms of 
enzymes in the folate/Hcy pathway and elevated Hcy levels. Since elevated Hcy is 
predictive of CAC scores (Von Feldt et al. 2006), associations between genetic variants 
and CAC scores was also analyzed. African Americans had significantly different 
genotype distributions than Caucasians and therefore the analyses were performed within 
each race. Previous reports have shown that African American and Caucasian genotype 
frequencies are significantly different. For example MTHFR 677C>T and 1298A>C 
polymorphisms have higher frequencies of the variant genotype in Caucasians as 
compared to African Americans (Tsai et al. 2009). Also MTR 2756A>G (Tsai et al. 
2009), MTRR 66A>G (Shi et al. 2003; Tsai et al. 2009), CBS 844ins68 (Pepe et al. 1999; 
Tsai et al. 2009), and TYMS 1494del6 (Ranganathan et al. 2004)  have all been reported 
to have different genotype frequencies when African Americans and Caucasians were 
compared. In the SLE study frequencies of DHFR c.86+60_78 genotypes also differed 
between races. None of the polymorphisms which were examined had significantly 
different distributions when comparing SLE cases and controls in each race. This 
indicated that none of the polymorphisms in the SLE study were related to increased risk 
of SLE. The literature suggests that in some populations these polymorphisms may carry 
increased risk. An Italian study reported that the MTHFR 677TT genotype was 
overrepresented in SLE patients (Afeltra et al. 2005). While a Polish study could not 
replicate the finding regarding MTHFR 677C>T genotypes but instead observed an 
overrepresentation of the MTR 2756G allele in SLE patients (Burzynski et al. 2007). 
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 As far as the effects of polymorphisms on Hcy levels of SLE patients there was a 
report in the literature which was consistent with our findings. A study by Fijnheer et al. 
(1998) found that MTHFR 677C>T genotypes were not associated with Hcy levels in 
SLE patients. In our control group the MTHFR 677TT genotype was associated with 
higher tHcy levels. Also in the control group MTHFR 1298C carriers had lower tHcy 
levels. These findings are consistent with reports from the literature. In healthy Irish men 
from the Industrial Workers study the MTHFR 677TT genotype was associated with 
elevated tHcy concentrations (Harmon et al. 1996). A study by Parle-McDermott et al. 
showed that the MTHFR 1298C allele was associated with increased RBC folate levels 
(Parle-McDermott et al. 2006b). There was a report from a large scale study that was not 
consistent with the MTHFR 1298 allele having a decreased Hcy/increased folate 
phenotype. The MTHFR 1298C allele was associated with higher Hcy levels and lower 
serum folate concentrations in a large scale study in healthy individuals (Ulvik et al. 
2007).   In the SLE study folate, B12, and B6 levels were not available but instead use of 
vitamin supplements was studied as a surrogate. Vitamin use did not have any effect on 
Hcy levels. Kidney function as measured by GFR was negatively correlated with Hcy 
levels, which was consistent with reports from the literature. A study in the US showed 
that low GFR was significantly associated with elevated Hcy concentrations (Francis et 
al. 2004).   
 Although the SLE study has some limitations, the magnitude of the difference in 
tHcy levels between SLE cases and controls suggested that genetic factors might be 
responsible for the elevation of tHcy in SLE cases. THcy concentrations of Caucasian 
controls were associated with MTHFR 677C>T and 1298A>C genotypes. In SLE cases 
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tHcy concentrations were not associated with any of the 7 polymorphisms even with 
adjustment for covariates, such as GFR. Also none of the 7 polymorphisms were 
associated with CAC scores. We acknowledge that the size of our study population 
precludes a conclusion that there are no contributing genetic factors for elevated tHcy 
levels. Our SLE study suggests that if genetic factors are involved it is likely that they 
would have a relatively small effect. The higher tHcy levels observed in SLE cases is 
likely due to inflammatory aspects of the SLE disease process itself, which might 
dominate over any genetic effects.  
In the RA study, which measured tHcy and folate derivatives using a high 
precision method, several polymorphisms in enzymes of the folate/Hcy metabolism were 
associated with levels of these metabolites in current MTX users. In Caucasians the 
MTHFR 677C>T polymorphism had a large impact on folate derivative levels. The 
distribution of RBC folate derivatives was significantly altered. RBC 5-MTHF levels in 
MTHFR 677TT homozygotes were much lower and RBC THF levels were much higher 
than 677C carriers. The ratio of 5-MTHF:THF was therefore impacted and was 
dramatically lower in 677TT individuals. Detection of RBC 5,10-MTHF was associated 
with the 677TT genotype. These results are similar to those observed in Caucasians in the 
Premenopausal Women study {{597 Summers,C.M. 2010}}, except that 677TT 
individuals in the Premenopausal Women study had increased tHcy levels while there 
was no such association in RA patients currently taking MTX.  The impact of this 
polymorphism was large enough to warrant the removal of individuals with the 677TT 
genotype from further analyses involving tHcy and folate derivatives in the RA study. 
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In Caucasian current users RFC1 80A>G was another polymorphism which was 
associated with altered levels of folate derivatives. RFC1 80AA homozygotes had lower 
total RBC folate and lower RBC 5-MTHF levels. This seems to be consistent with 
findings in the Premenopausal Women study where African American RFC1 80G 
carriers had lower RBC THF levels and higher ratios of 5-MTHF:THF (Summers et al. 
2010). In Caucasian current users the MTRR 66A>G polymorphism was found to be 
associated with lower RBC THF, higher ratios of 5-MTHF:THF, and also was associated 
with non-detectable RBC 5,10-MTHF. These were novel associations.   
In African Americans the DHFR del/del genotype was associated with lower RBC 
THF levels and higher ratios of 5-MTHF:THF. DHFR del/del genotype is associated in 
the literature with higher serum and RBC folate in healthy women (Stanislawska-
Sachadyn et al. 2008a). Our finding seems to be inconsistent, but since total RBC folate 
levels were not significantly different in African Americans with RA currently taking 
MTX it is hard to draw any final conclusion. African American DHFR del/del individuals 
were being prescribed lower doses of MTX. The TYMS 1494del6 polymorphism in 
African Americans was also associated with current MTX dose. TYMS ins/ins 
individuals were being prescribed lower doses of MTX.  These polymorphisms may be 
associated with efficacy at a lower dose of MTX but further studies will be needed to 
validate this observation. 
A Middle Eastern study in RA patients found that the MTR 2756GG genotype 
was overrepresented in RA patients when compared to controls (Berkun et al. 2007). The 
RA study did not have controls available to replicate this finding but instead found MTR 
2756G carriers were associated with attributable toxicities while taking MTX. It is 
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possible that this polymorphism may increase risk for RA as well as increase toxicities 
while on MTX therapy.  
In an RA study in Slovenia the MTHFR 1298CC genotype was associated with a 
protective effect, a decreased risk of overall toxicity (Bohanec Grabar et al. 2008). While 
the RA study did not replicate this finding we instead found that the MTHFR 1298CC 
genotype in Caucasians was associated with discontinuation of MTX therapy. This 
finding in Caucasians is consistent with a study in Dutch RA patients that found the 
MTHFR 1298AA genotype was associated with efficacy and less overall toxicities 
(Wessels et al. 2006). The RA study also found that the MTHFD1 1958GG genotype in 
Caucasians was associated with increased attributable toxicities. This finding was 
contradictory to the finding that the MTHFD1 1958AA genotype in African Americans 
was associated with discontinuation of MTX therapy. There is not any biological 
explanation as to why the same polymorphism in different races would carry very 
different associations.  
The RFC1 80GG genotype in an RA study in Slovenia was associated with 
increased risk of overall toxicity (Bohanec Grabar et al. 2008). A study in US RA 
patients found that a favorable response to MTX was associated with the RFC1 80AA 
genotype (Dervieux et al. 2004). Although the RFC1 80G>A polymorphism has 
consistent results in the literature, this finding was not replicated in the RA study. Overall 
the RA study has found that different polymorphisms in African Americans and 
Caucasians are associated with differences in tHcy and folate metabolites, being 
prescribed lower doses of MTX, and increased risk for attributable toxicities and 
discontinuation of MTX. 
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Elevated CRP levels are indicative of systemic inflammation, are associated with 
presence of an inflammatory disease, and are also associated with increased risk for 
cardiovascular disease (Windgassen et al. 2011). In the RA study CRP levels were 
positively associated with total RBC folate and specific RBC folate derivatives in both 
African American and Caucasian subjects. This association is not easily explained and it 
is possible that folic acid taken with MTX may be blocking some of its anti-inflammatory 
effect, although further studies are required to support this finding. The RA study has 
provided evidence that polymorphisms in enzymes of the folate/Hcy metabolic pathway 
may be able to predict therapeutic outcome. Larger studies with special attention to race 
and which make use of high precision methods for measurement of folate/Hcy 
metabolites will be required to validate these findings.   
  
101 
Chapter 5: The Effect of Methotrexate Alone and on the Activation of Endothelial 
Cells 
 
5.1 Abstract 
Mild folate deficiency is known to be associated with a proatherosclerotic 
phenotype in endothelial cells. EA.hy 926 endothelial cells grown in low (Lo) folate 
conditions had higher levels of monocyte chemoattractant protein 1 (MCP-1) then cells 
grown in normal (Hi) folate conditions. Methotrexate (MTX) is an anti-folate drug used 
to treat a broad range of diseases including inflammatory diseases. MTX seems to have 
conflicting properties of anti-folate and anti-inflammatory, therefore Hi and Lo cells were 
treated with MTX at concentrations relative to peak plasma concentrations after low dose 
administration in rheumatoid arthritis patients. Tumor necrosis factor alpha (TNF-α) is a 
cytokine which is involved in systemic inflammation. The effect of MTX in the presence 
of TNF- α, an inflammatory stimulus, was examined by pre-treating the cells with MTX 
for 24hrs before exposing the cells to TNF-α. Activation of endothelial cells by TNF-α 
stimulates inflammatory gene expression. It was investigated whether MTX treatment 
was associated with an anti-folate effect or an anti-inflammatory effect at concentrations 
relative to those seen in the treatment of rheumatoid arthritis. 
When Hi and Lo cells were treated with MTX cellular proliferation was inhibited, 
total intracellular folate was depleted, the composition of intracellular folate derivatives 
was altered, and levels of unmetabolized folic acid were higher. Microarray analysis was 
used to examine MTX induced gene expression in Hi and Lo cells. There were over 100 
two-fold or higher differentially expressed genes. Specifically there was differential gene 
expression of several inflammatory genes which included up regulation of C3 and IL-8, 
and down regulation of a large set of genes involved in mitosis. Dihydrofolate reductase 
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(DHFR), an enzyme in folate metabolism and target of MTX, was also down regulated. 
There was no change in MCP-1 levels. Selected targets were confirmed by quantitative 
RT-PCR and ELISA. MTX treatment may involve a more complex modulation of 
inflammation than previously assumed. 
5.2 Introduction 
Elevated circulating levels of the intermediate amino acid Hcy, referred to as 
hyperhomocysteinemia, has been associated with a wide range of human pathologies 
including cardiovascular disease, stroke (Refsum et al. 1998), Alzheimer’s disease 
(Mattson and Shea 2003), some cancers (Weinstein et al. 2001), and birth defects (van 
der Put et al. 2001). Hyperhomocysteinemia is generally underpinned by low folate 
status, in which both the absolute (Kang et al. 1987; Selhub et al. 1996) and relative 
(Mitchell et al. 2009) concentrations of intracellular folate derivatives may be altered. 
Historically elevated Hcy was considered to be the pathogenic component in the 
conditions with which hyperhomocysteinemia has been associated because of its direct 
toxic effects on redox thiol status and ER stress response (Koch et al. 1998). However, 
alternative causative mechanisms implicating low folate concentrations and their negative 
impact on processes such as nucleic acid synthesis and methylation have been suggested 
(Lucock 2000). 
Many of the medical conditions which are associated with a high Hcy and low 
folate phenotype have inflammatory aspects and involve damage to, or dysfunction of, 
the vasculature and its constituent cell types, in particular endothelial cells. Inappropriate 
or sustained activation of immunologically active endothelial cell products might 
contribute to ongoing pathology at the local and possibly also systemic level.  In recent 
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studies, EA.hy 926 endothelial cells grown under low folate conditions adopted a 
‘proatherosclerotic’ phenotype compared to cells grown under high folate conditions 
without displaying any significant differences in intracellular or extracellular Hcy levels 
(Brown et al. 2006). This low folate phenotype was characterized by elongated cell 
morphology with prominent networks of stress fibers and impaired barrier function. A 
significantly increased synthesis and export of monocyte chemoattractant protein 1 
(MCP-1) was observed in the cells grown under low folate conditions (Brown et al. 
2006). MCP-1, a potent chemokine encoded by the CCL2 gene, is synthesized by various 
cell types including vascular smooth muscle cells in response to oxidized lipid. MCP-1 
facilitates the transmigration of monocytes from the circulation across the endothelium 
and is a key contributor to the early stages of atheroma formation (Schwartz et al. 1991). 
In cultured human monocytes Hcy induced the secretion of MCP-1 and IL-8, a neutrophil 
chemoattractant (Zeng et al. 2003). The above in vitro observation has been corroborated 
in vivo in a study of young healthy adults in whom serum MCP-1 levels were inversely 
associated with serum and red blood cell folate concentrations, and positively associated 
with circulating tHcy concentrations (Hammons et al. 2009). These finding have 
reinforced speculation that folate stress, which is indicative of poor nutritional status, 
might augment aspects of baseline inflammatory preparedness to facilitate a more 
vigorous initial responses to infectious challenges in individuals weakened by 
malnutrition (Lu et al. 2009).  
The central role of folate in nucleotide synthesis has been exploited 
pharmacologically via the development of potent anti-folate drugs for the treatment of 
neoplastic and auto-immune conditions. One of the most widely used anti-folate drugs is 
  
104 
methotrexate (MTX), which inhibits the key enzymes dihydrofolate reductase (DHFR), 
thymidylate synthase (TYMS), glycinamide ribonucleotide transformylase (GART), and 
aminoimidazolecarboxamide ribonucleotide transformylase (AICART) (Kremer 
2004)(Figure 5-1). High dose MTX is a component of diverse therapeutic regimens for 
several cancers including acute lymphoblasic leukemia, while lower doses are used to 
treat inflammatory diseases such as rheumatoid arthritis (RA). In the latter condition, 
MTX tends to be well tolerated with relatively minor side effects and there is clear 
therapeutic benefit in reducing the inflammatory aspects of the disease that contribute to 
joint damage (Coury and Weinblatt 2010). However, RA patients have significant 
cardiovascular comorbidity (Nurmohamed 2009) and there is controversy as to whether 
MTX exacerbates or ameliorates this serious source of co-mortality.  An early study in 
the use of MTX in the treatment of rheumatoid arthritis patients with existing CVD 
indicated that mortality was increased (Landewe et al. 2000). Conversely, several more 
recent studies have suggested that MTX use is associated with a decrease in the incidence 
of CVD events and mortality (Choi et al. 2002; Naranjo et al. 2008; van Halm et al. 
2006), although it remains unclear whether such a decrease would reflect a full or only 
partial amelioration of inflammation-attributable CVD.  
 Over expression of TNF-α is involved in many inflammatory diseases including 
rheumatoid arthritis and atherosclerosis (Parameswaran and Patial 2010). The possibility 
that low folate status, due to nutritional variables or the use of anti-folate drugs, 
contributes to human disease by inducing a subset of potentially pathogenic 
inflammation-associated molecules, including MCP-1, is of considerable public health 
interest. The characterization of changes to the inflammatory profile that might be 
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induced by drugs such as MTX, alone and prior to exposure to TNF-α, would serve as the 
foundation for future studies to define the precise relationship between dysregulation of 
folate metabolism and inflammation. This study was designed to investigate the effect of 
pharmacologically relevant doses of MTX on the absolute and relative concentrations of 
key folate derivatives and gene expression in the EA.hy 926 endothelial cell line. The 
potential implications of observations concerning the up-regulation of key inflammatory 
proteins are discussed. 
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Figure 5-1. Folate/Homocysteine pathway and MTX inhibition. 5-MTHF, 5-
methyltetrahydrofolate; 5,10-MTHF, 5,10-methenyltetrahydrofolate; DHF, dihydrofolate; 
DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP, 
deoxyuridine monophosphate; Hcy, homocysteine; MTX, methotrexate; SAH, S-
adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate; TYMS, 
thymidylate synthase. 
 
5.3 Methods 
 5.3.1 EA.926 cell line experiments  
 Cell Culture 
The EAhy.926 cell line is a fusion product between human umbilical vascular 
endothelial cells (HUVECs) and the epithelial cell line A549 derived from a human lung 
carcinoma (Edgell et al. 1983). EA.hy 926 cells were maintained in DMEM with 10% 
fetal calf serum (FCS), gentamycin, penicillin, streptomycin, and fungizone. Lo cells 
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were adapted to growth under low folate conditions for three weeks in Medium 199 
(Gibco, Invitrogen, Carlsbad, CA), which contains 23nM folic acid, and supplemented 
with 10% FCS, non-essential amino acids, gentamycin, penicillin, streptomycin, and 
fungizone. Hi cells were cultured in parallel in Medium 199 with the addition of 4mg/L 
(9uM) folic acid and supplemented as above as previously described (Brown et al. 2006). 
 BrdU Cell Proliferation Assays 
Hi and Lo cells were seeded in their respective media into 96-well plates at a 
density of 1x10^4 cells per well. After overnight incubation triplicate cultures were given 
fresh media containing 0, 0.1, 0.25, or 0.5uM MTX (Sigma-Aldrich, St. Louis, MO). 
After 24 and 48 hours media was removed and adherent cells were fixed and stained 
using the Cell Proliferation ELISA, BrdU Colorimetric kit (Roche Diagnostics, 
Indianapolis, IN) according to the manufacturer’s instructions. Colorimetric analyses 
were performed with an ELISA plate reader (Dynex Technologies, Chantilly, VA).  
 Cell Viability Assays 
Hi and Lo cells, grown to confluence in 6-well plates, were maintained for 24 
hours in fresh medium prior to the addition of 0, 0.1, 0.25, or 0.5µM MTX. After a 
further 48 hours the numbers of live cells remaining were determined in duplicate with an 
electronic cell counter (Scepter, Millipore, Bedford, MA). For experiments involving 
TNF-α (Invitrogen), cells were treated for 24hrs with 0.5µM MTX followed by the 
addition of 10ng/mL TNF- α for an additional 24hrs.  The numbers of live and dead cells 
in each treatment group were also determined by counting using a hematocytometer and a 
dye exclusion assay using 0.4% w/v trypan blue solution (Mediatech, Herndon, VA).  
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Alamar Blue Assays 
Fresh medium was added to confluent Hi and Lo cell cultures grown in 96-well 
plates, and treated 24 hours later with 0, 0.1, 0.25, 0.5µM MTX. After 2, 8, 16, 24, and 48 
hours metabolic activity was measured in biological triplicates by Alamar Blue Assay 
(Trek Diagnostic Systems, West Lake, OH) according to the manufacturer’s directions. 
For experiments involving TNF-α, cells were treated for 24hrs with 0.5µM MTX 
followed by the addition of TNF- α for an additional 24hrs. 
 Biochemical Phenotyping 
Confluent Hi and Lo cells were maintained for 24 hours in fresh medium prior to 
treatment with 0.5µM MTX for 48hrs. For experiments involving TNF-α, cells were 
treated for 24hrs with 0.5µM MTX followed by the addition of TNF- α for an additional 
24hrs. Intracellular folate derivatives, i.e. 5-MTHF, THF, 5,10-methenyltetrahydrofolate 
(5,10-MTHF), and unmetabolized folic acid (FA), were measured in biological triplicates 
by stable isotope dilution liquid chromatography, multiple reaction monitoring, mass 
spectrometry (LC/MRM/MS) as described previously (Huang et al. 2008). 
 Affymetrix Microarrays 
RNA was isolated from biological triplicates with the RNeasy kit (Qiagen Inc., 
Valencia, CA) and reverse transcribed to cDNA using the Affymetrix WT Expression kit 
(Ambion, Austin, TX). Subsequent experimental procedures and statistical analyses of 
microarray signals were performed by the University of Pennsylvania Microarray and 
Bioinformatics core facilities respectively as follows. The purity and size distribution of 
cDNA was assessed using the Agilent Bioanalyzer and RNA6000 Nano LabChips 
(Agilent, Palo Alto, CA), and quantitation was performed using a Nanodrop 
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spectrophotometer (Thermo Scientific, Wilmington, DE), prior to their hybridization to 
Affymetrix Human Gene 1.0 ST microarrays. Washing and staining of the microarrays 
was done on an Affymetrix 450 series fluidics machine. Scanning of each microarray was 
performed with an Affymetrix Gene Chip Scanner 3000 to produce Cel files that were 
imported into Partek Genomics Suite v6.5 (Partek Inc., St Louis, MO) where robust 
multi-array analysis (RMA) was applied. A fold change of >2 and false discovery rate of 
5%, corresponding to a corrected p-value of <0.05 were chosen as the cutoffs. The 
microarray data have been deposited in the National Center for Biotechnology 
Information Gene Expression Omnibus (GEO, http://www.nlm.nih.gov/geo/) and are 
accessible through GEO Series accession number [will be available soon]. 
 Quantitative Real Time PCR (qRT-PCR) 
RNA was prepared from biological triplicates of control and MTX treated Hi and 
Lo cells using the RNeasy kit (Qiagen Inc.). For experiments involving TNF-α, RNA was 
prepared from biological triplicates of control, MTX treated, TNF-α treated, and 
MTX/TNF-α treated Hi and Lo cells. Reverse transcription was carried out with MMLV 
reverse transcriptase (Promega, Madison, WI) as described previously (Brown et al. 
2006). To determine the amount of target mRNA relative to that transcribed from the 
housekeeping gene GAPDH, qRT-PCR was carried out in 20ul reactions containing 1ul 
cDNA, 1ul Taqman Gene Expression Assay (Applied Biosystems, Foster City, CA) in 
Taqman Universal master mix (Applied Biosystems). The Applied Biosystems assay ID 
numbers were Hs01100879_m1 for C3, Hs00174103_m1 for IL-8 (encoded by CXCL8), 
Hs00758822_s1 for DHFR, Hs00365486_m1 for VCAM-1, Hs00164932_m1 for ICAM-
1, and Hs00174057_m1 for E-selectin. GAPDH and MCP-1 (encoded by CCL2) qRT-
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PCR assays were performed as previously described (Brown et al. 2006). All samples 
were assayed in duplicate. 
 ELISA Assays 
 Confluent Hi and Lo cells were maintained for 24 hours in fresh medium prior to 
treatment with 0.5µM MTX. After a further 48hrs MCP-1, IL-8, and C3 concentrations in 
medium from MTX treated and untreated control cells were measured in biological 
triplicates. For experiments involving TNF-α, cells were treated for 24hrs with 0.5µM 
MTX followed by the addition of TNF- α for an additional 24hrs. Secreted proteins were 
measured using an MCP-1 ELISA kit (PeproTech, Inc, Rocky Hill, NJ), an IL-8 ELISA 
kit (BD Biosciences, San Diego, CA), and a C3 ELISA kit (Innovative Research, Novi, 
MI) with adjustment for protein content in the corresponding cell fraction. All samples 
were assayed in duplicate. 
 Statistics 
 Differences between means were compared by two-tailed Student’s t-test. 
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC). 
5.4 Results 
5.3.1 EA.926 cell line experiments 
MTX Dose finding 
Peak concentrations of plasma MTX in patients undergoing treatment for RA 
have been reported to fall within a range of 0.37-1.36µM (Lebbe et al. 1994).  This 
guided our selection of test MTX doses (i.e. 0.1, 0.25, and 0.5µM) that were applied to 
Ea.hy 926 cells to identify a concentration that was pharmacologically relevant but did 
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not cause excessive cell death or compromise overall metabolic activity. Several methods 
were used as detailed below. 
The Effect of MTX on EA.hy 926 Cell Proliferation 
 BrdU cell proliferation assays were performed on Hi and Lo cells following 24 
and 48 hours of treatment with all test doses of MTX. A dose dependent inhibition of 
proliferation in MTX treated Hi cells was observed relative to control untreated cells 
(Figure 5-2A), whereas MTX significantly inhibited proliferation at all concentrations 
tested in Lo cells (p<0.05) (Figure 5-2B). Comparable proliferation readouts were 
observed for untreated Hi and Lo cells and similar levels of inhibition (approximately 
84%) were observed for both using the 0.5µM dose of MTX. 
The Effect of MTX and TNF-α on EA.hy 926 Cell Viability 
The proportions of Hi and Lo cells that remained viable after treatment with 
0.5µM MTX, TNF-α, and MTX/TNF-α were determined using two independent methods. 
By Trypan Blue exclusion assay, the percentages of live cells treated with MTX, TNF-α, 
MTX/TNF-α, and untreated Hi cells were 96%, 95%, 92%, and 99% respectively. The 
percentages of live cells treated with MTX, TNF-α, MTX/TNF-α, and untreated Lo cells 
were 67%, 94%, 53%, and 96% respectively (data not shown). Direct counting using a 
handheld electronic cell counter, the Scepter, indicated that MTX treated Hi cells had 
77% as many live cells as controls (p=0.001) and TNF-α treated had 81% (p=0.001) and 
MTX/TNF-α treated had 66% (p<0.0001). The percent of live cells for MTX treated Lo 
cells was 69% compared to controls (p=0.002) and TNF-α treated had 84% (p=0.020) 
and MTX/TNF-α had 53% (p<0.0001) (data not shown). Thus, by both methods 0.5µM 
MTX had only a minimal impact on Hi cell viability and a moderate impact on Lo cell 
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viability. TNF-α had a minimal impact on viability alone and therefore MTX/TNF- α 
treated cells showed similar viability to MTX treatment alone. 
The Effect of MTX on EA.hy 926 Cell Metabolic Activity 
Alamar Blue assays were performed on confluent Hi and Lo cell cultures 
following treatment with all test concentrations of MTX (i.e. 0.1, 0.25, 0.5µM) for 2, 8, 
16, 24, and 48 hours in order to estimate reductions in basic metabolic activity over time. 
None of the MTX concentrations had a substantial impact on metabolic activity in either 
series (Figure 5-2C and 5-2D). Hi and Lo cells treated with the highest dose of MTX 
(0.5µM) for 48 hours retained more than 79% (p= 0.005) and 82% (p=0.029) of the 
untreated control Alamar Blue readouts respectively, indicating that metabolism 
remained largely intact in MTX treated cells. 
Alamar blue assays were performed on Hi and Lo cells treated with 0.5µM MTX 
alone, TNF-α alone, and the combination of MTX/TNF-α and were compared to control 
readouts. MTX treated Hi cells maintained 78% metabolic activity (p=0.003) (Figure 5-
2E). TNF-α treated Hi cells had 99% and MTX/TNF-α treated Hi cells had 70% 
(p=0.005) metabolic activity compared to controls. In Lo cells treated with MTX 
metabolic activity was 72% (p=0.006) compared to controls. TNF-α treated Lo cells had 
83% (p=0.007) and MTX/TNF-α treated Lo cells had 67% (p=0.004) metabolic activity 
compared to controls. 
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2D 
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Figure 5-2. MTX dose finding and viability experiments. A, Recently plated EA.hy 
926 Hi cells were incubated overnight and plating medium was replaced with Hi medium 
containing various concentrations of MTX (0.1, 0.25, 0.5uM). After 24 and 48 hours the 
medium was removed and adherent cells were fixed and stained according to the 
manufacturer’s instructions for BrdU quantitation. Each bar represents the mean±SD of 
three samples. This experiment is representative of a total of three experiments with 
similar results. B, Lo cells were submitted to the above described experiments for BrdU 
quantitation. C, Hi confluent cells received a media change containing various 
concentrations of MTX (0.1, 0.25, 0.5uM). Cells were incubated with alamar blue for 2 
hours. After 2, 8, 16, 24, and 48 hours of exposure to MTX absorbance was measured 
and calculated as the percentage of control. Each bar represents the mean±SD of three 
samples. This experiment is representative of a total of three experiments with similar 
results. D, Lo cells were submitted to the above described experiments for the alamar 
blue assay. E, Confluent Hi and Lo cells received a media change, 24hrs later 0.5uM 
MTX was added. Then 24hrs later 10ng/mL TNF-α was added and after 22hrs alamar 
blue was incubated with the cells for 2hrs. Absorbance was measured and calculated as 
the percentage of control. Each bar represents the mean±SD of three samples. This 
experiment is representative of a total of three experiments with similar results.  *P 
values <0.05 compared with respective control. 
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Taken together the above results suggested that MTX at a concentration of 0.5µM 
would be an appropriate, pharmacologically relevant dose at which to explore the impact 
of anti-folate drug treatment on folate phenotype and gene expression profile. Also the 
above results suggested that TNF-α did not substantially impact cell viability and 
metabolic activity beyond that of MTX. 
Modulation of Folate Phenotype in EA.hy 926 Cells by MTX 
 Exposure of confluent Hi and Lo EA.hy 926 cell cultures to 0.5µM MTX for 48 
hours resulted in qualitative and quantitative changes to folate phenotype in both. There 
was a dramatic almost 20-fold increase in unmetabolized folic acid from a mean of 32.9 
ng per mg protein in untreated Hi cells to 630.4 ng per mg protein in MTX treated Hi 
cells (p=0.003, Figure 5-3A). This indicated that Hi cells were able to take up folic acid 
from the medium in the presence of MTX and that the drug efficiently inhibited DHFR 
activity to prevent the step-wise conversion of folic acid to DHF and THF and its 
subsequent entry into the cellular pool of natural folates. The accumulation of folic acid 
in MTX treated Hi cells was accompanied by a quantitative reduction in total intracellular 
folate (i.e. the sum of the three derivatives 5-MTHF, THF, and 5,10-MTHF) from 2099.1 
ng per mg protein in untreated cells to 144.2 ng per mg protein (p=0.003) in MTX treated 
cells, which is a reduction to only 7% of the levels observed in untreated control cells. 
Although the concentrations of each of the individual folate analytes also fell (i.e. 5-
MTHF levels from 901.8 to 8.9 ng per mg protein p<0.001, THF levels from 506.3 to 
45.5 ng per mg protein p=0.001, and 5,10-MTHF levels from 690.0 to 89.8 ng per mg 
protein p=0.008) they did so with different degrees. MTX treated Hi cells had 5-MTHF, 
THF, and 5,10-MTHF concentrations that were respectively 1%, 9%, and 13% those 
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observed in untreated cells. Thus the individual folates represented very different 
proportions of total folate in untreated Hi cells compared to MTX treated Hi cells (43% 
to 6% for 5-MTHF, 24% to 32% for THF, and 33% to 62% for 5,10-MTHF). 
Folic acid levels were estimated to be 12.4 ng per mg protein in untreated Lo cells 
compared to 22.6 ng per mg protein in MTX treated Lo cells (Figure 5-3B). Although 
this increase was not statistically significant Lo cells were able to take up folic acid in the 
presence of MTX but were unable to process it due to inhibition of DHFR. Total folate 
levels did not change significantly and went from 102.1 ng per mg protein in untreated 
Lo cells to 107.5 ng per mg protein in MTX treated Lo cells. Estimates of individual 
folate derivatives also did not change significantly. 5-MTHF levels were estimated to be 
16.8 ng per mg protein in untreated Lo cells compared to an estimate of 15.8 ng per mg 
protein in MTX treated Lo cells. THF levels were estimated to be 12.4 ng per mg protein 
in untreated Lo cells compared to an estimate of 15.8 ng per mg protein in MTX treated 
cells (p=0.005). 5,10-MTHF levels were 72.9 ng per mg protein in untreated Lo cells 
compared to 75.8 ng per mg protein in MTX treated cells. 
TNF-α treated Hi and Lo cells had folate derivative distributions that were similar 
to control cells (Figure 3C and 3D). MTX/TNF-α treated Hi and Lo cells had folate 
derivative distributions that were similar to MTX treated cells. The results described 
above regarding the effect of MTX alone were similar in this experiment. In Hi cells total 
folate decreased from 1241.7 ng per mg protein in control cells to 111.3 ng per mg 
protein in MTX treated cells, which represented a drop to 9% of control levels. Folic acid 
levels increased from 5.0 ng per mg protein in control Hi cells to 338.2 ng per mg protein 
in MTX treated Hi cells. This was a 67.6 fold increase in folic acid levels. In Lo control 
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cells total folate levels decreased from 19.1 ng per mg protein to 1.9 ng per mg protein in 
MTX treated Lo cells. Total folate levels dropped to 9.9% of control levels. Folic acid 
levels were not significantly different; they were 2.3 ng per mg protein in control cells 
and 3.8 ng per mg protein in MTX treated cells. This was a 1.7 fold increase in folic acid 
levels. 
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Figure 5-3. Folate derivatives measured by LC/MRM/MS. A, Hi confluent cells were 
treated with 0.5uM MTX for 48 hours. Each bar represents the mean±SD of three 
samples. This experiment is representative of a total of three experiments with similar 
results. B, Lo confluent cells were treated with 0.5uM MTX for 48 hours. Each bar 
represents the mean±SD of three samples. This experiment is representative of a total of 
three experiments with similar results except that in some experiments MTX treated Lo 
cells did have decreased levels of folate derivatives. C, Confluent Hi cells received a 
media change, 24hrs later 0.5uM MTX was added. Then 24hrs later 10ng/mL TNF-α was 
added and after 24hrs cells were harvested. Each bar represents a single sample and 
hence p values were not calculated. This experiment is representative of a total of three 
experiments with similar results. D, Lo cells were treated as in the above described 
experiment. *P values <0.05 compared with respective control. 
 
In Hi cells it was observed that MTX not only dramatically increased folic acid 
and decreased total folate, but also modified the relative proportions of folate derivatives, 
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while in Lo cells MTX was estimated to have little effect on folate derivative levels and 
only a small increase in folic acid. 
MTX Attributable Changes in Gene Expression 
The impact of the anti-folate drug, MTX, on gene expression was profiled in both 
Hi and Lo cells using Affymetrix Human Gene 1.0 ST microarrays. Using an arbitrary 
threshold of at least 2.0 fold change in microarray signal in reference to untreated 
controls and adjusted p value <0.05, expression doubled for 47 genes in MTX treated Hi 
cells and 48 genes in MTX treated Lo cells (Table 5-1); of these 37 were in common. 
When the threshold was broadened to include the top 200 positive fold changes which 
were significant, there were 22 inflammatory related genes in MTX treated Hi cells and 
18 in MTX treated Lo cells.  
Table 5-1. Genes Up Regulated by MTX in Hi and Lo Cells. 
   Hi MTX vs. Hi Control Lo MTX vs. Lo Control 
Gene name 
Gene 
Symbol RefSeq 
Corrected 
p-value 
Fold 
Change 
Corrected 
p-value 
Fold 
Change 
complement component 3 C3 NM_000064 0.004518 6.09 0.012688 4.26 
interleukin 1 receptor-
like 1 
IL1RL1 NM_016232 0.03152 5.44 0.064945 4.16 
DNA-damage-inducible 
transcript 3 
DDIT3 NM_004083 0.000816 5.10 0.000896 4.59 
amphiregulin AREG NM_001657 0.036354 4.74 0.037236 4.74 
spermidine/spermine N1-
acetyltransferase 1 
SAT1 NR_027783 0.004794 4.47 0.007019 3.98 
interleukin 8 IL8 NM_000584 0.035674 4.06 0.095036 3.00 
interleukin 1, alpha IL1A NM_000575 0.018629 3.32 0.021271 3.21 
myosin, heavy chain 16 
pseudogene 
MYH16 NR_002147 0.006217 3.20 0.012298 2.75 
ankyrin repeat, family A, 
2 
ANKRA2 NM_023039 0.003436 3.14 0.003602 3.10 
Rho family GTPase 3 RND3 NM_005168 0.014241 2.82 0.053128 2.15 
arginase, type II ARG2 NM_001172 0.000208 2.76 0.000332 2.45 
small nucleolar RNA 
host gene 12 (non-protein 
coding) 
SNHG12 AY277594 0.019755 2.68 0.018825 2.72 
enkurin, TRPC channel 
interacting protein 
ENKUR NM_145010 0.029449 2.63 0.073982 2.17 
basic helix-loop-helix 
family, member e40 
BHLHE40 NM_003670 0.017717 2.61 0.045509 2.17 
TNF receptor-associated 
factor 1 
TRAF1 NM_005658 0.004209 2.59 0.001149 3.43 
CCAAT/enhancer 
binding protein (C/EBP), 
CEBPB NM_005194 0.004179 2.57 0.009084 2.22 
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beta 
tumor necrosis factor 
receptor superfamily, 
member 9 
TNFRSF9 NM_001561 0.000725 2.50 0.000255 3.15 
interleukin 11 IL11 NM_000641 0.005749 2.45 0.006503 2.38 
NIPA-like domain 
containing 4 
NIPAL4 NM_0010992
87 
0.007065 2.44 0.012427 2.20 
jumonji C domain 
containing histone 
demethylase 1 homolog 
D 
JHDM1D NM_030647 0.032722 2.42 0.042911 2.30 
leukemia inhibitory 
factor (cholinergic 
differentiation factor) 
LIF NM_002309 0.026925 2.37 0.021945 2.48 
baculoviral IAP repeat-
containing 3 
BIRC3 NM_001165 0.017913 2.36 0.007347 2.82 
chromosome 9 open 
reading frame 72 
C9orf72 NM_018325 0.000208 2.33 0.000185 2.40 
ATP-binding cassette, 
sub-family A (ABC1), 
member 1 
ABCA1 NM_005502 0.002318 2.32 0.00375 2.12 
nuclear factor, interleukin 
3 regulated 
NFIL3 NM_005384 0.018743 2.30 0.067535 1.85 
kelch repeat and BTB 
(POZ) domain containing 
8 
KBTBD8 NM_032505 0.031108 2.30 0.025622 2.40 
GTP binding protein 
overexpressed in skeletal 
muscle 
GEM NM_005261 0.003204 2.24 0.005476 2.04 
ectonucleoside 
triphosphate 
diphosphohydrolase 7 
ENTPD7 NM_020354 0.004725 2.23 0.0067 2.10 
sestrin 2 SESN2 NM_031459 0.000397 2.21 0.000584 2.04 
arylacetamide 
deacetylase (esterase) 
AADAC NM_001086 0.02442 2.20 0.027336 2.17 
carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
CEACAM1 NM_001712 0.070458 2.20 0.039634 2.49 
ribosomal RNA 
processing 12 homolog 
RRP12 NM_015179 0.004518 2.18 0.00673 2.05 
tumor protein p53 
inducible protein 3 
TP53I3 NM_004881 0.032257 2.16 0.037508 2.11 
protein phosphatase 1, 
regulatory (inhibitor) 
subunit 15A 
PPP1R15A NM_014330 0.000131 2.14 5.13E-05 2.28 
growth arrest and DNA-
damage-inducible, alpha 
GADD45A NM_001924 0.000544 2.13 0.000302 2.32 
GTP cyclohydrolase 1 GCH1 NM_000161 0.011519 2.12 0.004697 2.45 
dual-specificity tyrosine-
(Y)-phosphorylation 
regulated kinase 3 
DYRK3 NM_0010040
23 
0.001218 2.12 0.001422 2.05 
major facilitator 
superfamily domain 
containing 2 
MFSD2 NM_0011364
93 
0.0273 2.10 0.034258 2.02 
nuclear factor of kappa 
light polypeptide gene 
enhancer in B-cells 2 
NFKB2 NM_002502 0.002867 2.09 0.00178 2.25 
zinc finger protein 79 ZNF79 NM_007135 0.003083 2.09 0.003641 2.04 
MAX dimerization 
protein 1 
MXD1 NM_002357 0.024596 2.08 0.022273 2.12 
TAF4b RNA polymerase TAF4B NM_005640 0.005503 2.06 0.007019 1.99 
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II, TATA box binding 
protein (TBP)-associated 
factor 
ankyrin repeat domain 
20B  
ANKRD20
B 
NR_003366 0.016499 2.06 0.032682 1.86 
ring finger protein 114 RNF114 NM_018683 0.000884 2.03 0.001126 1.92 
interleukin 32 IL32 NM_0010126
31 
0.001376 2.02 0.000794 2.15 
kelch-like 21 KLHL21 NM_014851 0.00111 2.01 0.001354 1.92 
alkaline ceramidase 2 ACER2 NM_0010108
87 
0.018718 2.01 0.063154 1.69 
   Greater than 2 fold change in Lo only 
SH2 domain protein 2A SH2D2A NM_0011614
41 
0.382362 1.69 0.049093 2.90 
CD274 molecule CD274 NM_014143 0.121863 1.81 0.034584 2.27 
activating transcription 
factor 3 
ATF3 NM_0010406
19 
0.004794 1.91 0.001585 2.26 
FBJ murine osteosarcoma 
viral oncogene homolog 
B 
FOSB NM_006732 0.070182 1.75 0.016166 2.21 
nuclear receptor 
subfamily 1, group D, 
member 1 
NR1D1 NM_021724 0.000599 1.89 0.000276 2.11 
NUAK family, SNF1-
like kinase, 2 
NUAK2 NM_030952 0.012792 1.76 0.003594 2.09 
SERTA domain 
containing 1 
SERTAD1 NM_013376 0.007894 1.81 0.002907 2.07 
interleukin 13 receptor, 
alpha 2 
IL13RA2 NM_000640 0.001225 1.80 0.000469 2.05 
tribbles homolog 3 TRIB3 NM_021158 0.032254 1.91 0.02104 2.05 
testis derived transcript TES NM_015641 0.001225 1.95 0.000796 2.03 
poliovirus receptor-
related 4 
PVRL4 NM_030916 0.009434 1.80 0.003985 2.00 
 
Two inflammatory genes, C3 and IL-8 topped the lists in both MTX treated Hi 
and Lo cells. C3 was number 1 on the list and was up regulated by 6.09 fold (p=0.005) in 
MTX treated Hi cells. C3 was number 3 on the list in MTX treated Lo cells and up 
regulated by 4.26 fold (p=0.013) (Table 5-1). C3 mRNA levels were verified by qRT-
PCR methods. C3 mRNA levels were confirmed to be significantly up regulated in MTX 
treated Hi and Lo cells (Figure 5-4A). Specifically C3 mRNA levels were up regulated 
by 158.4-fold in MTX treated Hi cells (p=0.018) and 3.9-fold in MTX treated Lo cells 
(p=0.003). Also Lo control cells had 15.4 fold more C3 mRNA than Hi control cells 
(p=0.034). C3 mRNA levels were also measured in TNF-α and MTX/TNF-α treated Hi 
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and Lo cells. MTX/TNF-α treated Lo cells had 2.2 fold more C3 mRNA than TNF-α 
treated Lo cells (p=0.0329) (Figure 5-4B). 
IL-8 was number 6 on the list in MTX treated Hi cells and was up regulated by 
4.06 fold (p=0.036). IL-8 was number 11 on the list and up regulated by 3.00 fold 
(p=0.095) in MTX treated Lo cells (Table 5-1). IL-8 mRNA levels were also confirmed 
by qRT-PCR to be significantly up regulated (Figure 5-4C), specifically IL-8 mRNA 
levels were up regulated by 36.2-fold in MTX treated Hi cells (p=0.041) and 1.9-fold in 
MTX treated Lo cells (p=0.015). Also Lo control cells had 6.7 fold more IL-8 mRNA 
than Hi control cells (p=0.010). 
Another inflammatory gene, MCP-1, that was previously shown to be regulated 
by folate status (Brown et al. 2006), was not significantly different in the microarray 
analysis of MTX treated Hi or Lo cells compared to their respective controls (data not 
shown).  
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4B 
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Figure 5-4. QRT-PCR. The mRNA expression of selected targets was studied by 
qRT-PCR. Gene expression of respective genes was calculated using the standard curve 
method using the endogenous housekeeping control gene GAPDH for normalization. 
Each bar represents mean±SD target expression levels normalized to GAPDH levels of 
three samples. These experiments are representative of a total of three experiments with 
similar results. A, C3. Hi and Lo cells were exposed to 0.5µM MTX for 48 hours. B, C3. 
Hi and Lo cells were treated with MTX prior to treatment with TNF-α. C, IL-8. Hi and 
0
0.5
1
1.5
2
2.5
Hi  Lo
IL
-
8 
N
o
rm
a
liz
ed
 
to
 
G
AP
D
H
Control MTX
* 
* # 
0
5
10
15
Hi  Lo
D
HF
R 
No
rm
al
iz
ed
 
to
 
G
AP
DH
Control MTX
* * 
0.0030.005
0.0570.004
0
0.5
1
1.5
2
2.5
3
Hi  Lo
C3
 
n
or
m
al
ize
d 
to
 
G
AP
DH
Control MTX TNF MTX/TNF
             # 
 
 
 * 
 
  
124 
Lo cells were exposed to 0.5µM MTX for 48 hours. D, DHFR. Hi and Lo cells were 
exposed to 0.5µM MTX for 48 hours. *P values <0.05 compared with respective control. 
#P values <0.05 for Hi control compared to Lo control. 
 
Conversely, expression was reduced by at least 50% for 83 genes in MTX treated 
Hi cells and 85 genes in MTX treated Lo cells (Table 5-2); of these 69 were in common. 
The most prominent in the list are a range of cell cycle related products as might be 
expected following treatment with an anti-folate drug. Also of interest DHFR, which is 
inhibited by MTX, was down regulated by 2.22 fold (p=0.003) in MTX treated Hi cells 
and 2.43 fold (p=0.002) in MTX treated Lo cells (Table 5-2). DHFR mRNA levels were 
confirmed by qRT-PCR to be down regulated, specifically DHFR mRNA levels were 
down regulated by 1.9-fold in MTX treated Hi cells (p=0.010) and 3.6-fold in MTX 
treated Lo cells (p=0.009) (Figure 5-4D). 
A complete list of MTX regulated genes has been deposited in the National 
Center for Biotechnology Information Gene Expression Omnibus (GEO, 
http://www.nlm.nih.gov/geo/) and is accessible through GEO Series accession number 
[will be available soon]. 
Candidate inflammatory gene mRNA levels were examined in TNF-α and 
MTX/TNF-α treated cells. The chosen candidate genes were ICAM1, VCAM1, and E-
selectin. None of the mRNA levels of these genes were significantly different between 
TNF-α and MTX/TNF-α treated cells (data not shown).   
Table 5-2. Genes Down Regulated by MTX in Hi and Lo Cells. 
   Hi MTX vs. Hi Control Lo MTX vs. Lo Control 
Gene name 
Gene 
Symbol RefSeq 
Corrected 
p-value 
Fold-
Change 
Corrected 
p-value 
Fold-
Change 
polo-like kinase 1 PLK1 NM_005030 1.88E-05 -5.25 3.80E-05 -4.68 
histone cluster 1, H2bm HIST1H2B
M 
NM_003521 0.000397 -4.98 0.000584 -4.26 
kinesin family member 
20A 
KIF20A NM_005733 0.009434 -4.11 0.028454 -3.03 
budding uninhibited by 
benzimidazoles 1 
BUB1 NM_004336 0.00019 -3.80 0.000206 -3.55 
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homolog 
protein regulator of 
cytokinesis 1 
PRC1 NM_003981 7.72E-05 -3.80 5.13E-05 -3.74 
DEP domain containing 1 DEPDC1 NM_0011141
20 
0.00138 -3.79 0.002273 -3.30 
topoisomerase II alpha  TOP2A NM_001067 0.000673 -3.63 0.000794 -3.30 
kinesin family member 
15 
KIF15 NM_020242 0.000884 -3.56 0.000502 -4.06 
cyclin A2 CCNA2 NM_001237 0.000891 -3.47 0.001298 -3.08 
proline rich 11 PRR11 NM_018304 0.000251 -3.40 0.000271 -3.43 
transmembrane protein 
71 
TMEM71 NM_144649 0.001489 -3.40 0.00321 -2.82 
NUF2, NDC80 
kinetochore complex 
component, homolog 
NUF2 NM_145697 0.000247 -3.33 0.000469 -2.84 
family with sequence 
similarity 111, member B 
FAM111B NM_198947 0.000616 -3.22 0.000449 -3.43 
centromere protein I CENPI NM_006733 0.000208 -3.15 0.000143 -3.40 
histone cluster 1, H2bb HIST1H2B
B 
NM_021062 0.002254 -3.04 0.003288 -2.77 
NDC80 kinetochore 
complex component, 
homolog 
SPC25 NM_020675 0.000431 -3.00 0.000372 -3.06 
cyclin B2 CCNB2 NM_004701 0.001084 -2.94 0.001676 -2.61 
discs, large (Drosophila) 
homolog-associated 
protein 5 
DLGAP5 NM_014750 0.000691 -2.86 0.001149 -2.50 
cell division cycle 2, G1 
to S and G2 to M 
CDC2 NM_001786 0.002365 -2.84 0.003357 -2.63 
WD repeat domain 76 WDR76 NM_024908 0.001858 -2.84 0.00217 -2.72 
nei endonuclease VIII-
like 3  
NEIL3 NM_018248 0.001214 -2.79 0.002907 -2.34 
cyclin-dependent kinase 
inhibitor 3 
CDKN3 NM_005192 0.010796 -2.79 0.01432 -2.61 
non-SMC condensin I 
complex, subunit H 
NCAPH NM_015341 0.000343 -2.78 0.000297 -2.87 
SHC SH2-domain 
binding protein 1 
SHCBP1 NM_024745 0.004586 -2.75 0.007303 -2.49 
centromere protein F CENPF NM_016343 0.000241 -2.69 0.000297 -2.58 
budding uninhibited by 
benzimidazoles 1 
homolog beta 
BUB1B NM_001211 0.000867 -2.62 0.000614 -2.70 
collagen and calcium 
binding EGF domains 1 
CCBE1 NM_133459 0.004156 -2.59 0.004322 -2.54 
hospholipid scramblase 4 PLSCR4 NM_0011283
04 
0.02513 -2.54 0.075709 -2.05 
KIAA0101 KIAA0101 NM_014736 0.000947 -2.54 0.000693 -2.62 
anillin, actin binding 
protein 
ANLN NM_018685 0.026609 -2.53 0.028161 -2.51 
NDC80 homolog, 
kinetochore complex 
component 
NDC80 NM_006101 0.00131 -2.53 0.002907 -2.19 
shugoshin-like 2 SGOL2 NM_152524 0.001592 -2.51 0.000776 -2.84 
Rho GTPase activating 
protein 11A 
ARHGAP1
1A 
NM_014783 0.001195 -2.51 0.000796 -2.63 
PDZ binding kinase PBK NM_018492 0.001148 -2.48 0.000584 -2.78 
citron (rho-interacting, 
serine/threonine kinase 
21) 
CIT NM_007174 0.00357 -2.48 0.003553 -2.48 
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centromere protein K CENPK NM_022145 0.005066 -2.43 0.003837 -2.56 
NDC80 kinetochore 
complex component, 
homolog 
SPC24 NM_182513 0.001261 -2.42 0.000622 -2.72 
kinesin family member 
11 
KIF11 NM_004523 0.000301 -2.41 0.000321 -2.36 
forkhead box M1 FOXM1 NM_202002 0.00153 -2.40 0.001491 -2.39 
hyaluronan-mediated 
motility receptor  
HMMR NM_0011425
56 
0.044808 -2.38 0.089897 -2.08 
membrane protein, 
palmitoylated 1 
MPP1 NM_002436 0.03532 -2.38 0.083699 -2.02 
cancer susceptibility 
candidate 5 
CASC5 NM_170589 0.000884 -2.36 0.000802 -2.32 
cell division cycle 20 
homolog 
CDC20 NM_001255 0.031901 -2.35 0.033656 -2.34 
kinesin family member 
C1 
KIFC1 NM_002263 0.000947 -2.33 0.000584 -2.49 
primase, DNA, 
polypeptide 1 
PRIM1 NM_000946 0.00197 -2.31 0.000799 -2.67 
meiosis-specific nuclear 
structural 1 
MNS1 NM_018365 0.005897 -2.31 0.002181 -2.80 
kinesin family member 
4A 
KIF4A NM_012310 0.001548 -2.31 0.000802 -2.54 
kinesin family member 
18B 
KIF18B NM_0010804
43 
0.000257 -2.30 0.000332 -2.19 
sperm associated antigen 
5 
SPAG5 NM_006461 0.009803 -2.29 0.017348 -2.08 
minichromosome 
maintenance complex 
component 6 
MCM6 NM_005915 0.001497 -2.27 0.00036 -2.99 
histone cluster 1, H1b HIST1H1B NM_005322 0.00767 -2.26 0.004734 -2.44 
nucleolar and spindle 
associated protein 1 
NUSAP1 NM_016359 0.002992 -2.23 0.003799 -2.15 
excision repair cross-
complementing rodent 
repair deficiency, 
complementation group 
6-like 
ERCC6L NM_017669 0.004792 -2.23 0.004222 -2.27 
dihydrofolate reductase DHFR AK293146 0.002732 -2.22 0.001585 -2.43 
G-protein signaling 
modulator 2 
GPSM2 NM_013296 0.039037 -2.22 0.056481 -2.08 
non-SMC condensin II 
complex, subunit G2 
NCAPG2 NM_017760 0.008014 -2.21 0.006481 -2.28 
transmembrane protein 
106C 
TMEM106
C 
NM_0011438
42 
0.005389 -2.21 0.003569 -2.38 
spindle and kinetochore 
associated complex 
subunit 3 
SKA3 NM_145061 0.020449 -2.20 0.02316 -2.16 
cyclin B1 CCNB1 NM_031966 0.004518 -2.20 0.001875 -2.56 
aldehyde dehydrogenase 
1 family, member A1 
ALDH1A1 NM_000689 0.002022 -2.18 0.005222 -1.88 
asp (abnormal spindle) 
homolog, microcephaly 
associated 
ASPM NM_018136 0.001036 -2.18 0.000728 -2.25 
polymerase, epsilon 2  POLE2 NM_002692 0.001716 -2.16 0.000932 -2.35 
BRCA1 interacting 
protein C-terminal 
helicase 1 
BRIP1 NM_032043 0.016101 -2.15 0.033478 -1.92 
integrin, beta-like 1 ITGBL1 NM_004791 0.017809 -2.15 0.035844 -1.92 
fidgetin FIGN NM_018086 0.000544 -2.14 0.001157 -1.88 
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lamin B1 LMNB1 NM_005573 0.00394 -2.13 0.00321 -2.20 
histone cluster 1, H3i HIST1H3I NM_003533 0.001916 -2.13 0.001864 -2.12 
Fanconi anemia, 
complementation group 
D2 
FANCD2 NM_033084 0.003083 -2.12 0.001318 -2.45 
ribonucleotide reductase 
M2 
RRM2 NM_001034 0.037498 -2.10 0.029957 -2.20 
kinesin family member 
23 
KIF23 NM_138555 0.001204 -2.10 0.001972 -1.93 
maternal embryonic 
leucine zipper kinase 
MELK NM_014791 0.000952 -2.09 0.000622 -2.18 
antigen identified by 
monoclonal antibody Ki-
67 
MKI67 NM_002417 0.00284 -2.08 0.012216 -1.71 
ASF1 anti-silencing 
function 1 homolog B  
ASF1B NM_018154 0.007787 -2.08 0.009392 -2.01 
Opa interacting protein 5 OIP5 NM_007280 0.003731 -2.07 0.00454 -2.00 
transmembrane protein 
195 
TMEM195 NM_0010043
20 
0.028216 -2.06 0.157843 -1.59 
cell division cycle 
associated 8 
CDCA8 NM_018101 0.001225 -2.06 0.000505 -2.36 
GINS complex subunit 2 GINS2 NM_016095 0.002318 -2.05 0.00058 -2.56 
S-phase kinase-
associated protein 2 
SKP2 NM_005983 0.000131 -2.05 5.13E-05 -2.23 
histone cluster 1, H2bh  HIST1H2B
H 
NM_003524 0.009348 -2.05 0.007019 -2.12 
aurora kinase A AURKA NM_198433 0.002761 -2.04 0.002068 -2.13 
spindle and kinetochore 
associated complex 
subunit 2 
SKA2 NM_182620 0.001868 -2.04 0.003569 -1.86 
GTPase, IMAP family 
member 2 
GIMAP2 NM_015660 0.029118 -2.02 0.058697 -1.81 
E2F transcription factor 8 E2F8 NM_024680 0.038974 -2.01 0.052401 -1.93 
   Greater than 2 fold change in Lo only 
ubiquitin-conjugating 
enzyme E2C 
UBE2C NM_181802 0.000673 -1.95 0.000255 -2.27 
ubiquitin-like with PHD 
and ring finger domains 1 
UHRF1 NM_0010482
01 
0.016634 -1.81 0.003569 -2.27 
replication factor C 4 RFC4 NM_002916 0.001858 -1.73 0.0003 -2.23 
high-mobility group box 
2 
HMGB2 NM_0011306
88 
0.00745 -1.94 0.003641 -2.15 
transmembrane protein 
97 
TMEM97 NM_014573 0.004009 -1.72 0.000796 -2.09 
transforming, acidic 
coiled-coil containing 
protein 3  
TACC3 NM_006342 0.003552 -1.84 0.001491 -2.07 
chromosome 12 open 
reading frame 48 
C12orf48 AK302724 0.00728 -1.72 0.001774 -2.06 
histone cluster 1, H3a HIST1H3A NM_003529 0.0481 -1.65 0.009468 -2.06 
kinesin family member 
14 
KIF14 NM_014875 0.008309 -1.95 0.005476 -2.05 
thyroid hormone receptor 
interactor 13  
TRIP13 NM_004237 0.010858 -1.87 0.005458 -2.05 
breast cancer 1, early 
onset 
BRCA1 NR_027676 0.012441 -1.72 0.003357 -2.05 
chromosome 1 open 
reading frame 110 
C1orf110 NM_178550 0.032012 -1.97 0.028158 -2.02 
single-minded homolog 1  SIM1 NM_005068 0.008161 -1.84 0.003979 -2.02 
butyrylcholinesterase BCHE NM_000055 0.061941 -1.71 0.021168 -2.00 
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KDEL (Lys-Asp-Glu-
Leu) containing 2 
KDELC2 NM_153705 0.000208 -1.86 9.71E-05 -2.00 
minichromosome 
maintenance complex 
component 10  
MCM10 NM_182751 0.010962 -1.83 0.005348 -2.00 
 
Secreted Protein Quantification 
 Secreted C3 levels were measured in the media of Hi and Lo cells treated with 0.5 
µM MTX for 48 hours. MTX treated Hi cells had 17.1 ng of C3 per mg protein, which 
was significantly higher than 5.7 ng per mg protein in untreated Hi control cells, this 
represented an up regulation of 3.0 fold (p=0.032) (Figure 5-5A). MTX treated Lo cells 
had a secreted C3 level of 38.5 ng per mg protein, which was significantly higher than 
29.3 ng per mg protein in untreated Lo control cells, this represented an up regulation of 
1.3 fold (p=0.018). Also Lo control cells had significantly more secreted C3 than Hi 
control cells, which represented an up regulation of 5.1 fold (p=0.001).  
Secreted IL-8 levels were measured in the media of Hi and Lo cells treated with 
0.5 µM MTX for 48 hours. MTX treated Hi cells had a secreted IL-8 level of 46.2 ng per 
mg protein, which was significantly higher than 3.7 ng per mg protein in untreated cells, 
which represented an up regulation of 12.5 fold (p=0.016) (Figure 5-5B). MTX treated 
Lo cells had a secreted IL-8 level of 42.5 ng per mg protein, which was significantly 
higher than 25.0 ng per mg protein in untreated cells, which represented an up regulation 
of 1.7 fold (p=0.008). Also Lo control cells had significantly more secreted IL-8 than Hi 
control cells, which represented an up regulation of 6.8 fold (p=0.007). Secreted IL-8 
levels were also measured in TNF-α and MTX/TNF-α treated Hi and Lo cells, but there 
was no significant difference (data not shown). 
Secreted MCP-1 levels were measured in the media of Hi and Lo cells treated 
with 0.5 µM MTX for 48 hours. MTX treated Hi cells had a secreted MCP-1 level of 14.4 
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ng per mg protein, which was higher but not significantly different from 11.4 ng per mg 
protein in untreated Hi cells (p=0.26) (Figure 5-5C). MTX treated Lo cells had a secreted 
MCP-1 level of 21.1 ng per mg protein, which was higher but not significantly different 
from 19.7 ng per mg protein in untreated Lo cells (p=0.53). Also Lo control cells had 
significantly more secreted MCP-1 than Hi control cells, which represented an up 
regulation of 1.7 fold (p=0.033). Secreted MCP-1 levels were also measured in TNF-α 
and MTX/TNF-α treated Hi and Lo cells, but there was no significant difference (data not 
shown). 
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5C 
 
Figure 5-5. ELISAs. Hi and Lo cells were exposed to 0.5uM MTX for 48 hours. 
Secreted target protein was measured in the media. Each bar represents the mean±SD of 
three samples. A, C3. B, IL-8. C, MCP-1. These experiments are representative of a total 
of three experiments with similar results. *P values <0.05 for MTX compared with 
control. #P values <0.05 for Hi control compared to Lo control.  
 
5.5 Discussion 
Elevated homocysteine is often accompanied by low folate status but is also 
influenced by dietary intake of vitamins, lifestyle, and genetic factors (Refsum et al. 
2006). A high homocysteine and low folate phenotype is associated with many conditions 
which also involve inflammation such as rheumatoid arthritis (RA) (Wallberg-Jonsson et 
al. 2002). Chronic inflammation of synovium in rheumatoid arthritis involves migration 
of leukocytes which interact with the endothelium via cell adhesion molecules and 
cytokine/chemokine signaling. The increase in inflammation in RA leads to increased 
comorbidity of cardiovascular disease (CVD) (Sattar et al. 2003). Methotrexate (MTX) is 
an anti-folate drug used to treat RA, which may have an effect on CVD comorbidity and 
mortality. The emerging consensus as reflected in a review by Westlake et al. (Westlake 
et al. 2010) is that the use of MTX in the treatment of RA is associated with a reduction 
in CVD comorbidity and mortality, due to its anti-inflammatory effects. We wanted to 
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examine how MTX treatment may influence the expression of inflammatory genes 
because of its conflicting properties of anti-folate and anti-inflammatory. We chose to 
investigate the effects of MTX within the context of a well defined model system, Hi and 
Lo EA.hy 926 endothelial cells adapted to normal and low folate, respectively. 
Doses of MTX were chosen in the range of concentrations relevant to the 
treatment of rheumatoid arthritis (Lebbe et al. 1994). In this study MTX was shown to 
inhibit proliferation of endothelial cells in the range of concentrations from 0.1 to 0.5 µM, 
and the 0.5 µM dose was chosen for further study. A study in human umbilical vein 
endothelial cells (HUVECs) showed an inhibition of proliferation when treated with 
doses of MTX comparable to in vivo levels after low dose administration (0.1-1.0 µM) 
(Yamasaki et al. 2003).   
Total intracellular folate was decreased in Hi cells when treated with 0.5 µM 
MTX. In MTX treated Hi cells the composition of intracellular folate derivatives was 
modified by MTX such that 5-MTHF levels were lower and folic acid levels were higher. 
The retention of unmetabolized folic acid, which cannot be utilized, indicates that 
dihydrofolate reductase (DHFR) was inhibited resulting in a change in the distribution of 
folate derivatives. These results are consistent with studies by Baram et al. (Baram et al. 
1987) on cultured human myeloid precursor cells (MPCs) that found MTX treated cells 
had decreased levels of 5-MTHF, 10-formylTHF, and 5-formylTHF and increased levels 
of DHF and 10-formylDHF, evident of inhibition of DHFR. We observed that Hi and Lo 
cells treated with MTX down regulated DHFR, which could also account for the increase 
in folic acid.  
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The effect of the anti-folate, MTX, was investigated using microarrays which 
covered most of the genes within the human genome. In the present study it was 
demonstrated that MTX increased the production of C3 and IL-8 in Hi as well as Lo cells 
with no change in MCP-1 levels. C3 activation is responsible for local inflammation and 
levels of which are known to be increased in synovial fluids of patients with rheumatoid 
arthritis (Okroj et al. 2007). Although not direct evidence, a small study showed that 
combination treatment with MTX and cyclophosphamide of pediatric SLE resulted in 
increased C3 levels in serum (Lehman et al. 2004). Hi cells treated with MTX had a 
much greater fold increase in C3 than MTX treated Lo cells, which could be related to 
the dramatic drop in folate levels in Hi cells. In Lo cells in the presence of an 
inflammatory stimulator, TNF-α, pre-treatment with MTX increased C3 levels. The anti-
folate properties of MTX seem to be capable of up regulating specific inflammatory 
proteins. 
It was previously published that Lo cells secreted more MCP-1 than Hi cells 
(Brown et al. 2006), therefore chronic folate insufficiency was able to up regulate an 
inflammatory protein. We have found that in Lo control cells C3 and IL-8 were more 
highly expressed and had increased synthesis and export of protein compared to Hi 
control cells. This finding may indicate that folate dysfunction is associated with a 
heightened state of immune readiness. 
In a study by Cascao et al. (2010) synovial fluid of rheumatoid arthritis patients 
had increased IL-8, a neutrophil chemoattractant. Rheumatoid arthritis patients also had 
increased circulating IL-8 levels, but after 4 months of MTX treatment circulating IL-8 
levels were not significantly changed. MTX treatment is associated with a serious side 
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effect, inflammation of the lung called pneumonitis, which has been shown to be related 
to an elevation of IL-8 (Yoshida et al. 1999). Subsequently Yamauchi et al. (2004) has 
shown that bronchial and alveolar epithelial cells treated with MTX up regulated IL-8. 
We have shown that IL-8 was up regulated with a greater fold increase in MTX treated 
Hi cells than MTX treated Lo cells, which again could be related to the dramatic drop in 
folate levels in Hi cells. 
MCP-1 is involved in both the recruitment of monocytes to atherosclerotic lesions 
and to synovium in RA patients. Although MTX did not influence MCP-1 levels in 
endothelial cells in this study, it remains to be seen whether MTX can influence MCP-1 
levels in RA patients. An etiological component of RA is up regulation of systemic 
inflammation, consequently these patients have an increased risk of developing CVD 
(Sattar et al. 2003). Treatment of RA with MTX has been associated with an overall 
decrease in CVD comorbidity and mortality in a recent meta-analysis (Westlake et al. 
2010), although in vitro evidence presented in this set of experiments points to increases 
in specific inflammatory products such as C3 and IL-8. This paradoxical decrease in 
CVD comorbidity observed in RA patients and up regulation of specific inflammatory 
genes in endothelial cells may mean that MTX treatment induces folate dysregulation 
which may counteract some of its anti-inflammatory actions. We have found C3 and IL-8 
to be up regulated in endothelial cells, but well designed studies in RA patients beginning 
MTX will be needed to validate this observation, and to assess the benefit to CVD risk to 
see if levels of these inflammatory products are related to modulation of CVD risk. 
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Chapter 6: General Discussion and Future Directions 
6.1 General Discussion 
 The overall conclusions that can be drawn from the research work in this thesis 
are: 
A) There was gene-gene interaction between CBS 844ins68 genotypes and MTHFR 
677C>T genotypes on tHcy and folate levels in healthy men. In healthy women 11 
polymorphisms were genotyped and several were associated with altered levels of tHcy 
as well as plasma and RBC folate derivatives.  
In healthy males from the Industrial Workers study CBS 844ins68 genotypes had 
no effect on tHcy and folate levels when considered alone but when considered in the 
context of MTHFR 677C>T genotypes there was an impact on tHcy and folate levels only 
within MTHFR 677TT individuals. The tHcy raising and folate lowering effect of the 
MTHFR 677TT genotype was counteracted in those who were CBS 844ins68 carriers. 
In the Premenopausal Women study tHcy levels in African Americans were 
associated with the polymorphisms MTR 2756A>G and TYMS 1494del6. THcy levels in 
Caucasians were associated with the polymorphisms MTHFR 677C>T, MTHFR 
1298A>C, and MTR 2756A>G. Plasma and RBC folate derivatives in African Americans 
were associated with the polymorphisms MTR 2756A>G, MTRR 66A>G, RFC1 80A>G, 
and TYMS 5’VNTR. In Caucasians plasma and RBC folate derivatives were associated 
with the polymorphisms MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, TYMS 
1494del6, and RFC1 80A>G. 
B) None of the 7 polymorphisms tested were associated with increased NTD risk in 
children and mothers by TDT analyses. 
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 Although TDT analyses did not find any significant associations there was 
evidence that rare crossover events between MTHFR 677 and 1298 polymorphisms may 
increase risk of NTDs because two such genotypes were present in mothers only. Also 
rare crossover events between TYMS 5’VNTR and 1494del6 were more frequent in 
children and mothers. 
C) None of the polymorphisms tested were associated with elevated tHcy levels or CAC 
scores in SLE cases. In RA patients taking MTX several polymorphisms were associated 
with altered levels of RBC folate derivatives. Several polymorphisms were associated 
with discontinuation of MTX and attributable toxicities.   
 In the SLE study GFR was negatively correlated to tHcy levels and was therefore 
used as a covariate in general linear models which examined the effects of genetic 
polymorphisms on tHcy levels. Although none of the polymorphisms were found to 
impact tHcy levels in SLE cases, the polymorphisms MTHFR 677C>T and 1298A>C 
were associated with tHcy levels in controls. 
 In the RA study the polymorphisms MTHFD1 1958G>A and MTHFR 1298A>C 
were associated with discontinuation of MTX therapy in African Americans and 
Caucasians, respectively. The polymorphisms MTR 2756A>G and MTHFD1 1958G>A 
were associated with attributable toxicities in African American and Caucasian current 
users, respectively.  The polymorphisms DHFR c.86+60_78 and TYMS 1494del6 were 
associated with currently prescribed MTX dose in African Americans. RBC folate 
derivatives were associated with the polymorphism DHFR c.86+60_78 in African 
Americans. In Caucasians RBC folate derivatives were associated with the 
polymorphisms MTHFR 677C>T, RFC1 80A>G, and MTRR 66A>G.  
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D) In EA.hy 926 endothelial cells MTX treatment resulted in depletion of total folate, 
altered composition of folate derivatives, and increased expression of the inflammatory 
genes, C3 and IL-8. 
 Hi and Lo cells were treated with MTX and cellular proliferation was inhibited. 
MTX treated Hi cells had depleted levels of total folate, an altered distribution of folate 
derivatives, and higher levels of unmetabolized folic acid. Microarray analyses identified 
a number of inflammatory genes which were up regulated in MTX treated Hi and Lo 
cells. C3 and IL-8 were verified by qRT-PCR to be up regulated in MTX treated cells. 
ELISAs also confirmed that secreted protein levels of C3 and IL-8 were higher in MTX 
treated cells.    
6.2 Future Directions 
 6.2.1 Healthy subjects 
 In the Industrial Workers study there are several polymorphisms which have been 
genotyped and remain to be analyzed and published even if there are no associations with 
tHcy and folate levels. These polymorphisms are: MTHFR 1298A>C, SHMT1 1420C>T, 
RFC1 80G>A, TYMS 1494del6, and MTHFD1 1958G>A. TYMS 5’VNTR and DHFR 
c.86+60_78 polymorphisms also need to be genotyped and analyzed. Although this study 
consists of only men and some of these polymorphisms are associated with differences in 
Hcy and folate levels only in women, the Industrial Workers study is large enough to 
permit the analyses of gene-gene interactions. 
 The Premenopausal Women study showed that polymorphisms in the enzymes of 
the folate/Hcy pathway impact tHcy and folate derivative levels. The use of high 
precision methods to measure individual folate derivatives should be expanded to studies 
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on healthy men. Also any subsequent studies should consider the number of subjects of 
each race that would need to be recruited because a large scale study would enable 
analyses of rare homozygotes. C3 and IL-8 levels could be measured in healthy 
individuals and examined for associations with tHcy and folate levels. 
6.2.2 Families with a child affected by NTDs 
As previously mentioned TDT analyses on specific subsets of the NTD study 
need to be performed. Subsets which may reveal increased genetic risk include maternal 
smoking status, maternal supplementation status, race, and year of birth, which would 
examine effects of genotypes prior to and after folic acid fortification in the US. TDT 
analyses are relatively simple and a more complex analysis such as log-linear modeling 
may uncover increased risk for NTDs associated with a particular genotype. 
Polymorphisms in C3 and IL-8 could be searched for and genotyped in the NTD study. 
6.2.3 Inflammatory diseases 
    In the SLE study only tHcy concentrations were measured. If another study was 
planned then whole blood should be collected in a method compatible with measurement 
of folate derivatives using LC/MRM/MS, which would require that whole blood be 
immediately diluted in ascorbic acid to prevent the oxidation of folate derivatives. The 
association between CAC scores and folate derivative levels could then be analyzed. The 
current SLE study has serum and/or plasma samples available and candidate 
inflammatory genes such as C3 and IL-8 could be measured and compared to controls. 
C3 and IL-8 would be considered because MCP-1 was another inflammatory gene which 
was first found to be up regulated in Lo compared to Hi cells. In the SLE study MCP-1 
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levels were shown to be higher in SLE cases compared to controls (Brown et al. 
2007).C3 and IL-8 levels should also be analyzed for association with CAC scores. 
In the RA study analyses are underway which include baseline measurements of 
tHcy and folate derivative levels prior to MTX therapy. Other future directions include 
restricting the analyses of current users to just females because a few of the 
polymorphisms seem to be associated with differences in Hcy and folate levels only in 
women. Since C3 and IL-8 were up regulated in MTX treated Hi and Lo cells, levels of 
these proteins should be measured in plasma samples and analyzed for associations with 
tHcy and folate levels. The changes in C3 and IL-8 levels as RA patients begin MTX 
therapy will also be of interest. 
6.2.4 Cell culture 
In cell culture experiments involving Hi and Lo cells treated with MTX and TNF-
α a future direction would be to measure secreted C3 levels in TNF-α and MTX/TNF-α 
treated cells. Since MTX treatment was associated with an inhibition of proliferation, an 
assay specific to cell death would be a better measure of MTX induced apoptosis than 
counting the number of live cells. The trypan blue assay was able to dye the dead cells 
but the length of time need to complete each assay limited the utility of this method. Even 
though MTX treatment was applied when cells were confluent it was apparent that cell 
division continued to take place after confluence and therefore the difference between the 
number of live control cells and live MTX treated cells after 48 hours may have been 
overestimated. Finally there are other inflammatory genes which were found to be 
significantly up regulated by MTX treatment in the microarray analysis, such as IL-1A, 
which need to be validated by qRT-PCR and ELISA.   
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